

@BAUSurology

#### **Contents**



Welcome from the President  Introduction by the Honorary Secretary  7  General Information  Abstract Book Accommodation Badge Scanning  10
Secretary 7  General Information 10  Abstract Book 10  Accommodation 10
Abstract Book 10 Accommodation 10
Accommodation 10
Badge Scanning 10
BAUS 2024 Format 10 Certificates of Attendance 10
Clean Air Zone 10
Cloakroom 10
Conference Catering 10
Continuing Medical Education 11
Delegate Badges 11
ePoster Sessions 11
Exhibition - Location and Opening Hours 11
Gallery Poster Display 11 Media Check-in 11
Photography 11
Prayer Room 11
Press Attendance 11
Programme 11
Registration Desk 11
Satellite Symposia 11
Scientific Session Access 11 Sustainability 12
Sustainability 12 Teaching & Skills Courses 12
Travel and Parking 12
X (Twitter) & Social Media 12
Venue 12
Virtual Interaction 12
Watch it Again 12
WiFi 12
Registration Fees 14
Registration Information 17
Badge Scanning 17
Cancellations 17
Exhibition-Only Registration 17 Letters of Invitation 17
Social Programme 18
Drinks Reception and Medal & Awards Presentation 18
Networking Reception 18
Satellite Symposia 19

Programme	23
Section of Andrology and Genito-Urethral Surgery Annual Meeting	23
Section of Female, Neurological and Urodynamic Urology Annual Meeting	24
Section of Endourology	26
Section of Oncology	27
Section of Trainees	29
British Urology Researchers in Surgical Training (BURST)	30
Main Programme	
Monday 24 June	32
Tuesday 25 June	44
Wednesday 26 June	60
ePosters & Gallery Posters	70
ePosters 1: Renal Cancer / Testis Cancer / Sarcoma	71
ePosters 2: Stones, Imaging and Upper Tract Disorders 1	73
ePosters 3: Female Urology and Bladder  Dysfunction	75
ePosters 4: Andrology, Genitourethral Reconstruction, Infertility & Male Genital Cancers	77
ePosters 5: Uro-technology / Artificial Intelligence & Urology Apps	79
ePosters 6: Management / Governance/ Education / Quality Improvement	81 1
ePosters 7: Bladder Cancer: Muscle & Non-Muscle Invasive	83
ePosters 8: Stones / Imaging / Upper Tract Disorders 2	85
ePosters 9: Prostate Cancer 1	87
ePosters 10: TUF-BAUS Best of the Regions	89
ePosters 11: General Urology	91
ePosters 12: Management / Governance/ Education / Quality Improvement	93 1
ePosters 13: Prostate Cancer 2	95
Gallery Poster Display and Q&A Presentations	
Prostate Cancer	97
Bladder Cancer	99
Management / Governance/ Education / Quality Improvement	93 101
Stones / Imaging / Upper Tract Disorders	102
Teaching & Skills Courses 1	04
Introduction by the Honorary Secretary Elect	104
Courses at a Glance	105
On-Site Courses	108
Emergency Procedures	119



#### **Diamond Sponsor**





#### **Platinum Sponsor**



#### **Gold Sponsor**





#### **Silver Sponsors**





: medac pharma

#### **Bronze Sponsors**







## Welcome from the President Jo Cresswell





#### Welcome to BAUS 2024...

It is hard to believe that this BAUS Annual Meeting will be my Presidential "swan-song". The President's Address will be an opportunity to thank all of you who have trusted and supported me over the last 2 years, and it will be my great honour to present the BAUS President's Badge to Prof Ian Pearce who will take over for the next 2 years. I will also be delighted to present our Medals and Awards to an inspirational and talented group of BAUS members and international leaders. It's always a tough ask for our awards committee to select from such a high calibre field – I am sure you will agree that all are very well-deserved. It is my honour to bestow the medals to an outstanding group of colleagues. Congratulations to Shamim Khan, Sanjay Kulkarni, Suzie Venn, Hashim Ahmed, Jean McDonald, Rob Feasey. Come along to congratulate all our inspiring recipients at the BAUS Welcome Drinks Reception in the Exhibition Hall on Monday evening.

One of the very few drawbacks of being President, is that I often don't have time to participate fully in the Annual Meeting as a BAUS member, because as you can imagine, our annual get-together is a great opportunity to schedule lots of meetings and workshops whilst we are all together. This year's program is packed with sessions that are "must see" as far as I am concerned. I may have to use outgoing President's privilege to excuse myself from some of my duties to join the audience.

I congratulate Joe Phillip (Honorary Secretary) and Mo Belal (Honorary Secretary Elect) along with Harry Heald (Events Manager) and Chloe Austin (Events Assistant), for delivering an incredible program. For any of you who have not yet organised a conference program, this represents a huge amount of work. Thank you to all our Section teams and partners for contributing to the program development and to all our speakers who put so much effort into their presentations. Remember all of this is impossible without two groups of very important people. The members of BAUS who input lively interaction and networking. I hope you will agree that this membership benefit is well worth your continued support to BAUS. The second group are our amazing sponsors and partners who contribute so much to this successful meeting each year.

There is so much to digest in this program, I suggest you spend some time taking it all in. Clinical and technical innovation for every aspect of our work. Some of which is for us to marvel at, in the hands of the subspecialist, and perhaps more importantly updates in techniques and knowledge for the general urologist. Specialty section sessions include both, and the BAUS Updates round-up at the end of the meeting will bring it all together for you. In an unselected non-elective take or general urology clinic, we are all generalists and I look forward to brushing up my clinical knowledge to benefit my patients.

#### **President's Welcome continued**



Alongside our clinical focus, the annual meeting is an opportunity to highlight and debate some of the political hot topics pf the year. At our opening session, we welcome the Presidents of all four Royal Colleges of Great Britain and Ireland. We have selected four controversial topics that none of you could have missed in the media. Each of the President's have courageously accepted an invitation to share their thoughts on topics that have vexed clinical leaders over the last twelve months. I know you all have a lot to say on these matters, make sure you get to Birmingham in time to join the conversation. Our BAUS, BJUI and JCU Guest Lectures provide insights from elite sports, industry and the highest levels of NHS leadership. Is there any similarity between delivering high performance clinical care year after year, and performing at a world class level in sports, join us to hear what Olympian, Colin Jackson has to say, and learn first hand about being a patient and its impact on the life of a professional athlete from John Hartson.

We also have plenty of sessions highlighting the wellbeing of clinicians and managing ourselves and our workload in a testing healthcare environment. Only the Annual Meeting can offer the forum to bring us all together to share experience and practice. A problem shared is a problem halved? Perhaps not, but never underestimate the value of conversations between peers, and the knowledge that you are not alone in facing challenges. Surely this is what Our BAUS community and all of our regional societies are all about.

Great to see BSoT highlighting some issues that are relevant to us all, the challenges we face are technical, personal, interpersonal and affect our wellbeing. Freedom to speak up will also be explored, from all perspectives. And who better than the consultants of the future, to lead the exploration of the impact of Artificial Intelligence. BURST will also have a strong presence, highlighting their portfolio of ongoing research work. Delighted that once again we can showcase the best papers from trainees representing every region in our TUF-BAUS Best Regional Paper session. Come along to support your regional champions. Thank you to TUF for sponsoring and providing a prize for the overall champion.

A final message to you all, is that we really do welcome suggestions for sessions at our Annual Scientific Meeting for 2025. Please do talk with Joe Philip, Mo Belal and Ian Pearce early if you have ideas. The program is often fairly well developed by September for the following June.

Looking forward to seeing you all in Birmingham, to celebrate and debate all that is UK Urology.

#### Jo Cresswell


President





## Welcome from the Honorary Secretary Joe Philip





This year's conference boasts an exceptional lineup curated by our esteemed Programme Committee, featuring over 20 international speakers hailing from regions spanning North America to New Zealand. With a lineup of more than 100 chairs and nearly 300 speakers across 62 sessions, we are poised to delve into a wide array of topics aimed at expanding clinical horizons, nurturing well-being, and fostering innovation.

gathering.

In a groundbreaking move, our inaugural session will witness representation from four Royal Colleges, engaging in discussions close to the hearts of urologists worldwide. From the evolving role of the Physician Associate to the imperative of addressing sexual misconduct in surgery, these sessions epitomize the depth and breadth of our shared interests and concerns. Moreover, this year's program features an increased emphasis on workforce dynamics, burnout prevention, and emergent themes such as the identity of the future emergency urology surgeon.

Ben Turney and colleagues will challenge us to contemplate the landscape of urology in 2040, while Angus Luk's session on surgeon sustainability underscores the pressing need to reassess traditional paradigms within our field. Drawing inspiration from diverse spheres including industry, healthcare, athletics, and journalism, we aim to glean insights on optimizing performance, maintaining well-being, and navigating the complexities of our profession.

Our schedule also includes sessions on innovation and artificial intelligence, spotlighting the latest advancements poised to transform urological practice. Notably, the session on reducing risk, enhancing patient safety, and optimizing team performance promises to be a highlight, featuring experts from realms as diverse as air traffic control and Formula One racing.

Monday sets the tone with a bustling evening reception in the exhibition hall, featuring Awards ceremony and live entertainment—a perfect opportunity for networking and camaraderie. Tuesday will witness the prestigious St. Paul's and St. Peter medal ceremony, alongside the BAUS Presidential handover, offering a moment for reflection on her successful past two years for Jo Cresswell and Ian Pierce presenting his vision for future endeavours.

Poster sessions, including the introduction of the new Gallery posters, will unfold on days two and three, showcasing a selection of high-quality research curated by our diligent abstract markers. Wednesday morning brings a focus on widening participation, with sessions tackling pertinent issues such as surgeon sex influencing outcomes, strategies for combating sexual misconduct in surgery and how to be an active bystander a must attend session.

#### **Honorary Secretary welcome continued**



As we draw the conference to a close, we invite you to partake in a two-hour "Best of BAUS" scientific bonanza, featuring dynamic presentations from young urologists highlighting the pinnacle of urological innovation and excellence.

I encourage all attendees to explore the Exhibition Hall and engage with our industry partners and sponsors, whose invaluable support has been instrumental in making #BAUS24 possible. Satellite sessions will offer further opportunities to delve into cutting-edge technologies, novel therapeutics, and innovative care approaches.

I eagerly anticipate reconnecting with each of you in Birmingham and collectively shaping the future of urology.

Warm Regards

Joe Philip

Honorary Secretary





## Morcellation in Urology

Your solution from KARL STORZ





#### **General Information**



#### **Abstract Book**

The BAUS 2024 Abstract Book will be available online in the Conference Edition of the JCU from 7am on Monday 24 June.

#### **Accommodation**

BAUS is pleased to offer delegates an accommodation booking service provided by Reservation Highway, the official accommodation providers for BAUS 2024.

Click here to book your accommodation.

Please book early to secure your preferred hotel - availability in June 2024 is likely to be extremely busy. Reservation Highway can assist with any bookings, particularly larger groups: Tel: 01423 525577 or Email: admin@reservation-highway.co.uk

#### **Badge Scanning**

We will be using badge scanning as lead retrieval. Exhibitors can hire scanners and scan delegate badge barcodes to download the following information:

- Name, Job Title, Place of Work (as you specify on your online registration form)
- Work Email address

(as you specify on your online registration form)

You will receive 1 CME point for attending a Satellite Symposium and getting your badge scanned, badge scanning by exhibitors is not compulsory. If you **DO NOT** wish to disclose this information to exhibitors, then do not allow your badge to be scanned. **Please Note:** BAUS Staff will scan you on the entrance into all sessions; this is purely for a count of attendance at the sessions.

#### **BAUS 2024 Format**

We are pleased to be returning to a face-to-face format for BAUS 2024 at the ICC Birmingham. Virtual attendance will be available, and content will be streamed live from the ICC Birmingham and available to watch via the BAUS 2024 Platform.

#### **Certificate of Attendance**

Certificates will be emailed to delegates from Monday 8th July. Certificates for onsite Teaching & Skills courses will only be issued to those whose attendance is registered by a member of staff.

#### Clean Air Zone

Birmingham operates a clean air zone. No vehicle is banned from the zone, but vehicles of specified classes that do not meet emissions standards will be required to pay a daily charge if travelling within the area. You can check if your car is eligible to drive within the Clean Air Zone without charge by visiting www.brumbreathes. co.uk. The daily charges apply to the following vehicles: cars, taxis, LGVs, HGVs, coaches and buses and range from £8 for a private car to £50 for HGVs. The criteria for not incurring a charge differs across diesel, petrol, gas, electric and hybrid vehicles. For further information, please click here.

#### Cloakroom

The complimentary Cloakroom is located along the main concourse and will be open at the following times:

Monday 24 June 0800-1930 Tuesday 25 June 0700-1900 Wednesday 26 June 0700-1800

#### **Conference Catering**

Delegate registrations will include complimentary lunch each day. Street-Food lunch will be served on Monday 24 June & Tuesday 25 June from 12.30-14.00 and Deli Bistro lunch will be served on Wednesday 26 June from 13.00-14.00. Lunch will be available from Exhibition Hall 3.

Dietary requirements will be requested at the time of registration. **Please note** we endeavour to accommodate all dietary requirements where possible with each venue. However, not all dietary requirements or preferences can be accommodated. If you would like further information, please email events@baus.org.uk

#### **General Information continued**



#### **Continuing Medical Education**

This meeting has been accredited with CME points as follows:

Monday 24 June 6 points Tuesday 25 June 6 points Wednesday 26 June 6 points

The Satellite Sessions are each accredited with 1 CME point.

#### **Delegate Badges**

For security purposes, all delegates and exhibitors must always wear the official BAUS 2024 delegate badge to be admitted to the conference centre and social events. Badges will be issued from the badge kiosks by the Registration Desk.

#### **ePoster Sessions**

Full details of the presenters and ePosters will be available on the BAUS 2024 online platform as well as the ePoster viewing wall in the Registration Foyer.

#### **Exhibition - Location and Opening Hours**

The exhibition is in Hall 3 of the ICC Birmingham and will be open at the following times:

Monday 24 June 0900 - 1900 Tuesday 25 June 0900 - 1800 Wednesday 26 June 0900 - 1415

**Please Note:** Entry to the conference or exhibition is **NOT** available to personnel from commercial companies who do not have an exhibition stand.

#### **Gallery Poster Display**

A selection of posters will be on display for the duration of BAUS 2024 on the Gallery Level of Hall 3 Exhibition.

#### Media Check-In

Media Check-In will be located near Hall 1 and a short walk from the Registration Foyer. Media Check-In will be clearly signed, and all speakers & presenters are required to upload slides via Media Check-In. Media Check-In will be open at the following times:

Monday 24 June 0730 - 1800 Tuesday 25 June 0700 - 1800 Wednesday 26 June 0700 - 1415 Full AV information will be sent to all speakers well in advance of the meeting. Any queries prior to the meeting should be directed to BAUS Events (events@baus.org.uk).

#### **Photography**

BAUS 2024 will have an official photographer and videographer who will be operating onsite. By registering for BAUS 2024, photographs may be taken, and this footage may be used by the organisers for marketing purposes. If you require further information on this, please email BAUS Events (events@baus.org.uk).

#### **Prayer Room**

A room will be available to delegates throughout the conference for private religious observance, please ask the BAUS Registration Desk for further details.

#### **Programme**

We will not have a printed programme for BAUS 2024; delegates should instead use the BAUS 2024 Platform/App. Printed 'Programme at a Glance' will be available to collect from the BAUS Registration Desk

#### **Registration Desk**

The desk will be situated in the Registration Foyer outside the Exhibition Hall 3. It will be open at the following times:

Monday 24 June 0800 - 1730 Tuesday 25 June 0800 - 1800 Wednesday 26 June 0800 - 1415

#### **Satellite Symposia**

Satellite Symposia will be held in Hall 1 Auditorium and Hall 3 Exhibition Hall (stand 230).

#### **Scientific Session Access**

Scientific sessions are only open to registered delegates and exhibitors with an all-access pass. **Please Note:** Entry to the conference or exhibition is **NOT** available to personnel from commercial companies who do not have an exhibition stand

#### **General Information continued**



#### **Sustainability**

For more information of ICC Birmingham's sustainability credentials, please visit: www.theicc.co.uk/about-us/sustainability/

We will have various water refill points available throughout the venue and encourage delegates to bring their own water bottles and re-usable coffee mugs.

#### **Teaching & Skills Courses**

**Teaching courses:** Paediatrics Urology, Succeed the Portfolio Pathway, Good Urodynamics Practice, The Medical Protection Society: Medico Legal Course, Simulated Course for Urology NTN Interviews, An Evidence Based Approach to Managing Active Surveillance for Prostate Cancer, Updates in Stone Management, Management of Functional Urology Emergencies

**Skills courses:** Hands on Ultrasound Training, Cognitive/MRI Fusion LA Transperineal Biopsy of Prostate, Introduction to Robotics will take place at the ICC Birmingham.

Places are strictly limited, and we encourage delegates to book early to avoid disappointment. Certificates for onsite Teaching & Skills courses will only be issued to those whose attendance is registered by a member of staff.

#### **Travel and Parking**

Birmingham is easily reached from Birmingham Airport, with Birmingham New Street a 10-minute train ride from the terminal.

There are three train stations in the city centre, and all just a short walk from the ICC with New Street Station the closest.

Parking is available the Arena Birmingham (B1 2AA) for delegates travelling by car - charges apply. If you would like any further information or assistance, please visit: www.theicc.co.uk/find-us/

#### X (Twitter) & Social Media

BAUS 2024 is on X (Twitter): @BAUSurology #BAUS24

Delegates are reminded of the GMC and BMA guidance in respect to social media.

#### **Venue**

The ICC Birmingham 8 Centenary Square Birmingham B1 2EA United Kingdom

#### Virtual Interaction

Q&A for virtual attendees will be available for all sessions taking place in Hall 1 only. There will be no Q&A for sessions taking place in Halls 4, 8, 9, 10, & 11. Virtual attendees can engage in discussion & debate with other virtual attendees via the chat function.

#### Watch it again

Recorded content from the meeting will be uploaded onto the BAUS 2024 platform and available to Watch Again for up to 6 months.

#### Wi-Fi

Free Wi-Fi is available throughout the ICC Birmingham.

All Conference content, speakers and timings are correct at time of publication. The Organisers cannot be held responsible for changes due to circumstances beyond their control, including the withdrawal of speakers from the programme, for any reason.



#### Registration Fees (£) - BAUS MEMBERS



	Early Ra Until 23:5 1 May 2	9 BST	Standard Rat 00:00 BST on 10:00 BST on 19	2 May to	Onsite Rate - From 09:30 BST on 24 June
DAUG Marahara	Monday / Tuesday / Wednesday (per day)	Whole Meeting	Monday / Tuesday / Wednesday (per day)	Whole Meeting	Monday / Tuesday / Wednesday (per day)
BAUS Members					
Specialist Register/ Urological Specialist/ International Members	240	590	305	765	335
Virtual attendance Specialist Register/ Urological Specialist/ International Members	n/a	400	n/a	600	n/a
Trainee / Allied Professionals	130	265	170	340	190
Virtual attendance Trainee/ Allied Professionals	n/a	200	n/a	600	n/a
Medical Students and Foundation Year Doctors	50	75	55	80	60
Virtual attendance Medical Students and Foundation Year Doctors	n/a	40	n/a	45	n/a
Retired Members	130	265	130	265	130
<b>Virtual attendance</b> Retired Members	n/a	130	n/a	130	n/a
Honorary Members	No Fee	No Fee	No Fee	No Fee	No Fee
Virtual attendance Honorary Members	No Fee	No Fee	No Fee	No Fee	No Fee

<sup>\*</sup>Delegate registrations will include complimentary lunch each day. Street-Food lunch will be served on Monday 24 June & Tuesday 25 June and Deli Bistro lunch will be served on Wednesday 26 June. Lunch will be available from Exhibition Hall 3.

#### Registration Fees (£) - NON-MEMBERS



	Early Ra Until 23:5 1 May 2	9 BST	Standard Rat 00:00 BST on 10:00 BST on 19	2 May to	Onsite Rate - From 09:00 BST on 24 June
	Monday / Tuesday / Wednesday (per day)	Whole Meeting	Monday / Tuesday / Wednesday (per day)	Whole Meeting	Monday / Tuesday / Wednesday (per day)
Non Members					
Urologist / Other (not appearing in categories below)	355	880	455	1,140	495
Virtual attendance Urologist / Other (not appearing in categories below)	n/a	700	n/a	900	n/a
<b>Urology Trainee</b>	195	390	255	505	280
<b>Virtual attendance</b> Urology Trainee	n/a	300	n/a	400	n/a
Allied Healthcare professionals (Nurses, Administrators, Radiographers, etc)	195	390	255	505	280
Virtual attendance Allied Healthcare Professionals (Nurses, Administrators, Radiographers, etc)	n/a	300	n/a	400	n/a
Scientists	95	195	125	250	n/a
<b>Virtual attendance</b> Scientist	n/a	150	n/a	200	n/a
Medical Students and Foundation Year Doctors	60	85	n/a	n/a	n/a
Virtual attendance Medical Students and Foundation Year Doctors	n/a	50	n/a	n/a	n/a

<sup>\*</sup>Delegate registrations will include complimentary lunch each day. Street-Food lunch will be served on Monday 24 June & Tuesday 25 June and Deli Bistro lunch will be served on Wednesday 26 June. Lunch will be available from Exhibition Hall 3.



#### **Registration Information**



#### **Badge Scanning**

We will be using badge scanning as lead retrieval. Exhibitors can hire scanners and scan delegate badge barcodes to download the following information:

#### • Name, Job Title, Place of Work

(as you specify on your online registration form)

#### • Work Email address

(as you specify on your online registration form)

You will receive 1 CME point for attending a Satellite Symposia and getting your badge scanned, Badge scanning by exhibitors is not compulsory. If you **DO NOT** wish to disclose this information to exhibitors, then do not allow your badge to be scanned. **Please Note:** BAUS Staff will scan you on the entrance into all sessions; this is purely for a count of attendance at the sessions.

#### **Cancellations**

Fees for the conference and teaching & skills courses, cannot be refunded after 01 May 2024. Cancellations before this date must be confirmed in writing and will be subject to a 10% administration charge.

#### **Letters of Invitation**

Official letters of invitation to help overcome administrative difficulties in some countries can be sent by the BAUS Office. Please email your request in writing before 31 May 2024 to BAUS Events (events@baus.org.uk). Please note these letters do not commit BAUS to any financial obligation.

#### **Social Programme**



#### **Drinks Reception and Medal & Awards Presentation**

#### Monday 24 June, 1730-1900

Enjoy a drinks reception hosted in the ICC Exhibition Hall 3 on Monday 24th June. Network with colleagues & Industry Representatives and browse the Exhibition Hall whilst enjoying an evening of drinks and canapes.

Dress Code: Smart Casual

#### **Awards**

The following will be awarded at the Drinks Reception:

#### **Gold Medal**

Presented to: Jean McDonald, North Middlesex University Hospital

Citation by: Ayo Kalejaiye, University Hospitals, Birmingham

#### Karl Storz Harold Hopkins Golden Telescope Award

Presented to: **Hashim Ahmed,** Charing Cross Hospital, London Citation by: **Taimur Shah,** Charing Cross Hospital, London

#### **John Anderson Award**

Presented to: Suzie Venn, University Hospitals Sussex NHS Foundation Trust

Citation by: Tamsin Greenwell, University College Hospital, London

#### **Certificate of Distinction**

Presented to: Rob Feasey, Karl Storz

Citation by: Sri Sriprasad, Darent Valley Hospital, Kent

#### **Keith Yeates Award**

Presented to: **Nick Simson,** Epsom General Hospital, Surrey (November 2023) Citation by: **Jo Cresswell,** President of BAUS and James Cook University Hospital,

Middlesbrough



**Monday 24 June: Bayer** 

1230-1300 Hall 1



#### **Details to Follow**

Monday 24 June: Karl Storz 1315-1400 Hall 3 Exhibition Hall (Stand 230)



#### **Details to Follow**



Monday 24 June: Coloplast 1530-1600 Hall 3 Exhibition Hall (Stand 230)



# Presenting the Safety and Efficacy of Coloplast TFL Drive in Stone Management, Focusing on ThuFLEP with Coloplast TFL Drive

New Thulium Fibre technology - Coloplast TFL Drive where in vitro tests comparing Coloplast TFL Drive vs Holmium technology has shown an increased ablation volume, finer dust quality and less energy consumption. Discussions and videos from an expert faculty sharing their experiences and perspectives on this technology in stones and BPH.



TFL Drive - Safety and Efficacy in Stones Professor Bhaskar Somani MRCS, FEBU, DM, FFSTEd, FRCS (Urol) Consultant Urological Surgeon, Honorary Senior Lecturer,

University Hospital

Southampton



ThuFLEP with Coloplast TFL Drive Mr Tamer el Husseiny MBBCh, MSc, MD, FEBU, FRCS (Urol) Consultant Urological Surgeon & Honorary Senior Clinical Lecturer, Imperial College London

**Tuesday 25 June: medac Pharma** 0900-0930 Hall 1 Auditorium

## **Are We Getting Intravesical Treatment Right in NMIBC?**

Join medac Pharma and an international panel led by Professor Mariappan, to discuss best practices for managing High-Risk NMIBC patients.

Intro and Initial Interventions - Real World Outcomes in the NHS

**Professor Param Mariappan,** Symposium Chair

Ideal Pathway for High-Risk NMIBC in the NHS **Professor James Catto** 

Sub-Stratification and Selecting the Right Intravesical Treatment

Ms Elsie Mensah

EAU Recommendations for Contemporary BCG Treatment in High-Risk NMIBC

**Professor Paolo Gontero** 

#### : medac pharma



Professor Param Mariappan Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, Edinburgh



**Professor James Catto**Sheffield University NHS
Foundation Trust



**Ms Elsie Mensah** Guy's and St Thomas' NHS Foundation Trust



Professor Paolo Gontero Molinette Hospital, University School of Medicine, Torino, Italy



**Tuesday 25 June: Procept Biorobotics** 1315-1400 Hall 1 Auditorium





#### **Details to Follow**

**Tuesday 25 June: Boston Scientific** 1730-1800 Hall 1 Auditorium




#### **Details to Follow**



Wednesday 26 June: AstraZeneca / MSD 0900-0930 Hall 1 Auditorium



## Time to Challenge Treatment Options in 1L metastatic Castrate Resistant Prostate Cancer (mCRPC)



AstraZeneca/MSD products will be discussed at this promotional meeting.

GB 52250 | February 2024



## Noel Clarke The Christie and Salford Royal Hospitals Manchester and Honorary Professor of Urological Oncology, Manchester University

Wednesday 26 June: BD 1330-1400 Hall 1 Auditorium

## **BD Marquee Kit: New device for TP Prostate Biopsy**

Video Demonstration of the Marquee Kit and Manchester Royal Infirmary experience of using the Kit followed by Q&A



**Amar Mohee,** Manchester Royal Infirmary





## **BAUS Section of Andrology and Genito-Urethral Surgery Annual Meeting**

#### Introduction

On behalf of the Andrology and GenitoUrethral Surgery committee I would like to welcome you all to BAUS 2024 in Birmingham, where cutting-edge advancements and critical discussions in andrology and urethral surgery take centre stage. From Monday, June 24th to Wednesday, June 26th, esteemed experts from across the country and beyond, will convene to explore the latest developments, offering invaluable insights into these rapidly evolving fields, as well as provide opportunities for you to speak to and network with colleagues.

We start on Monday, June 24th (Hall 9; 1100-1230) with our showcase "What's going on in Andrology", which sets the stage for a series of engaging and diverse discussions by world renowned experts from the US, UK and Europe including penile augmentation, trans health issues, testosterone replacement and Post Orgasmic Illness Syndrome.

In the afternoon (Hall 9; 1630-1730), we have the new and improved video session examining new, (and re-visiting some old but gold), surgical techniques including; infrapubic penile prosthesis, laparoscopic groin node dissection, grafting with collagen fleece and Nesbit procedures in Peyronie's disease, and emergency penile fracture repairs. A must see for tips and tricks and a chance to examine experts in their field.

On Tuesday we have the ever-popular joint session with our sister sections FNUU and BAGURS (Hall 8; 1400-1500hrs) and then in the afternoon we have an unmissable chance to update your knowledge with a run through of "The papers that Changed Andrology and urethral surgery in 2023."

Building on last year's highly rated sessions, the Benign Andrology MDT (25th June; Hall 9; 1630-1730) and Genital Cancer MDT (26th June; Hall 10; 1400-1500) returns, where experts will explore the uncertainties of diagnosis and management in erectile dysfunction, Peyronie's, infertility, testis and penile cancer.

On behalf of Vaibhav, Ayo, myself and the committee, we invite you to immerse yourself in the rich learning and networking opportunities that await. Whether you are a seasoned practitioner or a trainee seeking to expand your knowledge, BAUS 2024 promises to be a transformative experience, shaping the future of urological care.



Arie Parnham, Chair, BAUS Section of Andrology and Genito-Urethral Surgery



Ayo Kalejaiye, Vice-Chair, BAUS Section of Andrology and Genito-Urethral Surgery



Vaibhav Modgil, Secretary, BAUS Section of Andrology and Genito-Urethral Surgery

## **BAUS Section of Female, Neurological and Urodynamic Annual Meeting**

#### Introduction

A very warm welcome to BAUS 2024, on behalf of the BAUS Section of Female, Neurological and Urodynamic Urology (FNUU) or as we liked to be known – the FUN section. The FNUU Committee - Mo Belal (ex-chair) Suzanne Biers (Secretary), Hashim Hashim, Magda Kuwaja, Mahreen Pakzad, Nadir Osman, Ased Ali, Tina Rashid, Andrew Kozan (BSOT rep) and myself have created a stimulating educational program for this year. I would like to thank Mo Belal for his excellent leadership over the last 2 years. He has truly been a role model and an inspiration. I would like to thank Ased Ali and Tina Rashid for their valuable contributions as they leave the committee and welcome James Moore and Mehwash Nadeem to the FNUU family.

Over the 3 days we cover a range of functional and reconstructive topics and have joint sessions with the sections of oncology, endourology and AGUS/BAGURS. We are also excited to have Professor John Stoffel, MD from the University of Michigan, USA, Dr Benoit Peyronnet, Associate Professor at the Rennes University, France and Professor Helen O'Connell, University of Melbourne, Australia as our international guests speaking and / or chairing in the programme.

The program will start mid-morning on Monday with the FNUU highlights session, featuring updates from Sachin Malde, Chris Harding and Mo Belal on the latest developments in research, clinical trials, and mesh. Afterwards, we turn our focus to uro-neurology and will hear from Professor Stoffel on the USA Neurogenic Bladder Research Group Registry on LUTS, incontinence and bowel dysfunction. We will get an update on the spinal injuries and the UK network from Richard Nobrega, and finally hear on the fertility aspects and sexual dysfunction in spinal cord injured patients from Asif Muneer. Monday finishes with a 'How to do...' session and includes several robotic reconstructive procedures as well as the vaginal approach to vesicovaginal fistula repair from experts in the field including Anthony Koupparis, Hashim Hashim, Tamsin Greenwell, Benoit Peyronnet and Arjun Nambiar.

Tuesday's program includes 3 sessions. The first session covers all aspects on overactive bladder and we will hear presentations from Andy Kozan, Mehwash Nadeem, Mahreen Pakzad, Ased Ali and Simon Fulford. Following on from this we have the joint FNUU/AGUS/BAGURS session – 'widen our horizons – update on stricture, stenosis and prosthetics'. Speakers include Tony Mundy, Benoit Peyronnet, Suzanne Biers and Asif Muneer. Next is a very relevant session on 'diversifying the urology workforce' and we will be updated on workforce planning and the roles of advanced nurse practitioners and clinical scientists in urology departments. In the session we will hear views from Mark Rochester, Eskinder Solomon, Julie Jenks and Jonathan Broughton.

Wednesday's schedule includes a joint session with endourology on ureteric stricture management. Findlay MacAskill will deliver the final results from the REJOIN UK experience of ureteric injury management audit, and we will then hear about ureteric injury and stricture management – endoscopic, robotic buccal mucosa grafting and open reconstruction perspectives from Alistair Rogers, Rajesh Nair and Voula Granitsiotis, respectively.



Arun Sahai, Chair,
BAUS Section
of Female,
Neurological
and Urodynamic
Urology



Mo Belal, Immediate Past Chair, BAUS Section of Female, Neurological and Urodynamic Urology



Suzanne Biers, Secretary, BAUS Section of Female, Neurological and Urodynamic Urology

### **BAUS Section of Female, Neurological** and Urodynamic Annual Meeting continued



The session will finish with 'challenging ureter cases' from Joe Phillip, Nikesh Thiruchelvam and Muhammed Shamim Khan and will focus on uretero-ileal stenosis, endometriosis and radiation/RPF cases. The final session is joint with oncology and covers the topic of urinary diversion. There is a not to be missed debate of open versus robotic continent urinary diversion from James Catto and John Kelly, followed by a complications MDT run by Tamsin Greenwell and Rosie Blades. Next up is an incontinent diversion overview from James Dyer and, last but not least, Jeremy Ockrim will discuss continent catheterisable channels.

Our ePoster session is on Tuesday morning, featuring presentations from various UK functional units. We also have two excellent teaching courses. 'Good Urodynamics Practice' led by Hashim Hashim which will take place on Monday from 1630. A new and exciting course on the 'Management of Functional Urology Emergencies' will be led by Sachin Malde on Wednesday. 'Neurourology for the General Urologist' led by Sheilagh Reid is prerecorded and available to watch on the BAUS 2024 Platform.

I would like to thank all the speakers and chairs for their expertise, time and efforts in making this such a wonderful programme.

I hope you will join us for as many FNUU sessions as possible and look forward to seeing you in person. On behalf of the FNUU subcommittee, I wish you a productive and enjoyable BAUS 2024.

#### **BAUS Section of Endourology**

#### Introduction

Details to Follow



Subu Subramoniam, Chair, BAUS Section of Endourology



Hari Ratan, Vice Chair, BAUS Section of Endourology



**Jake Patterson,** Secretary, BAUS Section of Endourology

#### **BAUS Section of Oncology**

#### Introduction

Welcome to BAUS 2024 in Birmingham! The Section of Oncology is thrilled to extend a warm invitation to all participants, promising an engaging exploration of the latest advancements in uro-oncological care. Our meticulously crafted program, led by a consortium of esteemed international and national experts, offers a captivating journey into the depths of uro-oncological practice.

#### **Monday**

The inaugural oncology session promises an immersive dive into the realm of uro-oncological surgery. Chaired by Amit Mevcha, Karen Fransis and Philip Charlesworth, esteemed speakers from around the world and own national experts will unveil ground-breaking techniques aimed at revolutionizing patient care. From Karen Fransis's innovative roboticassisted radical prostatectomy techniques to N. Raghavan's insights into augmented reality's pivotal role in complex robotic partial nephrectomy, each presentation aims to inspire and inform. Bhaskar Somani will discuss expert techniques in the endoscopic management of Upper Tract Urothelial Cancers (UTUC), while BM Zeeshan Hameed will present En-Bloc Resection of Bladder Tumours using novel energy and non-energy sources. Campbell Tait will explore the evolving role of Transurethral Laser Ablation for Bladder Tumours, and Alistair Lamb will navigate the challenges of difficult Transperineal Prostate Biopsy, offering strategies for enhanced accuracy. Ashwin Sridhar will share points of technique in Robotic Intracorporeal Neobladders, aiming for optimal outcomes.

In the afternoon the discourse continues with sessions exploring synchronous pathologies in uro-oncology and navigating management challenges. The session is chaired by Nina Patrick, Gokul Kandaswamy and Elizabeth Bright. With insights from Param Mariappan, Alex Laird, Nikhil Vasdev, and Bill Cross, attendees can expect a comprehensive understanding of diagnostic and management strategies.

The final session on Monday will focus on "Navigating Urological Diagnostic Challenges: Strategies and Innovations." Facilitated by Mr. Ben Ayres and Karen Fransis, this session will guide participants through the intricate landscape of diagnostic hurdles encountered in urological oncology. Esteemed experts including Joe Philip, Benjamin Lamb, Asif Muneer, and Maxine Tran will contribute to this session.

#### **Tuesday**

Tuesday promises to be a bustling day for uro-oncology, featuring four exhilarating sessions. We commence with a "Fresh Off the Press" session, dedicated to exploring the most recent advancements and trial outcomes in the field. This session will be chaired by our national experts: Rakesh Heer, Grant Stewart and Caroline Moore. From the shifting paradigms in metastatic urothelial cancers, as presented by Thomas Powles, to the latest updates on NMIBC EAU guidelines, led by Paolo Gontero, attendees will be kept informed about the continuously evolving landscape of urological oncology. Alison Tree will delve into the updates from the PACE trial, while Prasanna Sooriakumran will address the necessity for a UK-based trial assessing the role of radical prostatectomy in metastatic prostate cancer. I will provide insights into the ongoing I-DUNC Audit.



**Jon Aning,** Chair, BAUS Section of Oncology



Vishwanath Hanchanale, Vice Chair, BAUS Section of Oncology



**Bhavan Rai,** Secretary, BAUS Section of Oncology

#### **BAUS Section of Oncology continued**



The second oncology session addresses the holistic needs of individuals with urological cancer, exploring end-of-life care pathways and mitigating treatment-related regret. Chaired by Murthy Kusuma, Helena Burden, and Mary Brown, expert speakers include Christopher Wallis, Kerem Atalar, and Alice Hartley.

At 15:30 to 16:30, a virtual multidisciplinary session moderated by Vijay Ramani and Tom Walton will replicate real-life practice with expert panellists.

The final session culminates with thought-provoking discussions on resilience and sustainability in complex uro-oncological procedures, chaired by Edgar Paez, Jon Anning, and Elizabeth Bright.

#### Wednesday

The final day features a session titled "Controversies in Uro-Oncology," with presentations and discussions on various contentious topics in the field. Chaired by Vish Hanchanale, Jo Creswell, and Jim Armitage, this session will address updates on prostate cancer screening by Hashim Ahmad, the role of lymph node dissection for high-risk renal cell carcinomas by Axel Bex, the ongoing debate surrounding pelvic lymph node dissection in prostate cancer by Krishna Narahari, management of persistent low-grade bladder recurrences despite previous intravesical therapy with MMC and BCG by Paolo Gontero, and whether molecular imaging should replace conventional imaging in the staging of advanced urothelial cancer by Prashanth Patel. The session will conclude with Jose Karam's presentation on screening for cytoreductive nephrectomy in patients with metastatic renal cancer.

The final oncology session is joint session between section FNUU and Oncology chaired by Vishwanath Hanchanale and Hazel Ecclestone. In this joint session, members from Section FNUU and Oncology convene to deliberate on the optimal surgical approach for radical cystectomy, discuss real-life scenarios in a Complication MDT, Incontinent Diversions and Continent Catheterizable Channels.

This year, we're proud to host several exceptional poster sessions, celebrating our excellence. We encourage you to visit these sessions, which are likely to be dominated by our talented trainees showcasing their latest research and findings.

Finally, we extend our heartfelt gratitude to our esteemed international speakers for their invaluable contributions to our program: Paolo Gontero, Karin Fransis, Christopher Wallis, and Jose Karam. Their expertise and insights enrich our conference, and we're honoured to have them join us.

We hope you thoroughly enjoy the uro-oncology sessions we've meticulously developed, and we look forward to a rewarding and enlightening experience together.

#### **BAUS Section of Trainees (BSoT)**



#### Introduction

The BAUS Section of Trainees (BSoT) is excited to welcome you all at BAUS 2024. Our Monday programme kicks off with our 'Challenges as a Surgeon' session. It will feature various topics that affect all surgeons including dealing with complications and conflict resolution. Ben Challacombe will conclude the session by delivering a talk on 'Taking care to avoid the 7 Deadly Sins of Surgery', which will no doubt be a must, given his vast experience in complex surgeries.

Tuesday is a jam-packed day, starting bright and early with the 5km BSoT Fun Run (don't forget your running shoes!) for TUF along the Birmingham Canal. Our 'Freedom to speak up... Or not' session is guaranteed to be one of the highlights of BAUS 2024. The session will explore the intricacies of whistleblowing and the implications for those involved. Ravi Jayaram will start the session with his account of whistleblowing in the Lucy Letby case that shook up the country. Peter Duffy, ex-urology consultant, will share his experience of the aftermath following whistleblowing. The partners of Cole Khan law firm will explain the existing laws that protect us and our careers. Our afternoon session 'Urology in the Age of Artificial Intelligence in Urology' will delve into the emerging use of AI in Urology, especially related to training. We finish a packed Tuesday schedule with the annual BSoT social dinner kindly sponsored by Karl Storz.

Concluding our programme on Wednesday is the "Future Directions for Urologists". This session will cover everything from fellowships, the new urology curriculum and infertility and pregnancy issues among doctors. This will also be a great opportunity for those in all training pathways to see what BSoT does and how to get involved. We will conclude the session with the presentation of the Silver and Bronze Cystoscope Awards.



Sarika Nalagatla, Chair, BAUS Section of Trainees (BSoT)



**Tony Tien,** Secretary, BAUS Section of Trainees (BSoT)

## **British Urology Researchers** in Surgical Training (BURST)

#### Introduction

We are delighted to welcome our colleagues and collaborators at BAUS 2024. BURST continues to grow from strength to strength and this is well represented in our BAUS activity this year. This year, for the first time, BURST will expand our programme across all three conference days to cover the wide range of our ongoing studies involving all sections of BAUS.

The first day will cover "Big Data, Al and International Collaboration", chaired by Jo Cresswell and Kevin Gallagher. We anticipate this topic will be timely, given growing interest in the use of artificial intelligence (Al) across urology. Our keynote speaker, Professor Nikhil Vasdev will explore how Al will be applied to our clinical practice in the coming years. Further, the recent release of our RESECT study results, the largest dataset on TURBT quality with nearly 20,000 patients, will be sure to generate a buzz. Our study leads Kevin Gallagher and Nikita Bhatt will be leading the discussion alongside our star-studded panel of Veeru Kasivisvanathan, Param Mariappan, Elsie Mensah and John Kelly.

Our second day introduces WASHOUT, our latest and greatest project investigating the management of inpatient haematuria. This session will be chaired by Kevin Byrnes and Nikita Bhatt. This session will involve a quick-fire MDT on emergency haematuria, with a selection of diverse specialists providing insights on CEPOD management (John McGrath), hyperbaric oxygen (Thomas Lynch), oncological management (Amy Clifford), interventional radiology (Conrad Von Stempel), surgical management (Jhumar Pati). Ben Challacombe will chair a round-table discussion and pitch clinically relevant cases to the panel to see how expert knowledge can be applied to achieve optimal patient management.

Our last session will include a pair of debates on controversial areas in urology, chaired by Veeru Kasivisvanathan and Hannah Warren. The first quick-fire debate will pitch Milan Gopan against Caroline MacDonald for the motion "Improving the Pathway in Testicular Torsion in the UK: More than a Pipe Dream?". We hope this subject will generate much discussion given the recent publication of GIRFT and CEPOD national guidance. It also bears direct relevance to the RESCUE study by BURST. Our second debate will see the motion "Anticoagulation in The Postoperative Period: How Do We Get the Balance Right?" debated by Kari Tikkinen and Alex Colquhoun. Accompanying this will be an introduction to the ARTs trial by Alex Ng. These debates promise to be a lively, engaging and interactive discussion.

We look forward to welcoming our project collaborators to the annual BURST dinner on Monday evening, but also welcome all attendees to join us for a welcome drink on Monday afternoon, just before we kick off the BURST programme.

We are looking forward to seeing you all in Birmingham!



**Kevin Byrnes,** Co-Chair, BURST



**Arjun Nathan,** Co-Chair, BURST



Cameron Alexander, BURST lead for BAUS programme, Co-Vice Chair, BURST

#### **SYMPOSIUM**

Tuesday 25<sup>th</sup> June 2024 | 09.00 - 09.30, Hall 1

## ARE WE GETTING INTRAVESICAL TREATMENT RIGHT IN NMIBC?

Join medac Pharma and an international panel led by Professor Mariappan, to discuss best practices for managing High-Risk NMIBC patients



Intro and Initial Interventions - Real World Outcomes in the NHS

Prof Param Mariappan (Symposium Chair), Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, Edinburgh



Ideal Pathway for High-Risk NMIBC in the NHS
Prof James Catto, Sheffield University NHS Foundation Trust



Sub-Stratification and Selecting the Right Intravesical Treatment

Ms Elsie Mensah, Guy's and St Thomas' NHS Foundation Trust



EAU Recommendations for Contemporary BCG Treatment in High-Risk NMIBC

Prof Paolo Gontero, Chair of EAU non-muscle invasive bladder cancer guidelines, Molinette Hospital, University School of Medicine, Torino, Italy

Plus... join us for a Q&A session Facilitated by Prof Param Mariappan All Faculty



: medac pharma

To register your interest, scan the QR code or sign up at: https://rb.gy/7wx3v8

#### **MONDAY 24 JUNE**

#### **PROGRAMME**



Hall 1

### o900-1015 Surgical Leadership in Challenging Times: A Year in Retrospect

Chairs: **Abhay Rane OBE**, East Surrey Hospital, Redhill, **Jo Cresswell**, President of BAUS and James Cook University Hospital, Middlesbrough and **Sarika Nalagatla**, Chair of BSoT and University Hospital Monklands

0900-0905	Introduction by Chairs
0905-0915	Physicians Associates: Will They Help or Hinder Surgical Training? Rowan Parks, RCS Edinburgh
0915-0925	Feminisation of the Surgical Workforce: Reduced Productivity or Better Outcomes?  Deborah McNamara, RCS Ireland
0925-0935	Sexual Misconduct: Did Our Profession Look Away? Tim Mitchell, RCS England
0935-0945	Surgical Royal Colleges: Nostalgic Tradition or Essential to the Modern Surgical Workforce Mike McKirdy, RCS Glasgow
0945-1005	Q&A

1015-1100 Refreshments, Networking and Exhibition Viewing

1005-1015

#### Hall 1

#### 1100-1230 International Best Practices: Lessons from Around the World

**Details to Follow** 

Chairs: **Bhavan Rai,** Freeman Hospital, Newcastle and **Anna Mainwaring,** Morriston Hospital, Swansea

**Concluding Remarks by Chairs** 

1100-1120	Why Don't We Talk About Dying - The British Experience Details to Follow
1120-1135	Public Health-Gender Based Violence as a Weapon of War in High Level Conflicts
	<b>Zeeshan Aslam,</b> Ninewells Hospital and Medical School, University of Dundee
1135-1150	Ensuring Equal Healthcare Access for Marginalized and Vulnerable Populations - Lessons Learned from New Zealand

32



Managing High-Volume Urological Trauma: Insights from the South African Experience
 Mumba Chalwe, Consultant Urological Surgeon, Ndola Teaching Hospital, Zambia and President of Women in Surgery Africa (WISA)

 1205-1220 Challenges and Distinctive Features of Urological Cancers in South Asia: Exploring the Need for Lower Diagnostic Thresholds in the Asian Subcontinent Population
 Narasimha Raghavan, Senior Consultant UroOncology & Robotics, Apollo Hospitals, Chennai, Dr MGR Medical University

 1220-1230 Q&A

#### Hall 4 1100-1230

### Semi-Live Video Session: Insights and Techniques for enhanced Uro-Oncological Care

Chairs: **Amit Mevcha**, University Hospitals of Dorset NHS Foundation Trust, **Karen Fransis**, Oncological Urologist and Robotic Surgeon, University Hospital Antwerp, Belgium and **Philip Charlesworth**, The Royal Marsden, London

1100-1103	Introduction by Chairs
1103-1120	Mastering Enhanced Continence Preservation Through Innovative Robotic-Assisted Radical Prostatectomy Techniques Karen Fransis, Oncological Urologist and Robotic Surgeon, University Hospital Antwerp, Belgium
1120-1123	Q&A
1123-1140	Augmented Reality's Pivotal Role in Complex Robotic Partial Nephrectomy: Insights from a High-Volume Robotic Surgeon  Narasimha Raghavan, Senior Consultant UroOncology & Robotics, Apollo Hospitals, Chennai, Dr MGR Medical University
1140-1143	Q&A
1143-1151	Elevating Expertise in UTUC Management: Becoming a Ureteroscopic Virtuoso  Bhaskar Somani, Southampton General Hospital and Editor-in-chief JCU
1151-1153	Q&A
1153-1201	Precision in Action: En-Bloc Resection of Bladder Tumours Zeeshan Hameed, Kasturba Medical College, Manipal, India
1201-1203	Q&A
1203-1208	Mastering Transurethral Laser Ablation for Bladder Tumors: Techniques Unveiled Campbell Tait, Freeman Hospital, Newcastle

Q&A

1208-1210



1210-1216	Navigating the Challenges of Difficult Transperineal Prostate Biopsy Alastair Lamb, Churchill Hospital, Oxford
1216-1218	Q&A
1218-1226	Robotic Intracorporeal Neobladders. Points of Technique Ashwin Sridhar, University College Hospital, London
1226-1228	Q&A
1228-1230	Conclusion by Chairs

#### Hall 8

#### **Renal and Transplant Urology** 1100-1230

Chairs: Subu Subramonian, Queen Elizabeth University Hospital, Glasgow and Rhana Zakri, Guy's & St Thomas' Hospitals, London

1100-1110	Renal Calculi in Live Renal Donor and Recipient  David Rix, Freeman Hospital, Newcastle
1110-1120	Surgery and Assessment for Bladder and Prostate in Transplant Recipients Claire Fraser Taylor, Consultant Transplant Urologist, St George's Hospital, London
1120-1130	Urological Complications in Transplant Recipients  Jonathon Olsburgh, Guy's & St Thomas' Hospitals, London
1130-1140	Retroperitoneal Fibrosis. IgG Immunosuppression Update Dimitrios Chanouzas, Consultant Nephrologist, University Hospitals Birmingham
1140-1150	Nephrology Update for Urologists  Miriam Berry, Consultant Nephrologist, University Hospitals Birmingham
1150-1155	Q&A
1155-1230	Case Discussions  Moderators: Alistair Pogers Freeman Hospital Newcastle and

Moderators: **Alistair Rogers**, Freeman Hospital, Newcastle and Rhana Zakri, Guy's & St Thomas' Hospitals, London

- Urological Complication in Transplant
- Retro-peritoneal fibrosis
- Stones in a recipient

#### Hall 9

#### What's Going on in the World of Andrology? 1100-1230

Chairs: Hussain Alnajjar, University College Hospital, London and Maria Satchi, Kings College Hospital, London

Welcome to BAUS 2024 1100-1105

> Arie Parnham, The Christie NHS Foundation Trust, Manchester



1105-1125	Penile Augmentation is Getting BIGGER. Showtime or Horror Show?
	Paul Perito, Perito Urology, Miami, United States
1125-1145	The Good, the Bad and the Orchidectomy: Navigating Crossroads in Trans Health
	Tina Rashid, St George's University Hospital, London
1145-1205	Traverse or Travesty? What Urologists Need to Know about Testosterone Treatment Geoff Hackett, Good Hope Hospital, Birmingham
1205-1220	What is Post Orgasmic Illness Syndrome- Allergic to Diagnosis and Treatment?
	Ege Serefoglu, Biruni University School of Medicine, Istanbul
1220-1230	Q&A

#### Hall 10

#### 1100-1215 FNUU Highlights

Chairs: **Arun Sahai,** Guy's & St Thomas' Hospital, London and **Mahreen Pakzad,** University College Hospital, London

1100-1105	Introduction
	Arun Sahai, Guy's & St Thomas' Hospital, London
1105-1125	Research Update
	Sachin Malde, Guy's & Thomas's Hospital, London
1125-1145	Literature Update
	Chris Harding, Freeman Hospital, Newcastle-Upon-Tyne
1145-1155	Mesh Update
	Mo Belal, Queen Elizabeth Hospital, Birmingham
1155-1215	Q&A

#### Hall 11A

#### 1100-1230 Challenges as a Surgeon

Chairs: **Omer Abdalla,** Arrowe Park Hospital, Wirral and **Jessica Whitburn,** Wycombe Hospital, High Wycombe

1100-1120	Complications - Reflect and Reset
	Abdullah Zreik, Queen Elizabeth University Hospital, Glasgow
1120-1140	<b>Circumcisions - The Complications and the Complaints</b>
	Hussain Alnajjar, University College Hospital, London
1140-1210	Civility and Conflict Resolution - Case Discussions
	<b>Mary Brown</b> , Glasgow Royal Infirmary and <b>Kevin Turner</b> , University Hospitals Dorset
1210-1230	Taking care to avoid the '7 Deadly Sins of Surgery'
	Ben Challacombe, Guy's & Thomas's Hospital



Hall 1 Auditorium

1230-1300

#### **Bayer Satellite Symposium**

See page 19 for details



#### 1230-1400 Lunch, Networking and Exhibition Viewing

Hall 3 Exhibition Hall (Stand 230)

1315-1400 Karl Storz Satellite Symposiumm

STORZ
KARL STORZ—ENDOSKOPE

See page 19 for details

Hall 1

1400-1500 Pre-habilitation & Frailty Management for the Complex Urology Patient

Chairs: **Aniruddha Chakravarti,** New Cross Hospital, Wolverhampton and **Katherine Warren,** Southmead Hospital, Bristol

Introduction

 Aniruddha Chakravarti, New Cross Hospital, Wolverhampton and Katherine Warren, Southmead Hospital, Bristol

 Enhanced Care for the Frail Urology Patient and Accelerating Safe Discharge

 David Shipway, Consultant Physician in Complex Care, North Bristol NHS Trust

 The Use of CPET Before Major Surgery

 Matthew Stott, Consultant Anaesthetist, Liverpool University Hospitals

1426-1438 Peri-operative Optimisation of Complex Urology Patients
Professor S. Ramani Moonesinghe, National Clinical Director for

Critical and Perioperative Care, NHS England, Director, NIHR Central London Patient Safety Research Collaboration and Professor and Head of Centre for Perioperative Medicine, University College Hospital,

London

1438-1458 Frailty and Peri-operative Enhanced Care MDT

All Faculty

1458-1500 **Summary** 

Aniruddha Chakravarti, New Cross Hospital, Wolverhampton and

Katherine Warren, Southmead Hospital, Bristol



#### 1400-1500

## Synchronous Pathology in Uro-Oncology: Challenges and Solutions

Chairs: **Elizabeth Bright,** Royal Cornwall Hospital, Truro, **Nina Patrick,** Arrowe Park Hospital, Wirral and **Gokul Kandaswamy,** Morriston Hospital, Swansea

1400-1402	Introduction by Chairs
1402-1414	Navigating Synchronous High-Grade Unilateral UTUC and High-Risk NMIBC in a Fit Patient Param Mariappan, Western General Hospital, Edinburgh
1414-1416	Q&A
1416-1428	Considerations in Managing Synchronous Bilateral Renal Masses: Expert Guidance Alexander Laird, Western General Hospital, Edinburgh
1428-1430	Q&A
1430-1442	Diagnostic and Management Strategies for Fit Patients with MIBC and High-Risk Prostate Cancer, including Pelvic and Retroperitoneal Lymphadenopathy Nikhil Vasdev, Lister Hospital, Stevenage
1442-1444	Q&A
1444-1456	Approach to Managing Cambridge Prognostic Score 4 Prostate Cancer in a Fit Man with Ulcerative Colitis in Their 50s William Cross, St James's University Hospital, Leeds
1456-1458	Q&A
1458-1500	Conclusion by Chairs

#### Hall 8

#### 1400-1500

## Minimally Invasive Treatments for BPH - Case Discussion

Chairs: **Feras Al Jaafari,** NHS Fife, Scotland, **Richard Hindley**, Basingstoke and North Hampshire Hospital and **Danielle Whiting**, Frimley Park Hospital

1400-1410	Rezum Details to Follow
1410-1420	<b>UroLift Ananda Dhanasekharan,</b> Sandwell District General Hospital, West Bromwich
1420-1430	iTind Toby Page, Freeman Hospital, Newcastle
1430-1440	Echo Laser Petre Cristian Ilie, Norfolk and Norwich University Hospital
1440-1500	Case Based Discussion



#### 1400-1500 Navigating Complex Urological Pain & Wellness

Chairs: **Mo Belal,** Queen Elizabeth Hospital, Birmingham and **Mahreen Pakzad,** University College Hospital, London

1400-1415 Chronic Testicular Pain: Evaluation and Multidisciplinary

Management

Johnny Boylan, Consultant Physician in Genitourinary Medicine,

Liverpool University Hospitals

1415-1420 **Q&A** 

1420-1435 Chronic Pelvic Pain: Unravelling the Complexity

Moein Tavakkoli, Consultant in Pain management and

Neuromodulation, National Hospital for Neurology and Neurosurgery,

The London Clinic

1435-1440 **Q&A** 

1440-1455 **Psychological Care for Genito-Urinary Pain: Beyond** 

**Organic Causes** 

Caroline Selai, Chartered Psychologist for Neurology and

Neurosurgery, University College Hospital, London

1435-1500 **Q&A** 

#### Hall 10

## 1400-1500 Lower Urinary Tract and Sexual Function Aspects of Neurological Injury

Chairs: **Nadir Osman,** Royal Hallamshire Hospital, Sheffield and **Richard Parkinson,** King's Mill Hospital, Nottinghamshire

1400-1425 Lessons Learnt from the USA Neurogenic Bladder

Research Group Registry on LUTS, Incontinence & Bowel

**Dysfunction** 

John Stoffel, University of Michigan, USA

1425-1430 **Q&A** 

1430-1445 Spinal Injury Update & UK Networks

Richard Nobrega, University College Hospital, London

1445-1500 Sexual Dysfunction & Infertility in Spinal Cord Injured

**Patients** 

Asif Muneer, University College Hospital, London



#### Hall 11A

#### 1400-1500 Paediatric Urology Debates

Chairs: **Shabnam Undre,** Consultant Adult and Paediatric Urological Surgeon, Lister Hospital, Stevenage and **Anu Paul,** Consultant in Paediatric Urology, Guy's & St Thomas' Hospitals, London

111011100 1100	ortais, Lorragin
1400-1415	NCEPOD Torsion Report  Martin Sinclair, Consultant General Surgeon and Clinical Coordinator, National Confidential Enquiry into Patient Outcome and Death (NCEPOD)
1415-1420	Q&A
1420-1440	Debate on Hypospadias Repair
1420-1422	Audience Poll
1422-1429	Nia Fraser, Paediatric Surgeon, Nottingham University Hospitals
1429-1436	Mohamed Shalaby, Paediatric Surgeon, Bristol Children Hospital
1436-1440	Audience Poll & Discussion
1440-1500	UTI & Bowel Management in Children
1440-1447	<b>UTI Management Anu Paul,</b> Consultant in Paediatric Urology, Guy's & St Thomas' Hospitals, London
1447-1454	Bowel Management
	Anne Wright, Consultant in Paediatric Urology, Guy's & St Thomas'

Hall 1

#### 1500-1530 BAUS Guest Lecture:

1454-1500

## Achieving High Clinical Standards & Looking after the 'Human Capital': Learning from Industry

Chairs: **Amol Pandit,** Morriston Hospital, Swansea and **Susan Hall,** Nottingham City Hospital

Ravi Limaye OBE, Managing Director of Wockhardt UK

Hospitals, London

**Discussion and Summary** 

Hall 3 Exhibition Hall (Stand 230)

1530-1600 Coloplast Satellite Symposium



See page 20 for details

1530-1630 Refreshments, Networking and Exhibition Viewing



#### 1630-1730 The Invisible Threat - Burnout and How to Avoid it

Chairs: **Alan McNeill,** Western General Hospital, Edinburgh, and Chair, BJU International and **Sarah Itam,** Frimley Health NHS Foundation Trust

1630-1642	Burnout Caroline Elton, Clinical Psychologist*
1642-1654	Data from BAUS & Bournemouth Steve Payne, BAUS Workforce Lead and Retired Consultant Urologist
1654-1702	How I Recognised I Was Burnout  Jim Adshead, The Lister Hospital, Stevenage
1702-1710	Sabbaticals and How to Use Them Ruth Doherty, Norfolk and Norwich University Hospital
1710-1718	Changing on Call Rotas and Other Tips for Surviving the Modern NHS Maeve Dooher, Ulster Hospital, Belfast
1718-1730	<b>Q&amp;A and Summary</b> *Pre-Recorded

#### Hall 4

## Navigating Urological Diagnostic Challenges: Strategies and Innovations

**Conclusion by Chairs** 

1728-1730

Chairs: **Ben Ayres,** St George's Hospital, London and and **Karen Fransis,** Oncological Urologist and Robotic Surgeon, University Hospital Antwerp, Belgium

1630-1632	Introduction by Chairs
1632-1644	Optimal Diagnostic Pathway for Suspected Upper Tract Urothelial Carcinoma (UTUC)
	<b>Joe Philip,</b> BAUS Honorary Secretary and Southmead Hospital, Bristol
1644-1646	Q&A
1646-1658	Risk Stratified Approach to PSA Persistence Following Radical Prostatectomy
	Benjamin Lamb, The Royal London Hospital
1658-1700	Q&A
1700-1712	Navigating Indeterminate Testicular Masses: Diagnostic and Management Approaches
	Asif Muneer, University College Hospital, London
1712-1714	Q&A
1714-1726	Approach to Indeterminate Renal Masses: Diagnosis and Management Strategies
	Maxine Tran, Royal Free Hospital, London
1726-1728	Q&A



#### **New Technology in Endourology - Balloon Debate** 1630-1730

Chairs: Sian Allen, University College Hospital, London and Matthew Bultitude, Guy's & St Thomas' Hospital, London

1630-1633	Introduction by Chairs  One speaker is eliminated via audience vote after each round
1633-1653	Round 1: 4-Minutes Per Speaker
1653-1655	Poll 1 & Elimination
1655-1707	Round 2: 3-Minutes Per Speaker
1707-1709	Poll 2 & Elimination
1709-1718	Round 3: 3-Minutes Per Speaker
1718-1720	Poll 3 & Elimination
1720-1724	Round 4: 2-Minutes Per Speaker
1724-1726	Poll 4 & Final Elimination
1726-1730	Conclusion

**Conclusion** 

Speakers:

**Disposable Scopes** 

Oliver Wiseman, Addenbrooke's Hospital, Cambridge

**New Lasers** 

Louise Paramore, University Hospital Southampton

**Al Application** 

Robert Geraghty, Freeman Hospital, Newcastle

**Suction Devices and Pressure Monitoring** 

Vimo Arumuham, University College Hospital, London

**Genetics Applications** 

Sarah Howles, Churchill Hospital, Oxford

#### Hall 9

#### I Have Always Wanted to See... an Instructional Video 1630-1730 Session

Chairs: Tet Yap, Guy's & St Thomas' Hospital, London and Ayo Kalejaiye, University Hospitals, Birmingham

**Infrapubic Penile Prosthesis** 1630-1640

Paul Perito, Perito Urology, Miami, United States

**VEILND/RAVEIL** 1640-1650

Vivekanandan Kumar, Norfolk and Norwich University Hospital



1650-1700 Grafting with Collagen Fleece
 Georgios Hatzichristodoulou, MD, MHBA, FEBU, FECSM, Department of Urology, Martha-Maria Hospital Nuremberg, Germany
 1700-1710 Nesbit Plication
 Kirby Sebro, Western General Hospital, Edinburgh
 1710-1720 Penile Fracture Repair
 Marta Skrodzka, St George's Hospital, London
 1720-1730 Q&A

Hall 10

#### 1630-1730 How to Do...

Chairs: **John Stoffel,** University of Michigan, USA and **Helen E. O'Connell** AO, President, Urological Society Australia and New Zealand (USANZ)

1630-1642 Robotic Ileocystoplasty & Male Artificial Urinary

**Sphincter Insertion** 

Anthony Koupparis, Southmead Hospital, Bristol and Hashim Hashim,

Southmead Hospital, Bristol

1642-1645 **Q&A** 

1645-1657 **VVF Repair** 

Tamsin Greenwell, University College Hospital, London

1657-1700 **Q&A** 

1700-1712 Robotic Female AUS

Benoît Peyronnet, University of Rennes, France

1712-1715 **Q&A** 

1715-1727 Robotic Mesh Removal

Arjun Nambiar, Freeman Hospital, Newcastle

1727-1730 **Q&A** 

Hall 11A

#### 1630-1730 **BURST**:

#### Big Data, Al and International Collaboration

Chairs: **Jo Cresswell,** President of BAUS and James Cook University Hospital, Middlesbrough and **Kevin Gallagher,** Western General Hospital, Edinburgh

1630-1640 Welcome and BURST Updates

Arjun Nathan, Royal Free Hospital, London and Kevin Byrnes, North

Middlesex University Hospital London

1640-1700 The BURST Guest Lecture: How will Artificial Intelligence

(AI) Transform your Clinical Practice?

Nikhil Vasdev, Lister Hospital, Stevenage



1700-1730 Results from the International RESECT Study: Will This Change the Way We Do TURBT Forever?

 $\textbf{Kevin Gallagher,} \ \ \textbf{Western General Hospital, Edinburgh and Nikita}$ 

Bhatt, Newcastle Upon Tyne Hospital

Panel:

**Param Mariappan**, Western General Hospital, Edinburgh **Elsie Mensah,** Guy's & Thomas's Hospital, London **John Kelly,** University College Hospital, London

Veeru Kasivisvanathan, University College Hospital, London

Exhibition Hall 3

1730-1900 Drinks Reception and Medal & Awards Presentation

#### **TUESDAY 25 JUNE**



#### **PROGRAMME**

Hall 1 Auditorium

0900-0930 medac Pharma Satellite Symposium : medac pharma

See page 20 for details

Hall 1

0930-0950 Presentation of the St Paul's & St Peter's Medal

Chair: Jo Cresswell, President of BAUS and James Cook University Hospital,

Middlesbrough

0930-0940 Presentation of the St Paul's Medal

Citation by: Majid Shabbir, Guy's & St Thomas' Hospital

Presented to: Sanjay Kulkarni, Endosurgery Institute, Pune, India and

Past-President, Urological Society of India (USI)

0940-0950 Presentation of the St Peter's Medal

Citation by: **Tariq Sami,** City Hospital Birmingham

Presented to: Muhammad Shamim Khan, Guy's & St Thomas' Hospitals,

London

Hall 1

0950-1010 President's Address

Jo Cresswell, President of BAUS and James Cook University Hospital, Middlesbrough

Hall 1

1010-1030 Presidential Handover

**Investiture of Ian Pearce as President of BAUS** 

Hall 1

1030-1100 BAUS Guest Lecture:

**Cancer: A Lived Experience** 

Chairs: **Amol Pandit,** Morriston Hospital, Swansea and **Narin Suleyman,** Lister Hospital. Stevenage

**John Hartson,** Welsh Former Professional Footballer, Coach & Sports Television Pundit

1100-1130 Refreshments, Networking and Exhibition Viewing

Hall 1

1130-1200 BJUI Guest Lecture: the NHS Today and the

**Opportunities for Transformation** 

Chair: **Alan McNeill,** Western General Hospital, Edinburgh, and Chair, BJU International

Richard Meddings CBE, Chair of NHS England



### 1130-1230 Fresh Off the Press: Urological Cancer Management

Chairs: **Rakesh Heer,** Charing Cross Hospital, London, **Grant Stewart,** University of Cambridge and Addenbrooke's Hospital, Cambridge and **Caroline Moore,** University College Hospital, London

oonogo noop	ital, Editadi.
1130-1132	Introduction by Chairs
1132-1143	Changing Paradigms in Metastatic Urothelial Cancers-Outcomes of the EV-302 Trial  Thomas Powles, Professor of Genitourinary Oncology, Queen Mary University of London's Barts Cancer Institute and the Director of the Barts Cancer Centre, St. Bartholomew's Hospital
1143-1145	Q&A
1145-1153	Stereotactic Body Radiotherapy for Localised Prostate Cancer-PACING Ahead Alison Tree, Consultant Clinical Oncologist, The Royal Marsden Hospital, London
1153-1155	Q&A
1155-1203	Is there a PRESIDENT for a UK-Based Trial: Evaluating the Role of Radical Prostatectomy in Low Volume Hormone-Sensitive Metastatic Prostate Cancer Prasanna Sooriakumaran, University College Hospital, London
1203-1205	Q&A
1205-1217	Highlights of the new NMIBC EAU Guidelines  Paolo Gontero, Professor of Urology, Chairman Department of Urology, Molinette Hospital, University School of Medicine, Torino, Italy
1217-1220	Q&A
1220-1226	Update from the I-DUNC Audit (Impact of Diagnostic Ureteroscopy on Radical Nephroureterectomy and Compliance with Standard Care Practices)  Bhavan Rai, Freeman Hospital, Newcastle
1226-1228	Q&A
1228-1230	Conclusion by Chairs

#### Hall 9

#### 1130-1230 Infections and UTI

Chairs: **Hari Ratan,** Nottingham University Hospitals and **Rashmi Singh,** Kingston Hospital, London

#### 1130-1140 **Pre-op Planning and Treatment**

**Annie Joseph,** Consultant Microbiologist, Nottingham University Hospitals



1140-1150	Fungal Infections Anna Wild, Specialist Registrar in Infectious Diseases & Microbiology, Nottingham University Hospitals
1150-1200	Future of UTI Research Zafer Tandogdu, University College Hospital, London
1200-1210	Upper Tract Instillation Rhana Zakri, Guy's & St Thomas' Hospitals, London
1210-1220	Small Stones and UTIs Angela Cottrell, Royal Devon and Exeter Hospital
1220-1230	Q&A

### 1130-1230 Everything You Need to Know to Manage Nonneurogenic Overactive Bladder Syndrome

Chairs: **Magda Kujawa**, Stepping Hill Hospital, Stockport and **Nicholas Faure Walker,** King's College Hospital, London

1130-1140	Assessment & Investigation Andy Kozan, St James's University Hospital, Leeds
1140-1150	Update on Medications Mehwash Nadeem, The James Cook University Hospital, Middlesbrough
1150-1200	Update on Botox Mahreen Pakzad, University College Hospital, London
1200-1210	Update on Neuromodulation Ased Ali, Pinderfields Hospital, Wakefield
1210-1220	Is There a Place for Bladder Augmentation in 2024? Simon Fulford, The James Cook University Hospital, Middlesbrough
1220-1230	Q&A

#### Hall 11A

### 1130-1230 Freedom to Speak Up...Or Not

Chairs: **Tony Tien,** Homerton University Hospital, London and **Radha Sehgal,** Royal Free Hospital, London

1130-1150	Whistleblowing and Being Heard - The Headlines That Shook Up the Country
	Ravi Jayaram, Consultant Paediatrician, Countess of Chester Hospital
1150-1210	The Aftermath from Whistleblowing - Lessons Learnt the Hard Way  Peter Duffy, ex-Consultant Urologist
1210-1230	Employment Law - Protecting Yourself and Your Career Shazia Khan, Cole Khan Solicitors LLP and Emilie Cole, Cole Khan Solicitors LLP



#### 1200-1230 The Urology Foundation Guest Lecture

Chairs: Mary Garthwaite, Chair of The Urology Foundation

#### **Welcome & Introduction**

Mary Garthwaite, Chair of The Urology Foundation

#### **Guest Speaker**

#### **Alfred Samuels**

In 2012, following a successful career in the entertainment industry spanning over 30 years, Alfred Samuels was diagnosed with advanced metastatic prostate cancer. He uses his life changing diagnosis to inspire and motivate men and their families, to challenge men's attitudes and the taboos surrounding prostate cancer and to champion the importance of research. Today Alfred is recognised and celebrated as a Patient Advocate, Author, Award Winning Documentary Filmmaker (A Survivor Amongst Survivors, 2021), Mentor and Inspirational Speaker. He has won 27 international awards, including at the London Cine Week and the Tokyo Short Film Fest.

#### 1230-1400 Lunch, Networking and Exhibition Viewing

Hall 1

1315-1400 Procept Biorobotics
Satellite Symposium

1437-1442

Q&A





See page 21 for details

Hall 4

## 1400-1500 Holistic Needs Assessment for People with Urological Cancer

Chairs: **Murthy Kusuma,** Royal Surrey Hospital, Guildford, **Helena Burden,** Southmead Hospital, Bristol and **Mary Brown,** Glasgow Royal Infirmary

1400-1402	Introduction by Chairs
1402-1417	Enhancing End-of-Life Care Pathways for Urological Malignancies Details to Follow
1417-1422	Q&A
1422-1437	Mitigating Treatment-Related Regret in Localized Prostate Cancer Patients: A Critical Analysis
	<b>Christopher Wallis,</b> Urologic Oncologist, Mount Sinai Hospital and Assistant Professor at the University of Toronto, Canada



1442-1448	Cardiovascular Well-Being in Men Undergoing Androgen Deprivation Therapy Kerem Atalar, Whipps Cross University Hospital, London
1448-1450	Q&A
1450-1456	Managing Small Renal Masses in Patients with Concurrent Illnesses or Elderly Patients: A Strategic Approach Alice Hartley, Sunderland Royal Hospital
1456-1458	Q&A
1458-1500	Conclusion by Chairs

### 1400-1500 Section of FNUU/AGUS/BAGURS Joint Session:

## Widen Your Horizons - Update on Stricture, Stenosis and Prosthetics

Chairs: **Ruth Doherty,** Norfolk and Norwich University Hospital and **Paul Anderson,** Russells Hall Hospital, Dudley

1400-1412	Bladder Neck Contracture Management Tony Mundy, University College Hospital, London
1412-1415	Q&A
1415-1427	Robotic VY Plasty for Bladder Neck Stenosis Benoît Peyronnet, University of Rennes, France
1427-1430	Q&A
1430-1500	Mx Complications of Prosthetics
1430-1442	Male AUS Complications and How to Manage Them Suzanne Biers, Addenbrooke's Hospital, Cambridge
1442-1445	Q&A
1445-1457	How to Manage Penile Prosthesis Complications Varun Sahdev, Southampton General Hospital
1457-1500	Q&A

#### Hall 9

#### 1400-1500 Update on PUJ Obstruction

Chairs: **Sandeep Pathak,** Consultant Radiologist, Barts Health NHS Trust, London and **Kim Davenport,** Cheltenham General Hospital

1400-1410	Radiology/Imaging in PUJO
	<b>Harry Bardgett,</b> Consultant Uro-radiologist, Bradford Teaching Hospitals NHS Trust
1410-1420	Conservative Management of PUJO
	Mohammed Aldiwani, Pinderfields General Hospital, Wakefield



Initial Management of Primary PUJO
 Muddassar Hussain, Frimley Park Hospital, London

 Surgical Management PUJO
 Anurag Golash, Royal Stoke University Hospital

 Q&A and Discussion

#### Hall 10

#### 1400-1500

## International British Urology Society (IBUS): Excellence and Empowering Solutions

Chairs: **Gokul Kandaswamy,** Morriston Hospital, Swansea and **Beenish Qamar,** Russells Hall Hospital, The Dudley Group NHS Foundation Trust

1400-1415 Cross-Cultural Insights in Urological Training and Patient Care: Bridging Practices Between India / South Asia and the UK

**Sanjay Kulkarni,** Endosurgery Institute, Pune, India and Past-President, Urological Society of India (USI)

1415-1430 Strategies for Winning National Clinical Excellence

**Awards: Optimizing Your CV** 

Naeem Soomro, Freeman Hospital, Newcastle

1430-1445 Navigating Intimidation, Bullying, and Harassment:

**Empowerment and Solutions** 

**Professor Geeta Menon,** National Clinical Director for Workforce for Cancer and Diagnostics, Senior Dean for Inclusive Integrated Careers

(Interim)- Workforce Training & Education Directorate, NHSE

1445-1450 **Q&A** 

1450-1500 PRISM Award 2024

#### Hall 11A

#### 1400-1500 Urolink

Chairs: **Suzie Venn,** University Hospitals Sussex NHS Foundation Trust and **Wilson To,** University College London Hospitals

Urolink Update
Suzie Venn, University Hospitals Sussex NHS Foundation Trust
 Opportunities for Advancing Surgical Practice in the Global South - the WISA Experience
Mumba Chalwe, Consultant Urological Surgeon, Ndola Teaching Hospital, Zambia and President of Women in Surgery Africa (WISA)
 Meditech Urogynae Workshop in Malawi Ala'a Sharaf, Addenbrooke's Hospital, Cambridge
 TUF Fellowship Experience

Wilson To, University College London Hospitals and Rory Ferguson,

Royal Cornwall Hospital, Truro

1450-1500 **Q&A** 



#### 1500-1530 Refreshments, Networking and Exhibition Viewing

#### Hall 1

#### 1530-1630 MDT Discussion

Chairs: **Vijay Ramani,** Wythenshawe Hospital, Manchester and **Tom Walton,** Nottingham City Hospital

#### **Panellists:**

**Imran Ahmad,** Queen Elizabeth University Hospital, Glasgow **Alison Tree,** Consultant Clinical Oncologist, The Royal Marsden Hospital, London

**Jose A. Karam,** MD Anderson Cancer Center, Texas, United States and Associate Secretary for Europe, Middle East and Africa, American Urological Association (AUA)

#### Hall 4

#### 1530-1630 What's New in Urology? Literature Overview

Chairs: Louise Paramore, University Hospital Southampton and Bhaskar Somani, Southampton General Hospital and Editor-in-chief JCU

1530-1538	Stones Benjamin Steen, Southern Health Care Trust, Northern Ireland
1538-1546	Benign Prostate Enlargement Zoe Panayi, Stockport NHS Foundation Trust
1546-1554	Upper Tract Urothelial Cancer, Pelvi-Ureteric Obstruction, Basic Research Xiang Wei Jonathan Lee, Queen Elizabeth University Hospital, Glasgow
1554-1604	Trials Update - PUrE  Daron Smith, University College Hospital, London and Oliver Wiseman, Addenbrooke's Hospital, Cambridge
1604-1619	Nephrostomy Audit Subu Subramonian, Queen Elizabeth University Hospital, Glasgow

#### Hall 8

#### 1530-1630 The Urology Foundation: Show Me the Money

Q&A

1619-1630

It's all about the money. We fundraise tirelessly so that we can support you, and the whole Urology community, to the ultimate benefit of Urology patients. The Urology Foundation alumni is extensive and ever growing. However, even if you haven't received direct assistance from us, you and your patients will be benefitting from a wealth of research and innovation supported by funding from The Urology Foundation.

The Urology Foundation welcomes you to a session that will look at how we use our fundraising to support and advance UK Urology. We will introduce our new 5-year research strategy, showcase our funding streams and the ways in which you have benefitted from them, highlight new funding opportunities, inform you on how to access these resources and how you can support us into the future.



Welcome and Overview  Mary Garthwaite, Chair of The Urology Foundation
The Urology Foundation Research Strategy 2024-2028 Rakesh Heer, Charing Cross Hospital, London
Stories from TUF Alumni - How Our Support Makes a Difference
A Current Perspective Samantha Conroy, Royal Hallamshire Hospital, Sheffield
A Retrospective View
Krishna Narahari, University Hospital of Wales, Cardiff
A Message from Overseas: The Malcolm Coptcoat Fellowship Eleanor Zimmermann, Derriford Hospital, Plymouth
BURST Collaborations
<b>Kevin Byrnes,</b> Barking, Havering and Redbridge University Trust and <b>Arjun Nathan,</b> Royal Free Hospital, London
Q&A
Chair: Mary Garthwaite, Chair of The Urology Foundation Panel: Ben Challacombe, Trustee of The Urology Foundation and Guy's & St Thomas' Hospitals, London Graeme McLennan, Director of the TUF Trials Unit
Louise de Winter, Director of Research & Grants, TUF Rakesh Heer, Charing Cross Hospital, London Samantha Conroy, Royal Hallamshire Hospital, Sheffield Eleanor Zimmermann, Derriford Hospital, Plymouth Krishna Narahari, University Hospital of Wales, Cardiff Kevin Byrnes, Barking, Havering and Redbridge University Trust Arjun Nathan, Royal Free Hospital, London

#### 1530-1630 The Papers that Changed Andrology in 2023

Chairs: **Ege Serefoglu,** Biruni University School of Medicine, Istanbul and **Paul Perito,** Perito Urology, Miami, United States and **Aditya Manjunath,** Southmead Hospital, Bristol

1530-1540 **Peyronie's Disease** 

Ameer Alarayedh, Guy's & St Thomas' Hospital, London and Raveen

**Sandher,** Guy's & St Thomas' Hospital

1540-1550 **Erectile Dysfunction** 

Christina Fontaine, Southmead Hospital, Bristol and Ayo Kalejaiye,

University Hospitals, Birmingham

1550-1600 Penile and Testis Cancer

Holly Ni Raghallaigh, St George's Hospital, London and Karen

Randhawa, Altnagelvin Area Hospital, Londonderry



1600-1610 Urethral Surgery

Eleanor Zimmerman, Derriford Hospital, Plymouth and Katie Moore,

Liverpool University Hospitals Foundation Trust

1610-1620 **Emergency Andrology** 

John Pascoe, Royal Devon & Exeter Hospital and Richard Pearcy,

University Hospitals Plymouth

1620-1630 Male Infertility

Theodora Stasinou, Manchester University Foundation Trust and Majid

Shabbir, Guy's & St Thomas' Hospital

#### Hall 10

#### 1530-1630 Innovation in Urology

Chairs: **Tamsin Greenwell,** University College Hospital, London and **Gianluca Maresca,** Western General Hospital, Edinburgh

1530-1533 Introduction by Chairs

1533-1548 Rise of the New Machines: Innovation in Clinical Robotic

**Technology** 

Ben Challacombe, Guy's & Thomas's Hospital

1548-1551 **Q&A** 

1551-1606 Urological Innovations in Emerging Countries: From Proof

of Concept to Reality

Zeeshan Hameed, Kasturba Medical College, Manipal, India

1606-1609 **Q&A** 

1609-1624 Impact of Digital Technology on Urology

Naeem Soomro, Freeman Hospital, Newcastle

1624-1630 **Q&A and Summary** 

#### Hall 11A

#### 1530-1630 **BURST**:

#### **Emergency Inpatient Haematuria - Time for Change!**

Chairs: **Nikita Bhatt,** Newcastle Upon Tyne Hospital, **Kevin Byrnes**, North Middlesex University Hospital London and **Ben Challacombe**, Guy's & Thomas's Hospital

1530-1540 WASHOUT: Ward Admission for Haematuria:

An Observational Multicentre Study

Nikita Bhatt, Newcastle Upon Tyne Hospital, Kevin Byrnes, North

Middlesex University Hospital London

1540-1625 The Quick-Fire MDT on Emergency Haematuria

**CEPOD Surgical Management: How and When to go to Theatre?** 

**John McGrath,** Royal Devon University Healthcare NHS Foundation

Trust

Hyperbaric Oxygen: Does it have a role in the emergency setting?

Thomas Lynch, St. James's Hospital and Trinity College, Dublin



When to Involve an Oncologist: Indications for Radiotherapy in the Acute Setting

**Amy Clifford,** Consultant Clinical Oncologist in Urological Cancers, The Royal Free Hospital, London

Interventional Radiology for Haematuria: Is it underutilised?
Conrad Von Stempel, Consultant Interventional Vascular and
Uroradiologist, University College London Hospital

End stage Surgical Strategies: Considerations for when

**End-stage Surgical Strategies: Considerations for when conservative measures fail** 

Jhumur Pati, Homerton University Hospital London

Round Table Case Discussion: The experts take on a difficult clinical case of emergency inpatient haematuria

Chair: Ben Challacombe, Guy's & Thomas's Hospital

Panel: All Faculty

1625-1630 The WASHOUT Study - Get Involved Now

Nikita Bhatt, Newcastle Upon Tyne Hospital, Kevin Byrnes, North

Middlesex University Hospital London

Hall 11B

#### 1600-1645 Medical Students in Urology

Chairs: **Ben Ayres,** St George's Hospital, London and **Holly Ni Raghallaigh,** St George's Hospital, London

1600-1615 Medical Student Essay: 'What is the Role of Artificial

Intelligence in Urology at Present and 'What Does the Future Hold?'

Details to Follow

1615-1620 Update on GMC Medical Licensing Assessment

Ben Ayres, St George's Hospital, London

1620-1630 Simulation Boot Camp for Medical Students

Thomas Fonseka, Urological Specialty Registrar, Royal Free Hospital,

London

1630-1640 The Benefits of Engaging with Medical Student Surgical

**Societies** 

James Akman, BSoT Medical Student Representative and Urological

Specialty Registrar, Royal Derby Hospital

1640-1645 The Benefits of Engaging with Medical Student Surgical

**Societies** 

Noor Haddad, St George's Surgical Society and Medical Student, St

George's Hospital, London

Elzbieta Gureviciute, St George's Surgical Society and Medical

Student, St George's Hospital, London

Konstantinos Devetzis, St George's Surgical Society and Medical

Student, St George's Hospital, London

Rebecca Beni, St George's Surgical Society and Medical Student, St

George's Hospital, London



### 1630-1730 Resilience and Sustainability of Complex Urooncological Procedures

Chairs: **Edgar Paez-Gueyraud,** Freeman Hospital, Newcastle, **Elizabeth Bright,** Royal Cornwall Hospital, Truro and and **Jon Aning,** Southmead Hospital, Bristol

1630-1632	Introduction by Chairs
1632-1645	Building a Thriving High-Volume Radical Cystectomy Program Matthew Perry, Royal Surrey Hospital, Guildford
1645-1647	Q&A
1647-1700	Balancing Surgeon Workloads: Considerations for On- Call Duties Among Complex High-Volume Procedure Specialists Rupesh Bhatt, Queen Elizabeth Hospital, Birmingham
1700-1702	Q&A
1702-1715	Mitigating Recruitment Challenges for Complex Urological Challenges Esther McLarty, Derriford Hospital, Plymouth
1715-1717	Q&A
1717-1726	Attracting the Next Generation of Surgeons to Excel in Complex Urological Procedures Omar El-Taji, Salford Royal Hospital
1726-1728	Q&A
1728-1730	Conclusion by Chairs

#### Hall 4 **1630-1730**

### **Common Dilemmas for the Endourology MDT**

Chairs: **Daron Smith,** University College Hospital, London and **Sara Ramsey,** Raigmore Hospital, Inverness

#### **Panel:**

**Sri Sriprasad,** Darent Valley Hospital, Kent **Jake Patterson,** Royal Hallamshire Hospital, Sheffield **Ninaad Awsare,** Whiston Hospital, Prescot **Hari Ratan,** Nottingham University Hospitals **Mo Sahu,** Queen Alexandra Hospital, Portsmouth



#### 1630-1730 Diversifying the Urology Workforce

Chairs: **Laura Thomas,** Clinical Scientist, Bristol Urological Institute and **Arun Sahai,** Guy's & St Thomas' Hospital, London

1630-1642 How Do We Optimise & Expand the Urology Workforce?

Mark Rochester, Norfolk and Norwich University Hospital

1642-1645 **Q&A** 

1645-1657 Does Every Urology Department Need a Clinical

**Scientist?** 

Eskinder Solomon, Consultant Clinical Scientist: Urology, Guy's & St

Thomas' Hospital, London

1657-1700 **Q&A** 

1700-1712 The Role of the ANP

Julie Jenks, Nurse Consultant, University College Hospital, London

1712-1715 **Q&A** 

1715-1727 Supporting Roles in the Acute Urology Setting

Jonathan Broughton, The James Cook University Hospital,

Middlesbrough

1727-1730 **Q&A** 

#### Hall 9

#### 1630-1730 Benign Andrology MDT

Chairs: Wai Gin (Don) Lee, University College Hospital, London and Vaibhav Modgil, Manchester Royal Infirmary

1630-1650 Peyronie's Disease - USA vs UK. Is it More Than a Ponds

Difference?

Case Presenter:

Katherine Guest, King's College Hospital, London

Panel:

**Asif Muneer,** University College Hospital, London **Chi-Ying Li,** Whipps Cross University Hospital, London

Paul Perito, Perito Urology, Miami, United States

1650-1710 The Infertile Man

Case Presenter:

Tet Yap, Guy's & St Thomas' Hospital, London

Panel:

Pippa Sangster, University College Hospital, London

Alex Lewis, Manchester University NHS foundation trust

(Endocrinologist)

Justin Chu, Birmingham Woman Hospital, Reproductive Medicine

consultant and lecturer with an interest in MFI

1710-1730 Gotta Get Up to Get Down- Erectile Dysfunction

Case Presenter: Rowland Rees, University Hospital Southampton

Panel:

**Suks Minhas,** Charing Cross Hospital, London **Maria Satchi,** Kings College Hospital, London **Paul Perito,** Perito Urology, Miami, United States



### 1630-1730 Section of SAS and Trust Urologists (SSTU)

Chairs: **Kathryn Bandeira de Mello,** Executive Committee Member, SSTU and Wycombe General Hospital, High Wycombe and **SS Murali,** Chair, SSTU and Lincoln County Hospital

1630-1635	Introduction
1030 1033	<b>Kathryn Bandeira de Mello,</b> Executive Committee Member, SSTU and Wycombe General Hospital, High Wycombe
1635-1643	The Evolution of the BAUS STU Section
	<b>Jo Cresswell,</b> President of BAUS and James Cook University Hospital, Middlesbrough
1643-1651	SSTU - BAUS' Vision for the Future
	lan Pearce, Vice-President of BAUS and Manchester Royal Infirmary
1651-1659	STUs Aspiring to Get onto the Specialist Register via the Portfolio Pathway
	Adham Ahmed, Vice-Chair SSTU and West Suffolk Hospital
1659-1707	STUs Aspiring to Become Specialists in the 2021 SAS Contract
	<b>Avinash Deodhar,</b> Specialist, Burns & Plastic Surgery, University Hospitals of Leicester NHS Trust
1707-1715	STUs Aspiring to be Designated as Autonomous Practitioner, as Specialty Doctors
	<b>Govindaraj Rajkumar,</b> Executive Committee Member, SSTU and Basingstoke and North Hampshire Hospital
1715-1720	Next Steps
	SS Murali, Chair, SSTU and Lincoln County Hospital
1720-1730	Q&A and Panel Discussion

#### Hall 11A 1630-1730

#### **Urology in the Age of Artificial Intelligence in Urology**

Chairs: **Joseph Gabriel,** Royal Surrey Hospital, Guildford and **Bushra Abdelqader,** St George's Hospital, London

1630-1650	The Future of Urology Training in the era of Artificial Intelligence
	Luis Ribeiro, Croydon University Hospital, Surrey
1650-1710	Deployment of AI in a Real-World Setting
	<b>Xiao Liu,</b> Clinician Scientist, AI and Digital Health Technologies and Ophthalmologist, University Hospitals Birmingham
1710-1730	Implementing Artificial Intelligence into Clinical Practice - How to Get it Tight?
	Details to Follow



#### Hall 11B

### 1645-1730 Foundation Years and Core Trainees in Urology

Chairs: **Kasra Saeb-Parsy,** Cambridge University Hospital, **Sophia Cashman,** Nottingham City Hospital and **Alexander Light,** Charing Cross Hospital

1645-1650	FY/CT Audit QuIP Competition Introduction Kasra Saeb-Parsy, Cambridge University Hospital
1650-1655	Presentation of the wining Audit QuIP Competition Details to Follow
1655-1705	Making a Surgeon: My Experience in the FY/CT Years Marena Gray, Peterborough City Hospital
1705-1715	Beyond the Cystoscope: Scripting your Life in FY/Core Training Nick Boxall, Sheffield Teaching Hospitals
1715-1725	Research and Early Career Urologist - Why and What For? Vincent Gnanapragasam, Cambridge University Hospital

1725-1730 Closing Remarks

Kasra Saeb-Parsy, Cambridge University Hospital

Hall 1

1730-1800 Boston Scientific Satellite Symposium



See page 21 for details

#### **TUESDAY 25 June ePosters**



Hall 4

osoo-osoo ePoster 1: Renal Cancer / Testis Cancer / Sarcoma

Chairs: **William Green,** Nottingham City Hospital & **Faith McMeekin,** Cheltenham General Hospital

Please see page 71 for the ePosters

Hall 8

o800-0900 ePoster 2: Stones / Imaging / Upper Tract Disorders 1

Chairs: **Marco Bolgeri,** St George's Hospital, London & **Suzanne Dunk,** Queen Elizabeth Hospital, Birmingham

Please see page 73 for the ePosters

Hall 9

o800-0900 ePoster 3: Female Urology and Bladder Dysfunction

Chairs: **James Moore**, Eastbourne District General Hospital and **Voula Granitsioti**, Western General Hospital, Edinburgh

Please see page 75 for the ePosters

Hall 10

o800-0900 ePoster 4: Andrology, Genitourethral Reconstruction,

Infertility & Male Genital Cancers

Chairs: **Susan Wong,** Manchester Royal Infirmary and **Michelle Christodoulidou,** Chelsea & Westminster Hospital, London

Please see page 77 for the ePosters

Hall 11A

osoo-osoo ePoster 5: Uro-technology /Artificial Intelligence &

**Urology Apps** 

Chairs: **Details to Follow** and **Sanjay Rajpal**, Airedale Hospital

Please see page 79 for the ePosters

Hall 11B

osoo-osoo ePoster 6: Management/Governance/Education/

**Quality Improvement 1** 

Chairs: **Brian Duggan,** The Ulster Hospital, Belfast and **Sarah Howles,** Churchill Hospital, Oxford

Please see page 81 for the ePosters

# TIMETO CHALLENGE



**EXPECTATIONS IN METASTATIC CASTRATION-RESISTANT** PROSTATE CANCER TREATMENT

LYNPARZA (olaparib) in combination with abiraterone and prednisone or prednisolone is NICE-recommended for the treatment of mCRPC in adults, where chemotherapy is not clinically indicated<sup>1,2</sup>



## Are you challenging mCRPC with LYNPARZA?

Visit LYNPARZA.co.uk to find out more.



#### 2 year median rPFS

(24.8 vs 16.6 months; HR 0.66 (95% CI: 0.54-0.81); p<0.001) (LYNPARZA + abiraterone vs placebo + abiraterone)<sup>3,4</sup>



#### A generally well-tolerated safety profile

when prescribed at the full dose for each individual drug (olaparib and abiraterone)3,5-7

**Great Britain Prescribing Information** 

**Northern Ireland Prescribing Information** 

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca (UK) by visiting <a href="https://contactazmedical.astrazeneca.com">https://contactazmedical.astrazeneca.com</a> or by calling 0800 783 0033.

LYNPARZA tablets are indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. LYNPARZA tablets are indicated as monotherapy for the treatment of adult patients with mCRPC and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included

a new hormonal agent.

**Abbreviations:** BRCA=BReast CAncer gene: CI=confidence interval: HR=hazard ratio: mCRPC=metastatic castration-resistant prostate cancer: rPFS=radiological progression-free survival.

#### References:

1. Olaparib with abiraterone for untreated hormone relapsed metastatic prostate cancer. NICETA951. February 2024. Available at https://www.nice.org.uk/guidance/ta951/resources/olaparib-with-abiraterone-foruntreated-hormonerelapsed-metastatic-prostate-cancer-pdf-82615723963333. Accessed February 2024. 2. LYNPARZA (olaparib), Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/9488/smpc#about-medicine. Accessed February 2024. 3. Clarke N, et al. N Engl J Med Evid. 2022. doi:https://doi.org/10.1056/EVIDoa2200043. 4. Saad F, et al. Presented at ASCO GU Annual Meeting 2022. 17–19 February. San Francisco, US. Oral Abstract 1. 5. Saad F, et al. Lancet Oncol. 2023;24:1094–1108. 6. Clarke N, et al. Presented at ASCO GU 2023. 16–18 February. San Francisco, US. Abstract #LBA16. 7. Thiery-Vuillemin A, et al. Presented at ASCO Annual Meeting 2022. 3-7 June. Chicago, US. Abstract 5019.

For UK healthcare professionals only.

This promotional asset has been fully developed and funded by AstraZeneca and MSD.





## **WEDNESDAY 26 JUNE**

#### **PROGRAMME**



Hall 1

**AstraZeneca MSD Satellite Symposium** 0900-0930

See page 22 for details





Hall 1

Widening Participation: Sex Matters 0930-1030

> Chairs: Ian Eardley, Leeds Teaching Hospital Trust and Susan Willis, Guy's & St Thomas' Hospital, London and Mumba Chalwe, Consultant Urological Surgeon, Ndola Teaching Hospital, Zambia and President of Women in Surgery Africa (WISA)

**How Surgeon Sex Influences Patient Outcomes** 0930-0945

Christopher Wallis, Urologic Oncologist, Mount Sinai Hospital and

Assistant Professor at the University of Toronto, Canada

0945-0950 Q&A

**Breaking the Silence: Sexual Misconduct in Surgery** 0950-1005

Carrie Newlands, Author of 'Breaking the Silence' and Co-Lead of the

Working party on Sexual misconduct in Surgery

1005-1010 Q&A

Supporting Colleagues: How to be an Active Bystander 1010-1025

Susan Willis, Guy's & St Thomas' Hospital, London

Q&A 1025-1030

Hall 1

**BAUS Guest Lecture:** 1030-1100

> Surgeons as High-Performance Athletes; Learning from a Triple World Champion

Chairs: Hrishi Joshi, University Hospital of Wales, Cardiff and Sophie Rintoul-Hoad, Epsom General Hospital, Surrey

Colin Jackson CBE, Triple World Champion Sprinter & Hurdling Athlete

Hall 1

**AGM** 1100-1130

> Chair: Jo Cresswell, President of BAUS and James Cook University Hospital, Middlesbrough

The AGM Agenda will be available to Members via the BAUS website.

1100-1130 Refreshments, Networking and Exhibition Viewing



#### 1130-1200 JCU Guest Lecture

Chair: Bhaskar Somani, Southampton General Hospital and Editor-in-chief JCU,

**Sanjay Kulkarni,** Endosurgery Institute, Pune, India and Past-President, Urological Society of India (USI)

Hall 4

#### 1130-1300 Controversies in Uro-Oncology

Chairs: **Vishwanath Hanchanale**, Liverpool University Hospitals Foundation Trust, **Jo Cresswell**, President of BAUS and James Cook University Hospital, Middlesbrough and **Jim Armitage**, Addenbrooke's Hospital, Cambridge

1100-1102	Introduction by Chairs
1102-1115	TRANSFORMing Prostate Cancer Screening-The Time Has Come Hashim Ahmed, Charing Cross Hospital, London
1115-1117	Q&A
1117-1130	Should We Be Performing Lymph Node Dissection for High Risk RCCs Axel Bex, Royal Free Hospital, London
1130-1132	Q&A
1132-1145	Pelvic Lymph Node Dissection in Prostate Cancer: The Debate Continues  Krishna Narahari, University Hospital of Wales, Cardiff
1145-1147	Q&A
1147-1200	Management of Persistent Low Grade Bladder Recurrences Despite Previous Intravesical Therapy with MMC and BCG Paolo Gontero, Professor of Urology, Chairman Department of Urology, Molinette Hospital, University School of Medicine, Torino, Italy
1200-1202	Q&A
1202-1215	Should Molecular Imaging Replace Conventional Imaging in the Staging of Advanced Urothelial Cancer Prashant Patel, University College Hospital, London
1215-1217	Q&A
1217-1226	Can we SCREEN for Cytoreductive Nephrectomy in Patients with Metastatic Renal Cancer  Jose A. Karam, MD Anderson Cancer Center, Texas, United States and Associate Secretary for Europe, Middle East and Africa, American Urological Association (AUA)
1226-1228	Q&A

**Conclusion by Chairs** 

1228-1230



#### 1130-1300

# BAUS & ESIU Joint Session: Navigating the Future of Urology: Tackling Antimicrobial Resistance and Redefining the Surgeon's Role

Chairs: **Zafer Tandogdu,** University College Hospital, London and **Mehwash Nadeem,** The James Cook University Hospital, Middlesbrough

Join us for an engaging session tailored for urologists at this year's conference, where we confront the pressing threat of Antimicrobial Resistance (AMR) in urology. Delve into the emerging consequences of AMR on urological procedures and gain practical insights into employing antimicrobial stewardship in clinical practice. Explore strategies for de-escalating antibiotic usage in antimicrobial prophylaxis specifically tailored for urological procedures. Dive into the exciting realm of emerging solutions, focusing on the potential of bacteriophages in urology as a novel approach to tackle AMR. Additionally, gain valuable insights into the DEEP-URO study, an international endeavor shaping the future of antimicrobial prophylaxis in urology. Don't miss this comprehensive exploration of the multifaceted challenges posed by AMR and the innovative tools and studies paving the way for a resilient and proactive urological practice.

1130-1135	Introduction & Welcome Zafer Tandogdu, University College Hospital, London
1135-1150	The Threat of AMR in Urology and Emerging Consequences  Bhaskar Somani, Southampton General Hospital and Editor-in-chief JCU
1150-1205	Tools That Clinicians Can Use in Their Clinical Work to Implement Antimicrobial Stewardship Effectively Philip Howard, Consultant Pharmacist in Antimicrobials, Leeds Teaching Hospitals NHS Trust
1205-1220	Emerging Strategies to Tackle AMR: Bacteriophages and Their Potential in Urology Details to Follow
1220-1230	DEEP-URO Study: An International Study in Setting Up the Future in Antimicrobial Prophylaxis Elizabeth Day, University College Hospital, London
1230-1245	Antibiotics in Urosepsis: Personalization vs Protocolization Details to Follow
1245-1300	Debate: What Are the Next Steps as the Urology Community We Need to Take in Tackling AMR?  All Speakers and Audience



## 1130-1300 Section of Endourology & FNUU Joint Session: Ureteric Stricture Management

Chairs: **Suzanne Biers,** Addenbrooke's Hospital, Cambridge and **Sri Sriprasad,** Darent Valley Hospital, Kent

1130-1142	REJOIN Audit Update 2024 Findlay MacAskill, Guy's & St Thomas' Hospital, London
1142-1145	Q&A
1145-1157	Endoscopic Management of Ureteric Strictures Alistair Rogers, Freeman Hospital, Newcastle
1157-1200	Q&A
1200-1212	An Alternative to Endoscopic Management in Robotic Buccal Mucosal Grafting Raj Nair, Guy's & St Thomas' Hospital, London
1212-1215	Q&A
1215-1227	Open Urinary Tract Reconstruction - Is It Still Relevant in 2024  Voula Granitsioti, Western General Hospital, Edinburgh
1227-1230	<b>Q&amp;A</b> MDT of Challenging Cases
1230-1237	Uretero-ileal Stenosis Joe Philip, BAUS Honorary Secretary and Southmead Hospital, Bristol
1237-1240	Q&A
1240-1247	Impact of Endometriosis on the Ureter Nikesh Thiruchelvam, Addenbrooke's Hospital, Cambridge
1247-1250	Q&A
1250-1257	Radiotherapy Impact on Upper Tracts and Tetroperitoneal Fibrosis Muhammad Shamim Khan, Guy's & St Thomas' Hospital, London
1257-1300	Q&A

Hall 10

## UroAl: Navigating the Future of Urology with Artificial Intelligence

Chairs: **Ivo Dukic,** Queen Elizabeth Hospital, Birmingham and **Ayo Kalejaiye,** University Hospitals, Birmingham

1130-1145 **Demystifying Al: Do we truly grasp its fundamentals?** 

**Jim Smith,** Department of Computer Science and Creative Technologies, University of the West of England, Bristol

1145-1155 **GPT inUrology: What's All the Chat About?** 

Anthony Noah, University College Hospital, London

#### **WEDNESDAY 26 June**



1155-1215	Revolutionising Prostate Cancer Care: The European Association of Urology's Cutting Edge AI and Big Data Initiatives  James N'Dow, Aberdeen Royal Infirmary
1215-1230	Empowering Urological Expertise: Advancing Training with Al Driven Solutions  Zeeshan Hameed, Kasturba Medical College, Manipal, India
1230-1250	Navigating the AI Era: Are We Embracing It Prematurely? Governance and Legal Implications Bjoern von Siemens, Founder of Caresyntax
1250-1300	Q&A

### Hall 11A

### 1130-1300 Future Directions for Urologists

Chairs: **Sarika Nalagatla,** Chair of BSoT and University Hospital Monklands and **Mark Yao**, Darent Valley Hospital, Kent

1130-1200	Future Specialist Consultant Practice - Are Fellowships Essential? - The Debate Ben Starmer, Royal Liverpool University Hospital Mohammed Aldiwani, Pinderfields General Hospital, Wakefield
1200-1220	Infertility and Pregnancy Issues Among Doctors Laura Hopper, ST7 in Obstetrics and Gynaecology, Princess Royal University Hospital
1220-1230	BAUS Section of Trainees (BSoT) - Vision and Mission Sarika Nalagatla, Chair of BSoT and University Hospital Monklands
1230-1250	The Urology Curriculum and BSoT Surveys
1230-1240	Emergency Urology Operative Experience Omer Abdalla, Arrowe Park Hospital, Wirral
1240-1250	Urology Special Interest Module  Joseph Gabriel, Royal Surrey Hospital, Guildford
1250-1300	Silver and Bronze Cystoscope Awards

#### Hall 1

### 1200-1300 Reducing Risk, Patient Safety & Team Performance

Chairs: **Suresh Venugopal,** Royal Liverpool University Hospital and **Yasmin Abu Ghanem,** Guy's and St Thomas Hospital, London

1200-1202	Introduction
1202-1218	<b>Professional Interactions and Impact on Patient Safety</b>
	<b>Neal Jones,</b> Director of Patient Safety, Royal Liverpool University Hospital

#### **WEDNESDAY 26 June**



1218-1234 **Team Culture and Developing a High Performing Team** 

Tom Briggs, Manager, McLaren Formula 1 Team

1234-1250 Reducing Risk - Lesson from a Self-Reporting System

(Confidential Reporting and CHIRP - Confidential Human

**Factors Incident Reporting Programme)** 

Magnus McCabe, Senior International Affairs Manager, NATS (National

Air Traffic Services)

1250-1257 **Q&A** 

1257-1300 Concluding Remarks

#### 1300-1400 Lunch, Networking and Exhibition Viewing

Hall 1

#### 1330-1400 BD Satellite Symposium



See page 22 for details

Hall 1

#### 1400-1500 Who will Deliver the Urology Service in 2040?

Chairs: **Ben Turney,** Churchill Hospital, Oxford and **Susannah La Touche,** St George's Hospital, London

1400-1405 Introduction & Audience Poll

1405-1420 Revamping Training Programs to Train More Urologists:

The Key to Addressing Urologist Shortages

Catherine Hobbs, Churchill Hospital, Oxford

1420-1435 Optimizing Urology Care: Transitioning to Office/

**Diagnostic Specialists and Subspecialist Surgeons** 

Tharani Mahesan, East Surrey Hospital, Redhill

1435-1450 Enhancing Urological Care: Leveraging Non-Medical Staff

for Diagnostic Services and Less Complex Procedures

William Britnell, University Hospitals Sussex

1450-1500 **Q&A, Audience Poll & Summary** 

Hall 4

## Section of FNUU & Oncology Joint Session: Urinary Diversion: Realm of the Functional Oncologist?

Chairs: **Vishwanath Hanchanale,** Liverpool University Hospitals Foundation Trust and **Hazel Ecclestone,** Te Whatu Ora Taranaki, New Zealand

1400-1430 Continent Urinary Diversion - Robotic vs Open

1400-1410 **Case for Open** 

James Catto, Royal Hallamshire Hospital, Sheffield

#### **WEDNESDAY 26 June**



1410-1420	Case for Robotic
	John Kelly, University College Hospital, London
1420-1430	Debate
1430-1500	Complications MDT (Case Presentation)
	• LUTS & Incontinence
	• Fistula
	Cancer Recurrence
	Tamsin Greenwell, University College Hospital, London and Rosie
	<b>Blades,</b> Royal Preston Hospital
1500-1515	Incontinent Diversion - New Techniques, Decision Making and Management of Complications in Ileal Conduit  James Dyer, Stepping Hill Hospital, Stockport
1500-1515 1515-1530	Incontinent Diversion - New Techniques, Decision Making and Management of Complications in Ileal Conduit
	Incontinent Diversion - New Techniques, Decision Making and Management of Complications in Ileal Conduit  James Dyer, Stepping Hill Hospital, Stockport  Continent Catheterisable Channels - Mitrofanoffs and

#### Hall 8

## Surgeon Sustainability - The Importance of Surgical Ergonomics

Chairs: **Angus Luk**, Freeman Hospital, Newcastle upon Tyne and **Charlotte Gunner,** Raigmore Hospital, Inverness

1400-1402	Introduction Angus Luk, Freeman Hospital, Newcastle upon Tyne
1402-1414	Surgical Ergonomics: More Than Just Your Office Chair Esther Moss, Associate Professor in Gynaecological Oncology, University of Leicester
1414-1426	The Cost of an Injured Surgeon Details to Follow
1426-1438	Physiotherapists' Perspective on Incorporating Surgical Ergonomics in your Practice Seth O'Neil, Physiotherapy Lecturer, University of Leicester
1438-1450	Practical Ergonomic Tips and Future Developments to Increase Nikhil Vasdev, Lister Hospital
1450-1500	Q&A and Panel Discussion



#### 1400-1500 Genital Cancer MDT

Chairs: **Duncan Summerton**, Leicester General Hospital and **David Hendry**, Queen Elizabeth University Hospital, Glasgow

1400-1420 Penile Cancer

Case Presenter:

Anna Mainwaring, Morriston Hospital, Swansea

Panel:

Ben Ayres, St George's Hospital, London

**Amarnath Challapalli,** Consultant Clinical Oncologist, University Hospitals Bristol and Weston NHS Foundation Trust (UHBW)

Anna Mainwaring, Morriston Hospital, Swansea

1420-1430 **Q&A and Discussion** 

1430-1450 **Testis Cancer** 

Case Presenter: Aziz Gulamhusein, The Christie & Manchester

University Hospitals NHSFT

Panel:

David Nicol, Royal Marsden Hospital, London

**Robert Huddart,** Clinical Academic Radiotherapy Team, The Institute of Cancer Research, London and Honorary Consultant in Urological

Oncology, The Royal Marsden NHS Foundation Trust

Aziz Gulamhusein, The Christie & Manchester University Hospitals

**NHSFT** 

1450-1500 **Q&A and Discussion** 

Hall 11A

## The Great BURST Debate: Finding Solutions to the Big Controversies in Urology

Chairs: **Veeru Kasivisvanathan,** University College Hospital, London and **Hannah Warren,** Royal Free Hospital, London

1400-1430 **Debate 1: Improving the Pathway in Testicular Torsion in** 

the UK: More than a Pipe Dream?

1400-1410 The RESCUE Study: Rapid Evaluation with Scrotal

**Ultrasound Prior to Scrotal Exploration** 

Hannah Warren, Royal Free Hospital, London and Cameron Alexander,

Colchester General Hospital

1410-1430 "Ultrasound is the Answer to Reducing High Negative

**Scrotal Exploration Rates**"

For: Milan Gopal, Consultant Paediatric Urologist, Great North

Children's Hospital, Newcastle Upon Tyne

Against: Caroline MacDonald, Sheffield Children's NHS Foundation

Trust

1430-1500 **Debate 2: Anticoagulation in The Postoperative Period:** 

**How Do We Get the Balance Right?** 



The ARTS Study in the UK: Avoiding Risks of Thrombosis and Bleeding in Surgery
 Alexander Ng, The Royal Free Hospital London and Aqua Asif,
 University College London, London
 "Minimally Invasive Surgery means we are now overutilising Anticoagulation in the Post-op Urological Patient"
 For: Kari Tikkinen, University of Helsinki and Helsinki University Hospital
 Against: Alexandra Colquhoun, Addenbrooke's Hospital, Cambridge
 The ARTS Study: How Do I Get Involved?
 Alexander Ng, The Royal Free Hospital London

#### Hall 1 **1500-1700**

#### What's New in Urology & Best of BAUS

Chairs: **Nadine McCauley,** University Hospital of Wales, Cardiff and **Ian Pearce,** Vice-President of BAUS and Manchester Royal Infirmary

1500-1512	BPH/LUTS and Paediatric Urology Ben Dreyer, Victoria Hospital, Kirkcaldy
1512-1524	Functional Urology Andy Kozan, St James's University Hospital, Leeds
1524-1536	Bladder Cancer & Upper Tract Urothelial Cancer Sarah Prattley, University Hospital of Wales, Cardiff
1536-1548	Benign Andrology, Urethroplasty and Infertility Adnan Ahmad, Royal Glamorgan Hospital
1548-1600	<b>Testis and Penile Cancer Abdullah Zreik,</b> Queen Elizabeth University Hospital, Glasgow
1600-1612	Renal Cancer and Retro-Peritoneal Fibrosis Sarika Nalagatla, Chair of BSoT and University Hospital Monklands
1524-1536	Bladder Cancer & Upper Tract Urothelial Cancer Sarah Prattley, University Hospital of Wales, Cardiff
1612-1624	Urolithiasis Suzanne Dunk, Queen Elizabeth Hospital, Birmingham
1624-1636	Prostate Cancer- Diagnostics  Eoin Dinneen, Homerton University Hospital
1636-1648	Prostate Cancer- Management Johann Boaz, Charing Cross Hospital
1648-1700	Uro-technology/Artificial Intelligence/Imaging/ Innovation
	<b>James Akman,</b> BSoT Medical Student Representative and Urological Specialty Registrar, Royal Derby Hospital

#### **WEDNESDAY 26 June ePosters**



Hall 4

osoo-osoo ePoster 7: Bladder Cancer: Muscle & Non-Muscle

**Invasive** 

Chairs: **Jayne Douglas Moore,** Leicester General Hospital and **James Douglas,** University Hospital Southampton

Please see page 83 for the ePosters

Hall 8

o800-0900 ePoster 8: Stones / Imaging / Upper Tract Disorders 2

Chairs: **Kay Thomas,** Guy's & St Thomas' Hospital, London and **Matthew Clark,** Royal Preston Hospital

Please see page 85 for the ePosters

Hall 9

osoo-osoo ePoster 9: Prostate Cancer 1

Chairs: **Ashwin Sachdeva,** The Christie NHS Foundation Trust, Manchester and **Catherine Hobbs,** Churchill Hospital, Oxford

Please see page 87 for the ePosters

Hall XXXX

o800-0930 ePoster 10: TUF-BAUS Best of the Regions

Chairs: Details to Follow

Please see page 89 for the ePosters

Hall 11A

0800-0900 ePoster 11: General Urology

Chairs: **Matthew Thomas,** Diana, Princess of Wales Hospital, Grimsby and **Melissa Davies,** Salisbury District Hospital

Please see page 91 for the ePosters

Hall 11B

o800-0900 ePoster 12: Management/Governance/Education/

**Quality Improvement 2** 

Chairs: **Shabi Ahmad,** Sandwell District General Hospital, West Bromwich and **Details to Follow** 

Please see page 93 for the ePosters

Hall 9

1400-1500 ePoster 13: Prostate Cancer 2

Chairs: Rohit Chahal, Bradford Royal Infirmary and Flora Rodger, Queen Elizabeth University Hospital, Glasgow

Please see page 95 for the ePosters





WHEN ELIGIBLE PATIENTS PRESENT WITH A PSA DOUBLING TIME ≤ 10 MONTHS,13\*

## THINK HIGH-RISK nmCRPC AND HELP EXTEND WHAT'S IMPORTANT<sup>1-3</sup>

NUBEQA® (darolutamide) is a second-generation AR inhibitor that in combination with ADT can help you extend MFS and OS† in high-risk nmCRPC, with low rates of treatment discontinuation due to adverse events (Nubeqa + ADT 8.9% vs placebo + ADT 8.7%) It can help to maintain QoL too. 1-3

Nubeqa + ADT significantly prolonged the time to deterioration of FACT-P PCS versus placebo + ADT (HR 0.80, 95% CI 0.70-0.91; P = 0.0005)



#### SAFETY PROFILE:

The most common adverse reactions in nmCRPC patients receiving darolutamide was fatigue/asthenic conditions (15.8%). The most common serious adverse reactions were ischaemic heart disease (1.9%), urinary retention (1.6%), pneumonia (1.4%), haematuria (1.0%) and heart failure (1.0%).3

NUBEQA is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease or with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.

ADT: androgen deprivation therapy; AE: Adverse event; AR: androgen receptor; MFS: metastasis free survival; nmCRPC: non-metastatic castration resistant prostate cancer; PSA: prostate specific antigen; OS: overall survival; QoL: quality of life.

\*nmCRPC is defined as no radiological evidence of metastatic disease, a rising PSA concentration and a PSA doubling time of ≤10 months.5

 $^{\dagger}$ Median MFS for NUBEQA + ADT was 40.4 months (n=955) and 18.4 months for placebo + ADT (n=554) (HR: 0.41; 95% CI: 0.34-0.50; p<0.001). At 3 years, NUBEQA + ADT significantly reduced the risk of death by 31% vs. placebo + ADT (83% vs. placebo + AD 77%; HR: 0.69; 95% CI: 0.53-0.88; p=0.003). A secondary endpoint was overall survival (OS). OS for Nubeqa was 78/955 and 58/554 (HR 0.71 (95% CI 0.50-0.99) p=0.045).2

References: 1. Fizazi K et al. N Engl J Med. 2019;380 [13]:1235-1246. 2. Fizazi K et al. N Engl J Med. 2020;383:1040-1049. 3. NUBEGA (darolutamide) Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/11324/smpc (Accessed February 2024). 4. Smith MR et al. Eur J Cancer. 2021;154:138-146. 5. Comford P et al. Euro Uro. 2021;79: 263-282. 6. NICE. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer. to 104761. 2020. Available at https://www.nice.org.uk/guidance/gid-la10476/documents/final-appraisal-determination-document (Accessed February 2024). 7. SMC. Darolutamide 300 mg film-coated tablets (Nubeqa@). SMC2297. November 2020. Available at https://www.scottishmedicines.org.uk/media/5563/darolutamide-nubeqa-final-october-2020-for-website.pdf (Accessed February 2024).

Be in the know at: oncology.bayer.co.uk

Or scan the QR code. This links to a Bayer promotional website.



NUBEQA®

(darolutamide) 300 mg tablets

NUBEQA® (darolutamide) 300 mg film-coated tablets Prescribing Information – Great Britain (Refer to full Summary of Product Characteristics (SmPC) before prescribinal

Presentation: Each film-coated tablet contains 300 mg of darolutamide. Indication(s): NUBEQA is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing disease or with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel. **Posology & method of administration**: Treatment should be initiated and supervised by a specialist physician experienced in treatment of prostate cancer. Medical castration with a luteinising hormone- releasing hormone (LHRH) analogue should be continued during treatment of patients not surgically castrated. For oral use. The tablets should be taken whole with food. Adults: 600 mg darolutamide (two tablets of 300 mg) taken twice daily, equivalent to a total daily dose of 1200 mg. mHSPC patients should start darolutamide in combination with docetaxel. The first of 6 cycles of docetaxel should be administered within 6 weeks affer the start of darolutamide treatment. Treatment with darolutamide should be continued until disease progression or unacceptable toxicity even if a cycle of docetaxel is delayed, interrupted, or discontinued. If a patient experiences a ≥ Grade 3 toxicity or an intolerable adverse reaction related to darolutamide, dosing should be withheld or reduced to 300 mg twice daily until symptoms improve. Treatment may then be resumed at a dose of 600 mg twice daily. Children & adolescents: There is no relevant use of darolutamide in the paediatric population. Eldenly: No dose adjustment is necessary. Renal Impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m²) not receiving haemodialysis, the recommended starting dose is 300 mg twice daily. **Hepatic Impairment**: No dose adjustment is necessary for patients with mild hepatic impairment. The available data on darolutamide pharmacokinetics in moderate hepatic impairment is limited. Darolutamide has not been studied in patients with severe hepatic impairment. For patients with moderate and severe hepatic impairment (Child-Pugh Classes B and C), the recommended starting dose is 300 mg twice daily. Contra- indications: Hypersensitivity to the active substance or to any of the excipients Women who are or may become pregnant. Warnings & precautions: How me draws substance or to any or the excipients. Women who are or may become pregnant. Warnings & precautions: Monitor for signs and symptoms of ischaemic heart disease. Optimise management of cardiovascular risk factors. Discontinue darolutamide for Grade 3-4 ischaemic heart disease. Seizure occurred in patients receiving darolutamide. Advise patients of the risk of developing a seizure while receiving darolutamide. Consider discontinuation of darolutamide in patients who develop a seizure during treatment. Cases of idiosyncratic drug-induced liver injury (DILI) with increases in alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) to ≥5 and ≥20 x upper limit of normal (ULN) have been reported. Idiosyncratic DILI has been reported in clinical trials and the post-marketing setting. Liver function test abnormalities were reversible upon darolutomide discontinuation. In case of liver function test abnormalities suggestive of idiosyncratic drug-induced liver injury, permanently discontinue darolutamide. The available data in patients with severe renal impairment are limited. As exposure might be increased those patients should be closely monitored for adverse reactions. The available data in patients with moderate hepatic impairment are limited, and darolutamide has not been studied in patients with severe hepatic impairment. As exposure might be increased those patients should be closely monitored for adverse reactions. Patients with clinically significant cardiovascular disease in the past 6 months including stroke, myocardial infarction, severe/ unstable angina pectoris, coronary/peripheral artery bypass graft, and symptomatic congestive heart failure were excluded from the clinical studies. Therefore, the safety of darolutamide in these patients has not been established. Use of strong CYP3A4 and P- gp inducers during treatment with darolutamide may decrease the plasma concentration of darolutamide and

less potential to induce CYP3A4 or P-gp should be considered. Patients should be monitored for adverse reactions of BCRP. OATP1B1 and OATP1B3 substrates as co-administration with darolutamide may increase the plasma concentrations of these substrates. Co-administration with rosuvastatin should be avoided unless there is no therapeutic alternative. In patients with a history of risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval, physicians should assess the benefit-risk ratio including the potential for Torsade de pointes prior to initiating NUBEQA. NUBEQA 300mg film-coated tablets contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose galactose malabsorption should not take this medicinal product. Interactions: For the effect of other medicinal products on the action of darolutamide (e.g. CYP3A4, P-gp inducers and CYP3A4, P-gp and BCRP inhibitors, UGT1A9 inhibitors and docetaxel) and the action of darolutamide on other medicinal products (BCRP, OATP1B1, OATP1B3 substrates, P-gp substrates, docetaxel, and ine datation and autonominate of other inedictional products (BCRP, OATP1B1, OATP1B3 substrates, P-gp substrates, docetaxel, CYP3A4 substrates and other medicinal products that prolong the QT interval) refer to the relevant SmPCs. **Pregnancy & lactation**: Darolutamide is not indicated in women of childbearing potential, and it is not to be used in women who are, or may be, pregnant or breast-feeding. Unknown whether darolutamide or its metabolites are present in semen. If the patient is engaged in sexual activity with a woman of childbearing potential, a highly effective contraceptive method (<1% failure rate per year) should be used during and for 1 week after completion of treatment. Unknown whether darolutamide or its metabolites are excreted in human milk. No studies in animals have been conducted to evaluate the excretion of darolutamide or its metabolites into milk. A risk to the breast-fed child cannot be excluded. There are no human data on the effect of darolutamide on fertility. Based on animal studies, darolutamide may impair fertility in males of reproductive potential. **Effects on ability to drive and use** animal studies, adroiterinde may impair terminy in males of reproductive potential. Literas or adminy to arrive and use machines. Darolutamide has no or negligible influence on the ability to drive and use machines. Undesirable effects:

Adverse reactions observed in patients with nmCRPC Very common: fatigue/asthenic conditions, neutrophil count decreased, bilirubin increased, AST increased. Common: ischaemic heart disease, heart failure, rash, pain in extremity, musculoskeletal pain, fractures. Serious adverse reactions: urinary retention, pneumonia, hematuria, seizure. Adverse reactions observed in patients with mHSPC treated with darolutamide in combination with docetaxel. Very common hypertension, rash, blood bilirubin increased, ALT increased, AST increased. Serious adverse reactions: fractures, ischaemic heart disease, seizure, febrile neutropenia, neutrophil count decreased, pneumonia. Prescribers should consult the SmPC in relation to other side effects (see section 4.8 of SmPC). Overdose: In the event of intake of a higher than recommended dose, treatment with darolutamide can be continued with the next dose as scheduled. There is no specific antidote for darolutamide and symptoms of overdose are not established. Legal Category: POM. Package Quantities & Basic NHS Costs: Pack of 112 film - coated tablets, £4,040. MA Number(s): PLGB 00010/0677. Further information available from: Bayer plc, 400 South Oak Way, Reading RG2 6AD, United Kingdom. Telephone: 0118 206 3000. Date of ration: November 2023

NUBEQA® is a trademark of the Bayer Group

Adverse events should be reported. Reporting forms and information can be found at <a href="https://yellowcard.mhra.gov.uk">https://yellowcard.mhra.gov.uk</a> or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Bayer plc.
Tel: 0118 206 3500, Fax: 0118 206 3703, Email: pvuk@bayer.com

### **EPOSTER SESSIONS**



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Tuesday 25 June, 0800-0900, Hall 4

#### **ePoster Session 1:**

### **Renal Cancer / Testis Cancer / Sarcoma**

Chairs: William Green, Nottingham City Hospital & Faith McMeekin, Cheltenham General Hospital

# P1-1 A retrospective cohort study demonstrating the utility of systemic anti-cancer treatment (SACT) to reduce venous tumour thrombus size in patients with T3b+ renal cell carcinoma (RCC) from the Scottish Renal Cancer Consortium (ScotRCC)

Mr Gianluca Maresca<sup>1</sup>, Dr Kay McGillivray<sup>2</sup>, Mr Saad Siddiqui<sup>3</sup>, Mr. James Donaldson<sup>3</sup>, Mr Grenville Oades<sup>2</sup>, Ms Flora Rodger<sup>2</sup>, Mr Alex Chapman<sup>4</sup>, Mr Alexander Laird<sup>1</sup>

<sup>1</sup>Western General Hospital, Edinburgh, United Kingdom, <sup>2</sup>Queen Elizabeth University Hospital, Glasgow, United Kingdom, <sup>3</sup>Aberdeen Royal Infirmary, Aberdeen, United Kingdom, <sup>4</sup>Victoria Hospital, Kirkaldy, Fife, United Kingdom

#### P1-2 Staging CT chest for cT1a renal masses: does it change management?

<u>Dr Sanjana Ilangovan</u><sup>1</sup>, Miss Hannah Warren, Dr Thet Paing, Dr Pyae Phyo Tun, Mr Prasad Patki, Mr. Faiz Mumtaz, Mr. Ravi Barod, Mr. Axel Bex, Miss Maxine Tran

<sup>1</sup>Royal Free Hospital London NHS Trust, London, United Kingdom

## P1-3 Radiomics and artificial intelligence in predicting heterogeneity and tumour grade in renal cell carcinoma: comparison with percutaneous biopsy

Miss Abeer Al-hussaini, Professor Douglas Steele, Dr Neil Kernohan, Professor Ghulam Nabi <sup>1</sup>University of Dundee, Dundee, United Kingdom

## P1-4 Evaluation of clinicopathological features and outcomes of squamous cell carcinoma of renal pelvis in a single tertiary care center

<u>Dr Aruj Shah</u><sup>1</sup>, Dr Victor Coelho<sup>1</sup>, Dr Abhishek Singh<sup>1</sup>, Dr Arvind Ganpule<sup>1</sup>, Dr Ravindra Sabnis<sup>1</sup>, Dr Mahesh Desai<sup>1</sup>

<sup>1</sup>Muljibhai Patel Urological Hospital (MPUH), Nadiad, India

## P1-5 The role of biopsy in small renal masses <4cm: A European Modified Delphi Consensus Statement

Mr Darryl Bernstein<sup>1</sup>, Ms Hannah Warren<sup>1</sup>, Mr Joseph Santiapillai<sup>1</sup>, Ms Geraldine Fox<sup>2</sup>, Professor Tze Wah<sup>3</sup>, Dr Riccardo Campi<sup>4</sup>, Professor Axel Bex<sup>1</sup>, Mr Ravi Barod<sup>1</sup>, Professor Kurinchi Gurusamy<sup>5</sup>, Professor Maxine Tran<sup>1</sup>, Wildgoose WH, Stewart GD, Armitage J, Le Roux P, Keeley Jr FX, Campain N, Challacombe B, Warburton H, Palumbo C, Muselaers CHJ, Yu D, Oliveira P, Calio A, El-Sheikh S et al. et al.

<sup>1</sup>Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom, <sup>2</sup>Kidney Cancer UK, Surrey, United Kingdom, <sup>3</sup>The Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom, <sup>4</sup>Unit of Urologic Robotic, Minimally-Invasive Surgery and Renal Transplantation of Careggi University Hospital, Florence, Italy, <sup>5</sup>Division of Surgery and Interventional Science, University College London, London, United Kingdom

## P1-6 Concordance between renal tumour biopsy and robotic-assisted partial and radical nephrectomy pathology; a 10-year experience

<u>Dr Anushree Kucheria</u><sup>1</sup>, Dr Catherine Ogbechie<sup>1</sup>, Dr Sana Adam, Mr Andrew Brodie<sup>1</sup>, Dr Anushree Kucheria<sup>1</sup>, Mr Ben Pullar<sup>1</sup>, Mr Jim Adshead<sup>1</sup>

<sup>1</sup>Lister Hospital, Stevenage, United Kingdom



## P1-7 Active Surveillance for the T1a Renal Mass is effective and safe: A retrospective data analysis

Mr Darryl Bernstein<sup>1</sup>, Mr Mehar Bijral<sup>2</sup>, Miss Shira H Dworkin<sup>2</sup>, Mr Hao Gao<sup>2</sup>, Mr Keval Patel<sup>2</sup>, Miss Thiara Rupasinghe<sup>2</sup>, Mr Chandran Tanabalan<sup>3</sup>, Professor Axel Bex<sup>1</sup>, Mr Ravi Barod<sup>1</sup>, Professor Maxine Tran<sup>4</sup>, Warren H, Santiapillai J, Grant L, Walkden M, Etessami N, Tran-Dang M, El-Sheikh S, Patki P, Mumtaz F et al. et al.

<sup>1</sup>Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, London, United Kingdom, <sup>2</sup>University College London, London, United Kingdom, <sup>3</sup>Northampton General Hospital, Northamptonshire, United Kingdom, <sup>4</sup>Division of Surgery and Interventional Science, London, United Kingdom

#### P1-8 Malignancy Rate of Bosniak 3 and 4 Complex Renal Cystic Lesions

Mr Abhishek Reekhaye<sup>1</sup>, Mrs Kathryn Brown<sup>1</sup>, Mrs Joanne Oakley<sup>1</sup>, Mr Harbinder Sharma<sup>1</sup>, Mr Amr Emara<sup>1</sup>, Mr Manar Malki<sup>1</sup>, Mr Neil Barber<sup>1</sup>, Mr Muddassar Hussain<sup>1</sup>
<sup>1</sup>Frimley Park Hospital, Frimley, United Kingdom

## P1-9 Patient outcomes following surgical treatment of retroperitoneal sarcoma in a tertiary centre

Mr Mark Hanson, Mr George Hill<sup>1</sup>, Mr Tim Whittlestone, Mr Salah Al-Buheissi, Mr Ahmed Mahrous <sup>1</sup>North Bristol Nhs Trust, Bristol, United Kingdom

## P1-10 Malignant progression outcomes of Bosniak graded renal cysts in the modern era of better imaging and uro-radiology subspecialisation

<u>Dr Francesca Speck</u><sup>1</sup>, Dr Egiz Abdullah<sup>1</sup>, Mr Barnaby Barrass<sup>1</sup>, Dr Ramkumar Somasundaram<sup>1</sup>, Mr Faroog Khan<sup>1</sup>, Mr Anish Pushkaran<sup>1</sup>

<sup>1</sup>Bedfordshire Hospitals NHS FT (Luton & Dunstable Site), Luton, United Kingdom



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Tuesday 25 June, 0800-0900, Hall 8

#### **ePoster Session 2**

#### Stones / Imaging / Upper Tract Disorders 1

Chairs: **Marco Bolgeri,** St George's Hospital, London & **Suzanne Dunk,** Queen Elizabeth Hospital, Birmingham

P2-1 Offering primary extracorporeal shockwave lithotripsy for ureteric stones, should high skin to stone distance and high density dissuade treatment decisions?

Mr Saad Siddiqui<sup>1</sup>, Mr Abhilash Cheriyan<sup>1</sup>, Ms Anna Longshaw<sup>1</sup>, Ms Catriona Campbell<sup>1</sup>, Dr Mark Gandhi<sup>1</sup>, Mr Nicholas Cohen<sup>1</sup>, Mr Ismail El-Mokaddem<sup>1</sup>

<sup>1</sup>Aberdeen Royal Infirmary, Aberdeen, United Kingdom

P2-2 Streamlining the management of small distal ureteric stones using a Stone MDT and virtual clinic approach - Is it safe to discharge small distal ureteric stones with patient initiated follow up?

Mr Saad Siddiqui<sup>1</sup>, Mr Abhilash Cheriyan<sup>1</sup>, Ms Anna Longshaw<sup>1</sup>, Ms Nicola Little<sup>1</sup>, Dr Mark Gandhi<sup>1</sup>, Mr Nicholas Cohen<sup>1</sup>, Mr Ismail El-Mokkadem<sup>1</sup>

<sup>1</sup>Aberdeen Royal Infirmary, Aberdeen, United Kingdom

P2-3 Virtual biopsy in upper tract urothelial cancers: radiomics and machine learning approach

Mr Abdulsalam AL Qahtani, Mr Abdulrahman Al-mopti, Dr Neil Kernohan, Professor Ghulam Nabi

<sup>1</sup>University of Dundee, DUNDEE, United Kingdom

P2-4 Multi-centre study comparing outcomes of retrograde intrarenal surgery (RIRS) using traditional suction ureteral access sheath (SUAS) and flexible-navigable suction UAS (FANS)

<u>Dr Carlotta Nedbal</u><sup>1</sup>,<sup>6</sup>, Dr Vineet Gauhar<sup>2</sup>, Dr Chloe Shu Hui Ong<sup>2</sup>, Dr Ben Hall Chew<sup>3</sup>, Dr Ho Yee Tiong<sup>2</sup>, Dr Chin Tiong Heng<sup>2</sup>, Dr Nariman Gadzhiev<sup>4</sup>, Dr Jeremy Yuen-Chun Teoh<sup>5</sup>, Dr Daniele Castellani<sup>6</sup>, Prof Olivier Traxer<sup>7</sup>, Prof Bhaskar Kumar Somani<sup>1</sup>

<sup>1</sup>University Hospitals Southampton, NHS Trust, Southampton, United Kingdom, <sup>2</sup>Ng Teng Fong General Hospital, National University Health Systems, Singapore, Singapore, <sup>3</sup>University of British Columbia, Vancouver, Canada, <sup>4</sup>Pavlov First Saint Petersburg State Medical University, Saint- Petersburg, Russian Federation, <sup>5</sup>The Chinese University of Hong Kong, Hong Kong, China, <sup>6</sup>Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy, <sup>7</sup>Sorbonne University, Hôpital Tenon, Paris, France

P2-5 24 hours after Retrograde intrarenal surgery for solitary renal calculi using a Flexible And Navigable Suction access sheath (FANS): Results from a prospective global multicentre study by the EAU section on urolithiasis (EULIS)

<u>Dr Carlotta Nedbal</u><sup>1,2</sup>, Dr Vineet Gauhar<sup>3</sup>, Khi Yung Fong<sup>4</sup>, Dr Saeed Bin Hamri<sup>5</sup>, Dr M.I Gokce<sup>6</sup>, Dr M Corrales<sup>7</sup>, Dr Soebhali Boyke<sup>8</sup>, Dr Deepak Ragoori<sup>9</sup>, Dr V Malkhasyan<sup>10</sup>, Dr K Tan<sup>11</sup>, Prof Bhaskar Kumar Somani<sup>1</sup>

<sup>1</sup>University Hospitals Southampton, NHS Trust, Southampton, United Kingdom, <sup>2</sup>Urology Unit, Azienda Ospedaliero-Universitaria delle Marche, Università Politecnica delle Marche, Ancona, Italy, <sup>3</sup>Ng Teng Fong general hospital, Singapore, Singapore, <sup>4</sup>Yong Loo Lin School of Medicine National University of Singapore, Singapore, Singapore, Singapore, Singapore, Sopecialised medical center, urology, Riyadh, Saudi Arabia, <sup>6</sup>Ankara University, School of Medicine, Ankara, Turkey, <sup>7</sup>Sorbonne University Tenon, Paris, France, <sup>8</sup>Abdul Wahab Sjahranie Hospital Medical Faculty Mulawarman University, East Java, Indonesia, <sup>9</sup>Asian Institute of Nephrology and Urology, Hyderabad, India, <sup>10</sup>Moscow State University of Medicine and Dentistry Urology Unit, Moscow, Russia, <sup>11</sup>Veterans Memorial Medical Center, Qezon City, Philippines



#### P2-6 Analysis of tube placement in a totally tubeless PCNL practice

Mr Leo Kretzmer<sup>1</sup>, Dr Muhammed Haris Saleem, Dr Ragaul Rajagopal, Dr Gulzar Dhanoya, Dr Aisha Awil, Dr Freya Harding, Mr Mohammed Kamil Quraishi, Mr Simon Mackie <sup>1</sup>Eastbourne District General Hospital, Eastbourne, United Kingdom

#### P2-7 Day-case mini percutaneous nephrolithotomy (mini-PCN): A feasibility study

Mr Sadeesh Hewa Kodikarage<sup>1</sup>, Ms Meghana NarayanaswamyRamachandra<sup>1</sup>, Mr YC Phan<sup>1</sup>, Ms Samantha Farrington<sup>1</sup>, Mr Carl Rowbotham<sup>1</sup>, Mr Andreas Auer<sup>1</sup>, Mr Mohamed Ismail<sup>1</sup> Portsmouth Hospital University Nhs Trust, Porttsmouth, United Kingdom

### P2-8 Is prophylaxis required for all patients undergoing flexible cystoscopy and ureteric stent removal in the age of antibiotic stewardship?

<u>Dr Helen Massy</u><sup>1</sup>, Mr Sean Marshall-Kellie<sup>1</sup>, Mr Alexander MacInnes<sup>1</sup>, Dr Christoph Schregel<sup>1</sup>, Mr Matthew Shaw<sup>1</sup>, Mr Christopher Harding<sup>1</sup>, Mr Alistair Rogers<sup>1</sup>

<sup>1</sup>Freeman Hospital, Newcastle Upon Tyne, United Kingdom

#### P2-9 Preoperative Urine culture vs Renal Pelvic Urine culture: A better predictor of urosepsis in patients undergoing percutaneous nephrolithotomy

<u>Dr Nagabhairava Manu Kaushik</u><sup>1</sup>, Dr Mylarappa Yashas, Dr Sampathirao Gopal, Dr Thimmegowda Manasa, Dr P Sandeep, Dr Mylarappa Prasad, Dr J Tarun, Dr D Ramesh, Dr Kulkarni Abhishek

<sup>1</sup>Ms Ramaiah Hospital, Bengaluru, India

### P2-10 Paediatric percutaneous nephrolithotomy: Predictors of outcomes and validation of pre-treatment scoring systems

Mr Sudhindra Jayasimha<sup>1</sup>, Dr Selvin Theodore Jayanth<sup>1</sup>, Mr Rajadoss M Pandian<sup>1</sup>, Dr J Chandrasingh<sup>1</sup>

<sup>1</sup>Christian Medical College Vellore, Ranipet campus, Ranipet, India



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Tuesday 25 June. 0800-0900, Hall 9

#### **ePoster Session 3**

#### Female Urology and Bladder Dysfunction

Chairs: **James Moore,** Eastbourne District General Hospital and **Voula Granitsiotis,** Western General Hospital, Edinburgh Hospital

## P3-1 9 year analysis of the efficacy, longevity and safety of the Adjustable Transobturator Male System® (ATOMS) in managing Stress Urinary Incontinence (SUI) in men

<u>Dr Axelle Lavigne</u><sup>1</sup>, Dr Sinead Rosser<sup>1</sup>, Mr Stephen Foley<sup>1</sup>, Mr Bob Yang<sup>1</sup> Royal Berkshire Hospital, Reading, United Kingdom

### P3-2 Radiotherapy in men with post prostatectomy incontinence - before or after artificial urinary sphincter insertion?

Mr Bogdan Toia<sup>1</sup>, Ms Kelly Ong<sup>1</sup>, Mr Richard Nobrega<sup>1</sup>, Mr Anthony Noah<sup>1</sup>, Ms Helena Gresty<sup>1</sup>, Ms Mahreen Pakzad<sup>1</sup>, Mr Jeremy Ockrim<sup>1</sup>, Ms Tamsin Greenwell<sup>1</sup>

<sup>1</sup>University College London Hospitals, London, United Kingdom

#### P3-3 Effective Psychological Interventions for Functional Urological Disorders: Outcomes from the Urology Psychology Service Pilot

<u>Miss Rebecca Adam</u><sup>1</sup>, Dr Lynda Teape<sup>1</sup>, Miss Suzanne Biers<sup>1</sup>, Miss Felicity Reeves<sup>1</sup>, Mr Nikesh Thiruchelvam<sup>1</sup>

<sup>1</sup>Addenbrooke's Hospital, Cambridge, United Kingdom

#### P3-4 A review into the current status of paediatric urology transition services in the UK

Ms Charlotte Hughes<sup>1</sup>, Ms Katherine Kitchener<sup>2</sup>, Ms Joanne Parr<sup>2</sup>, Ms Stephanie Jeary<sup>1</sup>, Ms Lucy Watson<sup>2</sup>, Ms Charlotte Dunford<sup>1</sup>, Mr Ravindar Anbarasan<sup>2</sup>, Mr Azad Mathur<sup>2</sup>, Mr Milind Kulkarni<sup>2</sup> Department of Urology, Norfolk & Norwich University Hospital, Norwich, United Kingdom, <sup>2</sup>Department of Paediatric Surgery, Jenny Lind Children's Hospital, Norfolk & Norwich University Hospital, Norwich, UK

### P3-5 Intravesical Gentamicin: Is it the new Gold Standard to manage Refractory Urinary Tract Infections? - Experience from a dedicated complex UTI clinic

Miss Pragnitha Chitteti<sup>1</sup>, Mr Inyang Ekpeno, Miss Jayne Morris- Laverick, Miss Stephanie Bezemer, Dr Igor Kubelka, Dr Victoria McCune, Miss Mehwash Nadeem, <u>Dr James Leighton</u><sup>2</sup> 'South Tees NHS Hospitals Foundation Trust, Middlesbrough, United Kingdom, <sup>2</sup>The Newcastle Upon Tyne Hospitals NHS Foundation Trust

## P3-6 Medical-grade Manuka honey and a sugar-free Manuka honey extract inhibit allergic IgE-induced mast cell degranulation: Potential role as intravesical agents in Interstitial Cystitis/ Bladder Pain Syndrome (BPS/IC)

<u>Dr Omar Abdelwahab</u><sup>1</sup>, Mr Oliver Miller<sup>3</sup>, Professor Bashir Lwaleed<sup>1</sup>, Honorary Associate Professor Brian Birch<sup>2</sup>

<sup>1</sup>School of Health Sciences, University of Southampton, Southampton, United Kingdom, <sup>2</sup>University Hospital Southampton NHS FT, Southampton, United Kingdom, <sup>3</sup>Faculty of Medicine, University of Southampton, Southampton, United Kingdom



## P3-7 Efficacy and Safety of Oral Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection: Results of Two Randomised, Multicentre Phase 3 Trials (EAGLE-2and EAGLE-3)

<u>Prof. Florian Wagenlehner</u><sup>1</sup>, Dr Caroline Perry<sup>2</sup>, Prof. Thomas M. Hooton<sup>3</sup>, Ms Nicole E. Scangarella-Oman<sup>2</sup>, Dr Helen Millns<sup>4</sup>, Dr Hwa-ping (Ed) Feng<sup>2</sup>, Dr Marcy Powell<sup>2</sup>, Ms Emily Jarvis<sup>4</sup>, Dr Jeremy Dennison<sup>5</sup>, Dr Amanda J. Sheets<sup>2</sup>, Ms Deborah Butler<sup>2</sup>, Mr John Breton<sup>2</sup>, Dr Salim Janmohamed<sup>5</sup>

<sup>1</sup>Justus-Liebig-University, Giessen, Germany, <sup>2</sup>GSK, Collegeville, USA, <sup>3</sup>University of Miami, Miami, USA, <sup>4</sup>GSK, Stevenage, UK, <sup>5</sup>GSK, Brentford, UK

### P3-8 Management of Female Urethral Strictures (FUS) with Ventral-onlay buccal mucosa graft substitution urethroplasty (VOBMG) - Is this the best treatment?

Mr Efstathios Papaefstathiou<sup>1</sup>, Mr Brendan Berry<sup>1</sup>, Mr Ala'a Sharaf<sup>1</sup>, Ms Amna Butt<sup>1</sup>, Mr Richard Nobrega<sup>1</sup>, Mr Anthony Noah<sup>1</sup>, Ms Helena Gresty<sup>1</sup>, Ms Mahreen Pakzad<sup>1</sup>, Mr Jeremy Ockrim<sup>1</sup>, Ms Tamsin Greenwell<sup>1</sup>

<sup>1</sup>UCLH, London, United Kingdom

#### P3-9 Robotic ureteric reimplantation for benign disease in a tertiary UK centre: safe and effective

Mr Samuel Folkard<sup>1</sup>, Miss Martina Spazzapan<sup>1</sup>, Dr Harry Sharples<sup>1</sup>, Dr Lucy Chapman<sup>1</sup>, Mr Calum Clark<sup>1</sup>, Mr Shamim Khan<sup>1</sup>, Mr Raj Nair<sup>1</sup>, Mr Sachin Malde<sup>1</sup>, Mr Arun Sahai<sup>1</sup>
<sup>1</sup>Guy's Hospital, London, United Kingdom

# P3-10 Urethral pressure profile (UPP) and external urethral sphincter electromyography (EUS-EMG) in the diagnostic pathway of women with idiopathic non-obstructive urinary retention (NOUR): are they necessary before a trial of sacral nerve stimulation (SNS)?

Mr Alejandro Mercado-Campero<sup>1</sup>, Dr Marc Furrer<sup>1</sup>, Miss Habiba Yasmin<sup>1</sup>, Mr Richard Nobrega<sup>1</sup>, Mr Anthony Noah<sup>1</sup>, Ms Helena Gresty<sup>1</sup>, Mr Jeremy Ockrim<sup>1</sup>, Prof Jalesh Panicker<sup>1</sup>, Ms Tamsin Greenwell<sup>1</sup>, Ms Mahreen Pakzad<sup>1</sup>

<sup>1</sup>University College London Hospitals Nhs Foundation Trust, London, United Kingdom



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Tuesday 25 June, 0800-0900, Hall 10

#### **ePoster Session 4**

## Andrology, Genitourethral Reconstruction, Infertility & Male Genital Cancers

Chairs: **Susan Wong,** Manchester Royal Infirmary and **Michelle Christodoulidou,** Chelsea & Westminster Hospital, London

#### P4-1 Clinical Pathway for Painful Nocturnal Erections (PNE): A Prospective Single-Centre, Observational Cohort Study

Mr Ameer Alarayedh<sup>1</sup>, Mohamed Gad<sup>1</sup>, Kenji Tomita<sup>1,2</sup>, Celina J Pook<sup>1,2</sup>, Muza Rexford<sup>1</sup>, Igualada-Martinez Paula<sup>1</sup>, Colette Pollard<sup>1</sup>, Arunan Sujenthiran<sup>1</sup>, Joerg Steier<sup>1,3</sup>, Tet Yap<sup>1</sup>

<sup>1</sup>Guy's and St Thomas' NHS Foundation Trust, United Kingdom, <sup>2</sup>GKT School of Medical Education, King's College, United Kingdom, <sup>3</sup>Faculty of Life Sciences and Medicine, King's College, United Kingdom

### P4-2 Exploring the Complexities of Problematic Pornography Use: An Unveiling of Its Impact on Mental and Sexual Health

Mr Ibrahim Samy<sup>1,2</sup>, Miss Nadine Elshafei<sup>3</sup>, Mr Tet Yap<sup>1</sup>

<sup>1</sup>Guy's And St Thomas' Nhs Trust, London, United Kingdom, <sup>2</sup>Cairo University Hospitals, Cairo, Egypt, <sup>3</sup>American University in Cairo, Cairo, Egypt

#### P4-3 Phentolamine and Aviptadil as second-line injection therapy for refractory erectile dysfunction

Mr Abdullah Al-Mitwalli<sup>1</sup>, Ms F Holden<sup>1</sup>, Mr G Chiriacò<sup>1</sup>, Mr D Ralph<sup>1</sup>, Mr WG Lee<sup>1</sup> <sup>1</sup>University College London Hospital, London, United Kingdom

# P4-4 Comparing Chlorhexidine 0.05% Antiseptic Monotherapy to Conventional Combined Antibiotic Irrigation During Penile Prosthesis Implantation: A Two-Center Prospective Randomized Controlled Non-Inferiority Study (Preliminary Data)

Mr Elsayed Desouky<sup>1</sup>, Mr Peter Tsambarlis<sup>1</sup>, Mr Laurence A. Levine<sup>1</sup> Rush University Medical Center, Chicago, United States

### P4-5 The use of CircCurer™ Stapler Circumcision in Adults in the United Kingdom: first large case series

Dr Ruhul Amin<sup>1</sup>, Dr Samuel Ghani<sup>1</sup>, Mr Matthew Liew<sup>2</sup>

 $^1$ Circumcision Pro, London, United Kingdom,  $^2$ Liverpool University Hospitals NHS Foundation Trust, , Liverpool, UK

#### P4-6 The impact of microfluidic sperm selection on Assisted Reproductive outcomes

Mr Ibrahim Samy<sup>1,4</sup>, Mr Yau Thum<sup>2</sup>, Mr Tim Bracewell-Milnes<sup>2</sup>, Mr Suks Minhas<sup>3</sup>, Mr Jonathan Ramsay<sup>2</sup>, Mr Tet Yap<sup>1</sup>

<sup>1</sup>Guy's And St Thomas' NHS Trust, London, United Kingdom, <sup>2</sup>The Lister Hospital HCA, London, United Kingdom, <sup>3</sup>Imperial College Hospital, London, United Kingdom, <sup>4</sup>Cairo University Hospitals, Cairo, Egypt



#### P4-7 Factors associated with gonadal recovery in men stopping anabolicandrogenic steroids

<u>Dr Anjali Pradeep</u><sup>1</sup>, Mr John Campbell<sup>2</sup>, Miss Anjali Pradeep<sup>1</sup>, Angela D. Burns<sup>3</sup>, Mr Paul Bassett<sup>4</sup>, Dr Ali Abbara<sup>1</sup>, Dr Priyardarshi Saket<sup>2</sup>, Professor Sukhbinder Minhas<sup>5</sup>, Professor James McVeigh<sup>6</sup>, Dr Channa Jayasena<sup>1</sup>, et al.,

<sup>1</sup>Section Of Investigative Medicine, Imperial College London, London, United Kingdom, <sup>2</sup>Glasgow Alcohol & Drug Recovery Services, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom, <sup>3</sup>Department of Clinical Biochemistry, Queen Elizabeth University Hospital, Glasgow, United Kingdom, <sup>4</sup>Statsconsultancy Ltd, Bucks, United Kingdom, <sup>5</sup>Department of Urology, Charing Cross Hospital, London, United Kingdom, <sup>6</sup>Department of Sociology, Manchester Metropolitan University, Manchester, United Kingdom

#### P4-8 A prospective audit evaluating the efficacy of Optilume balloon dilation of bulbar urethral strictures

Mr Muhesh Taheem, Miss Holly Ni Raghallaigh, Miss Pareeta Patel, Professor Nicholas Watkin <sup>1</sup>Epsom & St Helier University Hospitals, London, United Kingdom, <sup>2</sup>St. George's University Hospitals NHS Foundation Trust, London, United Kingdom

## P4-9 Comparison of oncological outcomes and survival between video endoscopic and open inguinal lymph node dissection for penile cancer over a 15-year period

Miss Ranya Vardini Kumar<sup>1</sup>, Professor Krishna Sethia<sup>2</sup>, Mr Vivekanandan Kumar<sup>2</sup>
<sup>1</sup>University Of Cambridge, The School Of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, United Kingdom, <sup>2</sup>Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom

### P4-10 Optimising surveillance imaging in high risk nodal (N+) penile cancer: proposal of an updated surveillance protocol

Mr Thomas Kynaston<sup>1</sup>, Mr Benjamin Ayres<sup>1</sup>, Professor Nicholas Watkin<sup>1</sup>, Miss Sylvia Yan<sup>1</sup>, Mr Michael Ager<sup>2</sup>, Dr Angela Pathmanathan<sup>3</sup>

<sup>1</sup>St Georges University Hospitals NHS Trust, London, United Kingdom, <sup>2</sup>Charing Cross Hospital, London, United Kingdom, <sup>3</sup>Royal Marsden Hospital, London, United Kingdom



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Tuesday 25 June, 0800-0900, Hall 11A

# ePoster Session 5 Uro-technology /Artificial Intelligence & Urology Apps

Chairs: Details to Follow and Sanjay Rajpal, Airedale Hospital

### P5-1 Novel Patient Information Video - a pilot study assessing feasibility and appetite for shared decision-making to enhance the surgical consent process

Mr Ankur Mukherjee<sup>1</sup>, Miss Pragnitha Chitteti<sup>1</sup>, Mr Raj Gowda<sup>1</sup>, Mr Abdalla Deb<sup>1</sup>, Mr Gianmarco Isgro<sup>1</sup>, Mr Brian Chaplin<sup>1</sup>

<sup>1</sup>The James Cook University Hospital, South Tees NHS Trust, Middlesbrough, United Kingdom

#### P5-2 Revolutionizing patient information and enhanced consent in Urology - The impact of simulation and multimedia tools

<u>Dr Carlotta Nedbal</u><sup>1,2</sup>, Dr Patrick Juliebø-Jones<sup>3</sup>, Dr Eamonn Rogers<sup>4</sup>, Dr Clara Cerrato<sup>1</sup>, Dr James N'Dow<sup>5</sup>, Dr Maria Ribal<sup>6</sup>, Dr Jens Rassweiler<sup>7</sup>, Dr Evangelos Liatsikos<sup>8</sup>, Dr Hein Van Poppel<sup>9</sup>, Prof Bhaskar Kumar Somani<sup>1</sup>

<sup>1</sup>Southampton University Hospital, Southampton, United Kingdom, <sup>2</sup>Azienda Ospedaliero-Universitaria delle Marche, Polytechnic University of Le Marche, Ancona, Italy, <sup>3</sup>Haukeland University Hospital, Bergen, Norway, <sup>4</sup>University College Hospital, Galway, Ireland, <sup>5</sup>University of Aberdeen, Aberdeen, UK, <sup>6</sup>Hospital Clinic, University of Barcelona, Barcelona, Spain, <sup>7</sup>Danube Private University (DPU), Krems-Stein, Austria, <sup>8</sup>University of Patras, Greece, <sup>9</sup>KU Leuven, Leuven, Belgium

### P5-3 Artificial Intelligence Versus Human Touch : Can Artificial Intelligence Accurately Generate A Litterature Review On Laser Technologies ?

<u>Dr Frederic Panthier</u><sup>1</sup>, Dr Alberto Melchionna<sup>1</sup>, Dr Hugh Crawford-Smith<sup>1</sup>, Mrs Daniela Velinova<sup>1</sup>, Ms Ikran Mohamed<sup>1</sup>, Ms Siobhan Price<sup>1</sup>, Dr Simon Choong<sup>1</sup>, Dr Vimoshan Arumuham<sup>1</sup>, Dr Sian Allen<sup>1</sup>, Dr Daron Smith<sup>1</sup>

Department of Urology, Westmoreland Street Hospital, UCLH NHS Foundation Trust, London, United Kingdom

### P5-4 Evaluating the performance of an AI Large Language Model (ChatGPT-4) in the classification of CT kidney ureter and bladder (KUB) radiology reports

<u>Dr Habeeb Abdulrasheed</u><sup>1</sup>, Mr Waleed Elsayed<sup>1</sup>, Mr Ivo Dukic<sup>1</sup>

<sup>1</sup>Heartland Hospital, University Hospital Birmingham NHS Trust, Birmingham, United Kingdom

## P5-5 A Machine Learning (ML) Predictive Model for Ureteroscopy lasertripsy (URSL) Outcomes in a Paediatric Population - Results from a large Endourology Tertiary Centre

<u>Dr Carlotta Nedbal</u><sup>1</sup>, V.A Sairam<sup>2</sup>, Shilpa Gite<sup>2</sup>, Nithesh Naik<sup>3</sup>, Prof Bhasar Kumar Somani<sup>1</sup> University Hospitals Southampton, NHS Trust, Southampton, United Kingdom, <sup>2</sup>Symbiosis institute of technology, Pune, India, <sup>3</sup>Manipal Academy of Higher Education, Manipala, India

### P5-6 A new innovative EPR (electronic patient records) integrated Ureteric Stent Register

Mr Damiete Harry<sup>1</sup>, Miss Nisa Sekhon<sup>1</sup>, Ms Eleanor Buck<sup>1</sup>, Mr Ifthekhar Khan<sup>1</sup>, Ms Surbjit Kudhail<sup>1</sup>, Ms Priya Parasuraman<sup>1</sup>, Mr Junaid Masood<sup>1</sup>

Barking, Havering and Redbridge University Hospitals NHS Trust, Romford, United Kingdom



### P5-7 Quantitative Evaluation of Vascular Pattern of Intra-Testicular Lesions on High Frequency Colour Doppler Ultrasound Examination

Dr Michael Conroy<sup>1</sup>, Dr Dean Huang<sup>2</sup>

<sup>1</sup>Kent & Canterbury Hospital, Canterbury, United Kingdom, <sup>2</sup>King's College Hospital, London, United Kingdom

#### P5-8 Enhancing Non-Muscle Invasive Bladder Tumour Identification and Resection: A Machine-Learning Driven Map and Co-Pilot

<u>Mr Kirandeep Saini</u><sup>1,2</sup>, Mr Felix Holm<sup>2,5</sup>, Ms. Hanna Hoffmann<sup>2,4</sup>, Mr Vivek Singh<sup>2,6</sup>, Dr Rafael Moreta Martínez<sup>2</sup>, Dr Monica Ortenzi<sup>2,3</sup>

<sup>1</sup>Churchill Hospital, Oxford, United Kingdom, <sup>2</sup>SDS, Institute of Image Guided Surgery, University of Strasbourg, France, <sup>3</sup>Universita Politecnica delle Marche, Ancona, Italy, <sup>4</sup>NCT Dresden, Dresden, Germany, <sup>5</sup>TUM School of Computation, Information and Technology, Technical University of Munich, Munich, Germany, <sup>6</sup>Boston University School of Medicine, Boston, USA

## P5-9 Using wearable device monitoring and artificial intelligence to develop predictive moels for predicting survival after radical cystectomy for bladder cancer - a secondary outcome analysis of the iROC trial

Mr Pramit Khetrapal<sup>1</sup>, Mr Yansong Liu<sup>2</sup>, Prof Nikhil Vasdev<sup>3</sup>, Prof Imran Ahmed<sup>4</sup>, Mr Philip Charlesworth<sup>5</sup>, Prof Muhammad Shamim Khan<sup>6</sup>, Mr Vishwanath Hanchanale<sup>7</sup>, Mr Sanjeev Kotwal<sup>8</sup>, Mr Ed Rowe<sup>9</sup>, Mr John McGrath<sup>10</sup>, et. al, et. al,

<sup>1</sup>King George's Hospital, London, United Kingdom, <sup>2</sup>University College London, London, United Kingdom, <sup>3</sup>Lister Hospital, Stevenage, Stevenage, United Kingdom, <sup>4</sup>University of Glasgow, CRUK Scotland Institute and the School of Cancer Sciences, Glasgow, United Kingdom, <sup>5</sup>Royal Berkshire Hospital, Reading, United Kingdom, <sup>6</sup>Guy's Hospital, London, United Kingdom, <sup>7</sup>Royal Liverpool University Teaching Hospital, Liverpool, United Kingdom, <sup>8</sup>St James University Hospital, Leeds, United Kingdom, <sup>9</sup>North Bristol NHS Trust, Bristol, United Kingdom, <sup>10</sup>Royal Devon and Exeter Hospital, Urology, Exeter, United Kingdom

### P5-10 Using an Artificial Intelligence-based Machine Learning Models to predict postoperative complications after robot-assisted partial nephrectomy

<u>Dr Gopal Sharma</u><sup>1</sup>, Dr Gurpremjit Singh<sup>1</sup>, Dr Sudheer Rawal<sup>2</sup>, Dr Arvind Ganpule<sup>3</sup>, Dr T A Kishore<sup>4</sup>, Dr Deepak Dubey<sup>5</sup>, Dr Ravimohan Mavuduru<sup>6</sup>, Dr Ginil Kumar Pooleri<sup>7</sup>, Dr Anant Kumar<sup>8</sup>, Dr Gagan Gautam<sup>1</sup>, et al.

<sup>1</sup>Medanta Hospital, Gurgaon, India, <sup>2</sup>RGCI, Delhi, India, <sup>3</sup>MPUH, Nadiad, India, <sup>4</sup>Aster Medicity, Kochi, India, <sup>5</sup>Manipal hospital, Bengaluru, India, <sup>6</sup>PGIMER, Chandigarh, India, <sup>7</sup>Amrita Institute of Medical Sciences, Kochi, India, <sup>8</sup>Max Hospital, Saket, India



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Tuesday 25 June, 0800-0900, Hall 11B

#### **ePoster Session 6**

## Management/Governance/Education/Quality Improvement 1

Chairs: Brian Duggan, The Ulster Hospital, Belfast and Sarah Howles, Churchill Hospital, Oxford

#### P6-1 Medical Students' Outpatient Skills Experiences and Training in Urology Clinics: A quality improvement project

<u>Usaamah Ramzan<sup>2</sup></u>, <u>Dr Nadeem AlShunaigat<sup>2</sup></u>, <u>Dr Ravi Banthia<sup>1</sup></u>, <u>Mr Steve Leung<sup>1,2</sup></u>

<sup>1</sup>Western General Hospital, Edinburgh, United Kingdom, <sup>2</sup>University of Edinburgh, Edinburgh, United Kingdom

### P6-2 The introduction of a Urology Foundation Doctor Mentorship Scheme at a District General Hospital

<u>Miss Vishali Sharma</u><sup>1</sup>, Mr Joshua Rabinowitz<sup>1</sup>, Mr Ray Hsu<sup>1</sup>, Miss Shabnam Undre<sup>1</sup>, Mr Andrew Brodie<sup>1</sup>

<sup>1</sup>Lister Hospital, East and North Herts NHS Trust, Stevenage, United Kingdom

## P6-3 Supporting performance from outside the operating theatre: A pilot study of the acceptability and relevance of performance enhancement coaching to newly appointed urology trainees

<u>Miss Lilli Cooper</u><sup>1</sup>, Mr Karan Wadhwa<sup>2</sup>, Mr Mark Rochester<sup>3</sup>, Mr Chandra Shekhar Biyani<sup>4</sup>, Mrs Ruth Doherty<sup>3</sup>

<sup>1</sup>Real Battersea Clinic, London, United Kingdom, <sup>2</sup>Broomfield Hospital, Chelmsford, United Kingdom, <sup>3</sup>Norfolk & Norwich University Hospital, Norwich, United Kingdom, <sup>4</sup>Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

#### P6-5 DiffErential attainment and Factors AssoCiated with Training applications and Outcomes (DE FACTO) Study: Urology in the United Kingdom

<u>Miss Martina Spazzapan</u><sup>1</sup>, Mr Siddarth Raj<sup>2</sup>, Miss Sarika Grover<sup>2</sup>, Dr Beth Russell<sup>3</sup>, Mr Simon Fleming<sup>4</sup>, Ms Stella Vig<sup>5</sup>, Mr Sachin Malde<sup>1</sup>

<sup>1</sup>Urology Department, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, <sup>2</sup>University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, <sup>3</sup>Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom, <sup>4</sup>Department of Trauma and Orthopaedics, Barts Health NHS Trust, London, United Kingdom, <sup>5</sup>Department of Vascular and General Surgery, Croydon Health Services NHS Trust, London, United Kingdom

### P6-6 The Surgeon as the Second Casualty: Results from a National Survey on the Personal Impact of Complications in Surgeons

Ms Sorcha O'Meara<sup>1</sup>, Prof. Eva Doherty<sup>2</sup>, Prof Kilian Walsh<sup>3</sup>

<sup>1</sup>Dept. of Surgery, Royal College Of Surgeons of Ireland, Dublin, Ireland, <sup>2</sup>Dept. of Surgical Affairs, Royal College of Surgeons of Ireland, Dublin, Ireland, <sup>3</sup>Dept. of Urology, University College Hospital Galway, Galway, Ireland

### P6-7 Litigation trends in Urology compared to other surgical specialties in the UK National Health Service: an analysis of claims over 17 years

Dr Abhinav Tiwari<sup>1</sup>, Miss Jenni Lane<sup>1</sup>, Professor Bhaskar Somani<sup>1,2</sup>

<sup>1</sup>University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, <sup>2</sup>Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, United Kingdom



### P6-8 Have Information Videos Improved Patient Understanding of Complex Urological Surgeries?

Mr Chris Richards<sup>1</sup>, Dr Sohail Nakhuda<sup>1</sup>, Mr Craig Jones<sup>1</sup>, Mr Pete Smith<sup>1</sup>, Mr Yuhao Zhang<sup>1</sup>, Ms Emma Ryan<sup>1</sup>, Mr Steve Bromage<sup>1</sup>, Mr James Dyer<sup>1</sup>, Mr Paul Cleaveland<sup>1</sup>

Stockport Nhs Foundation Trust, Manchester, United Kingdom

#### P6-9 Use of QR codes in the urology outpatient department: Acceptability for patients and staff

<u>Dr Ashwini Kulkarni</u><sup>1</sup>, Ms Jessica Gallagher<sup>1</sup>, Prof Hashim Hashim<sup>1</sup> <sup>1</sup>Bristol Urological Institute, Bristol, United Kingdom

#### P6-10 Exploring Sustainable Practices: Unveiling Evidence in Urology

<u>Dr Habeeb Abdulrasheed</u><sup>1</sup>, Mr Daniel Madarshahian<sup>1</sup>, Mrs Banan Osman<sup>1</sup> <sup>1</sup>Heartland Hospital, University Hospital Birmingham NHS Trust, Birmingham, United Kingdom

#### P6-3 Emergency Urology Crash Course: Teaching Frontline Non-Urologists Pays Back

<u>Mr Elsayed Desouky</u><sup>1</sup>, Mr Mohamed Ibrahim<sup>2</sup>, Mr mohamed Koura<sup>2</sup>, Mr Mohamed Dallash<sup>2</sup>, Mr Jas Kalsi<sup>2</sup>

<sup>1</sup>RUSH University Medical Center, Chicago, USA, <sup>2</sup>Wexham Park Hospital, Slough, UK



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Wednesday 26 June, 0800-0900, Hall 4

#### **ePoster Session 7**

#### **Bladder Cancer: Muscle & Non-Muscle Invasive**

Chairs: **Jayne Douglas Moore,** Leicester General Hospital and **James Douglas,** University Hospital Southampton

### P7-1 Quality improvement in TURBT: Experience from one centre with 45 years of prospectively collected data

<u>Professor Paramananthan Mariappan</u><sup>1,2</sup>, Mrs Tanya Lord-McKenzie<sup>1</sup>, Ms Silje Welsh<sup>3</sup>, Dr Joni Miller<sup>3</sup>, Dr Sorna L Paramananthan<sup>4</sup>, Dr Amy Forbes<sup>3</sup>, Ms Grace Loy<sup>4</sup>, Dr Serena Baker<sup>4</sup>, Mr Roland Donat<sup>3</sup>, Mr Gordon Smith<sup>3</sup>

<sup>1</sup>Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, Edinburgh, United Kingdom, <sup>2</sup>The University of Edinburgh, Edinburgh, United Kingdom, <sup>3</sup>Department of Urology, Western General Hospital, Edinburgh, United Kingdom, <sup>4</sup>Edinburgh Medical School, The University of Edinburgh, Edinburgh, United Kingdom

## P7-2 Does enhanced audit and feedback with education improve quality indicator (QI) achievement and reduce early recurrence rates in TURBT surgery for NMIBC? Results from the RESECT cluster randomised trial

Mr Kevin Gallagher<sup>1,5,9,10</sup>, Miss Nikita Bhatt<sup>2,9</sup>, Mr. Keiran Clement<sup>3,9</sup>, Mr. Sinan Khadhouri<sup>11,9</sup>, Dr. Fortis Gaba<sup>4,9</sup>, Miss Aqua Asif<sup>5,9</sup>, Dr. Alexander Light<sup>6,9</sup>, Mr. Steven MacLennan<sup>7</sup>, Professor Paramananthan Mariappan<sup>8</sup>, Mr. Veeru Kasivisvanathan<sup>5,9</sup>, RESECT Global Study Group<sup>9</sup>
<sup>1</sup>Department of Urology, Western General Hospital, Edinburgh, United Kingdom, <sup>2</sup>Department of Urology, Newcastle Hospitals NHS Trust, Newcastle, United Kingdom, <sup>3</sup>Department of Urology, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, <sup>4</sup>Department of Urology, Albany Medical Centre, Albany, United States, <sup>5</sup>Division of Surgery and Interventional Science, University College London, London, United Kingdom, <sup>6</sup>Department of Surgery and Cancer, Imperial College London, London, United Kingdom, <sup>7</sup>Health Services Research Unit, University of Aberdeen, Aberdeen, United Kingdom, <sup>8</sup>Edinburgh Bladder Cancer Surgery, Western General Hospital, Edinburgh, United Kingdom, <sup>9</sup>British Urology Researchers in Surgical Training, London, United Kingdom, <sup>10</sup>Cancer Informatics, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United

## P7-3 Effectiveness of joint specialist POPS (Peri-Operative care of Older People undergoing Surgery) and Urology management in bladder cancer patients with apparent frailty

Kingdom, "University of St. Andrews School of Medicine, St. Andrews, United Kingdom

<u>Professor Paramananthan Mariappan</u><sup>1,2</sup>, Dr Helen Jones<sup>3</sup>, SN Rebecca Dryburgh<sup>3</sup>, SN Patsy Bathgate<sup>3</sup>, SN Yolonde Mackie-Titterton<sup>3</sup>, Dr Deborah Morley<sup>4</sup>, Mr Suriaraj Karppaya<sup>1</sup>, Dr Irwin Foo<sup>4</sup>, Dr Elizabeth MacDonald<sup>3</sup>

<sup>1</sup>Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, Edinburgh, United Kingdom, <sup>2</sup>The University of Edinburgh, Edinburgh, United Kingdom, <sup>3</sup>Peri-Operative care of Older People undergoing Surgery (POPS), Medicine of the Elderly Department, Western General Hospital, Edinburgh, United Kingdom, <sup>4</sup>Department of Anaesthetics and Critical Care, Western General Hospital, Edinburgh, United Kingdom

### P7-4 Oncological and Urological Outcomes after Total Pelvic Exenteration for Advanced Pelvic Cancers: A Single-Center Study

<u>Dr Shri-Ishvarya Rajamoorthy</u><sup>1</sup>, Dr Alexandra Uren, Mr Karthik Rajan<sup>2</sup>, Mr Mohamed Mubarak<sup>2</sup>, Miss Catherine Dixon<sup>1</sup>, Miss Faye Jeavons<sup>1</sup>, Mr Pradeep Bose<sup>1</sup>, Mr Jonathan Featherstone<sup>1</sup>, Mr Nicholas Gill<sup>1</sup>. Mr Gokul Vignesh Kandaswamv<sup>1</sup>

<sup>1</sup>Department of Urology, Morriston Hospital, Swansea, United Kingdom, <sup>2</sup>Department of Urology, Sunderland Royal Hospital, Sunderland, United Kingdom, <sup>3</sup>Department of Urology, University Hospital of Wales, Cardiff, United Kingdom



### P7-5 The unmet need for bladder sparing treatments in BCG Failure in the UK - mapping to emerging treatment options

<u>Miss Elizabeth Day</u><sup>1</sup>, Ms Rachel Aquilina<sup>2</sup>, Mr Ashwin Sridhar<sup>1</sup>, Mr John Kelly<sup>1</sup>, Ms Bernadett Szabados<sup>1</sup>

<sup>1</sup>University College London Hospital, London, United Kingdom, <sup>2</sup>University College London, London, United Kingdom

### P7-6 Long term outcomes of low grade upper tract urothelial cancer following radical nephroureterectomy

Mr Kalpesh Parmar<sup>1</sup>, Mr Karthik Rajan<sup>1</sup>, Mr Bhavan Prasad Rai<sup>1</sup> Freeman Hospital, New Castle, United Kingdom

### P7-7 Fluorescence confocal microscopy performed by the surgical team for the analysis of margins during robotic radical cystectomy – a feasibility study

<u>Dr Ricardo Almeida-Magana</u><sup>1</sup>, Miss Elizabeth Day<sup>1</sup>, Dr Alex Freeman<sup>1</sup>, Dr Aiman Haider<sup>1</sup>, Mr Anthony Ta<sup>1</sup>, Prof. John Kelly<sup>1</sup>, Prof Greg Shaw<sup>1</sup>

<sup>1</sup>University College London Hospital, London, United Kingdom

#### P7-8 Impact of palliative cystectomy on the quality of life and hospital admissions in bladder cancer patients

Dr Rui Luo, Dr Maham Zaidi, Mr Ghulam Nandwani

<sup>1</sup>Department of Urology, Ninewells Hospital, Dundee, United Kingdom

### P7-9 Could we use the bladder tissue microbiome to identify which bladder cancer patients may not respond to standard treatments

<u>Miss Madhavi Natarajan</u><sup>1</sup>, Dr Nicola Annels<sup>2</sup>, Mr Matthew Perry<sup>1,2</sup>, Dr Izhar Bagwan<sup>1</sup>, Prof Hardev Pandha<sup>1,2</sup>

Royal Surrey Hospital, Guildford, United Kingdom, <sup>2</sup>University of Surrey, Guildford, United Kingdom

### P7-10 Long term outcomes of low grade upper tract urothelial cancer following radical nephroureterectomy

Mr Kalpesh Parmar<sup>1</sup>, Mr Karthik Rajan<sup>1</sup>, Mr Bhavan Prasad Rai<sup>1</sup>

<sup>1</sup>Freeman Hospital, New Castle, United Kingdom



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Wednesday 26 June, 0800-0900, Hall 8

## ePoster Session 8 Stones / Imaging / Upper Tract Disorders 2

Chairs: **Kay Thomas**, Guy's & St Thomas' Hospital, London and **Matthew Clark,** Royal Preston Hospital

## P8-1 Manual Hand-Pump versus Pressurised-Bag Irrigation During Flexible Ureterorenoscopy and the Impact on Intrarenal Pressure : A Multicentre Randomized Trial

Ms Stefanie Croghan<sup>1,2,3</sup>, Ms. Sorcha O'Meara<sup>1,2,3</sup>, Dr. Eoghan M. Cunnane<sup>4</sup>, Prof. Michael T. Walsh<sup>4</sup>, Prof. Fergal J. O'Brien<sup>5</sup>, Prof. Rustom P. Manecksha<sup>6,7</sup>, Prof. Barry B. McGuire<sup>8,9,10</sup>, Mr. Kieran J. Breen<sup>8,9</sup>, Prof. Niall F. Davis<sup>1,2,10</sup>

<sup>1</sup>Beaumont Hospital, Dublin, Ireland, <sup>2</sup>Blackrock Clinic, Dublin, Ireland, <sup>3</sup>Royal College of Surgeons in Ireland (StAR Programme), Ireland, <sup>4</sup>School of Engineering, Bernal Institute, University of Limerick, Ireland, <sup>5</sup>Tissue Engineering Research Group (TERG), Royal College of Surgeons in Ireland, Ireland, <sup>6</sup>Tallaght University Hospital, Ireland, <sup>7</sup>Department of Surgery, Trinity College Dublin, Ireland, <sup>8</sup>St. Michael's Hospital, Dublin, Ireland, <sup>9</sup>St. Vincent's Hospital, Dublin, Ireland, <sup>10</sup>Department of Surgery, Royal College of Surgeons in Ireland, Ireland

#### P8-2 Causal effects of renal cysts on kidney stone disease

<u>Miss Catherine Lovegrove</u><sup>1,2</sup>, Professor John Sayer<sup>3</sup>, Professor Rajesh Thakker<sup>1</sup>, Professor Michael Holmes<sup>4</sup>, Professor Dominic Furniss<sup>1,2</sup>, Dr Sarah Howles<sup>1,2</sup>

<sup>1</sup>University of Oxford, Oxford, United Kingdom, <sup>2</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, <sup>3</sup>Newcastle University, Newcastle, United Kingdom, <sup>4</sup>University of Bristol, Bristol, United Kingdom

## P8-3 Genetic variants associated with DGKD, CYP24A1, and SLC34A1 predisposing to increased risk of kidney stone disease via effects on serum calcium or phosphate concentrations

<u>Miss Catherine Lovegrove</u><sup>1,2</sup>, Michelle Goldsworthy<sup>1</sup>, Jeremy Haley<sup>3</sup>, Diane Smesler<sup>3</sup>, Fadil Hannan<sup>1</sup>, Monish Suri<sup>4</sup>, Omid Sadeghi-Alavijeh<sup>5</sup>, Daniel Gale<sup>5</sup>, Michael Holmes<sup>6</sup>, Rajesh Thakker<sup>1</sup>, Dominic Furniss<sup>1,2</sup>, Sarah Howles<sup>1,2</sup>

<sup>1</sup>University of Oxford, Oxford, United Kingdom, <sup>2</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, <sup>3</sup>Geisinger Medical Center, Danville, USA, <sup>4</sup>Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, <sup>5</sup>University College London, London, United Kingdom, <sup>6</sup>University of Bristol, Bristol, United Kingdom

## P8-4 Adverse events related to holmium laser fibers and laser machines during ureteroscopy and stone lithotripsy: Insights from an updated 10-year analysis of the US MAUDE database

<u>Patrick Juliebø-Jones</u><sup>1</sup>, Dr Francesco Ripa<sup>5</sup>, Mathias Sørstrand Æsøy<sup>1</sup>, Christian Beisland<sup>1</sup>, Vincent de Coninck<sup>2</sup>, Etienne Xavier Keller<sup>3</sup>, Lazaros Tzelves<sup>4</sup>, Peter Gjengstø<sup>1</sup>, Christian Arvei Moen<sup>1</sup>, Øyvind Ulvik<sup>1</sup>, Bhaskar Somani<sup>5</sup>

<sup>1</sup>Haukeland University Hospital, Bergen, Norway, <sup>2</sup>AZ Klina, Brasschaat, Belgium, <sup>3</sup>University Hospital Zurich, Zurich, Switzerland, <sup>4</sup>National and Kapodistrian University of Athens, Athens, Greece, <sup>5</sup>University Hospital Southampton NHS Trust, Southampton, United Kingdom

## P8-5 Comparative study of Thulium fibre laser vs Holmium laser for kidney stones in miniaturized percutaneous nephrolithotomy: A randomised controlled single centre trial

<u>Dr Aruj Shah</u>¹, Dr Deval Parikh¹, Dr Abhishek Singh, Dr Arvind Ganpule, Dr Ravindra Sabnis, Dr Mahesh Desai

<sup>1</sup>Muljibhai Patel Urological Hospital (MPUH), Nadiad, India



### P8-6 How much energy do we need to ablate 1 cubic millimeter of stone during Thulium Fiber laser lithotripsy? An in vitro study

<u>Dr Frederic Panthier</u><sup>1,2,3</sup>, Dr Marie Chicaud<sup>1,2,3</sup>, Dr Steeve Doizi<sup>1,2,3</sup>, Dr Laurent Berthe<sup>3</sup>, Dr Mariela Corrales<sup>1,2</sup>, Pr Olivier Traxer<sup>1,2,3</sup>

<sup>1</sup>GRC <sup>2</sup>O Urolithiasis, Sorbonne University-Tenon Hospital, Paris, France, <sup>2</sup>Urology Department, Sorbonne University-Tenon Hospital, Paris, France, <sup>3</sup>PIMM Lab, UMR <sup>8</sup>O0<sup>6</sup> CNRS-Arts et Métiers ParisTech, Paris, France

## P8-7 Comparative study of Thulium fibre laser vs Holmium laser for kidney stones in miniaturized percutaneous nephrolithotomy: A randomised controlled single centre trial

<u>Dr Aruj Shah</u><sup>1</sup>, Dr Deval Parikh<sup>1</sup>, Dr Abhishek Singh, Dr Arvind Ganpule, Dr Ravindra Sabnis, Dr Mahesh Desai

<sup>1</sup>Muljibhai Patel Urological Hospital (MPUH), Nadiad, India

#### P8-8 NEW IMAGING FINDINGS RATE AND IMPACT DURING STONE MULTIDSCIPLINARY TEAM MEETING: A RETROSPECTIVE ANALYSIS

Ms Eduarda Alvarez<sup>1</sup>, Dr Frederic Panthier<sup>1</sup>, Dr Clare Allen<sup>2</sup>, Dr Daron Smith<sup>1</sup>

<sup>1</sup>Department of Urology,Westmoreland Street Hospital,UCLH NHS Foundation Trust, London, United Kingdom, <sup>2</sup>Department of Radiology, University College London Hospitals, London, United Kingdom

#### P8-9 Patients' priorities in kidney stone disease

<u>Mr Victor Popoola</u><sup>1</sup>, Miss Grace Wheeler<sup>1</sup>, Dr Sarah Howles<sup>2,3</sup>, Dr Catherine Lovegrove<sup>2,3</sup>
<sup>1</sup>Oxford University Medical School, Oxford, United Kingdom, <sup>2</sup>Nuffield Department of Surgical Sciences at the University of Oxford, United Kingdom, <sup>3</sup>Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

## P8-10 Clinical significance of stone culture during endourological procedures in predicting post-operative urinary sepsis - Should it be a standard of care? Evidence from a systematic review and meta-analysis

<u>Dr Francesco Ripa</u>¹, Clara Cerrato², Carlotta Nedbal², Zafer Tandogdu³, Mr Simon Choong³, Professor Bhaskar Somani²

<sup>1</sup>Whittington Health NHS Trust, London, United Kingdom, <sup>2</sup>University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, <sup>3</sup>University College London Hospitals NHS Foundation Trust, London, United Kingdom



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Wednesday 26 June, 0800-0900, Hall 9

#### ePoster Session 9

Prostate Cancer 1

Chairs: **Ashwin Sachdeva,** The Christie NHS Foundation Trust, Manchester and **Catherine Hobbs,** Churchill Hospital, Oxford

P9-1 Early return to continence, oncological safety and significance of membranous urethral length in anterior Retzius sparing (ARS) robot assisted radical prostatectomy (RARP)

Mr Nithesh Ranasinha<sup>1,2</sup>, Mr Anthony Bates<sup>1</sup>, Mr Thineskrishna Anbarasan<sup>2</sup>, Mr Abhishek Sharma<sup>1</sup>, Prof Richard Bryant<sup>1,2</sup>, Mr Aaron Leiblich<sup>1</sup>, Mr Tom Leslie<sup>1</sup>, Mr Francisco Lopez<sup>1</sup>, Mr Alastair D Lamb<sup>1,2</sup>

<sup>1</sup>Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, <sup>2</sup>Nuffield Department of Surgical Science, University of Oxford, Oxford, United Kingdom

P9-2 Cardiovascular Risk associated with LHRH analogue treatment and assessing those at risk: A Retrospective Cohort Study

Dr John Gibson<sup>1</sup>, Mr Stephen Bromage<sup>2</sup>

<sup>1</sup>East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom, <sup>2</sup>Stockport NHS Foundation Trust, Stockport, United Kingdom

P9-3 Correlation between MRI and Pathological Primary Tumour Staging in T3a Prostate Cancers with Broad Capsular Contact: A Study on 383 Patients

Mr Jonathan Ferguson<sup>1</sup>, Dr Jonathan Ferguson<sup>1</sup>, Mr Dimitrios Papadopoulos<sup>1</sup>, Mr Constantinos Adamou<sup>1</sup>, Mr Julian Peacock<sup>1</sup>, Mr Torath Ameen<sup>1</sup>, Mr Umberto Carbanara<sup>1</sup>, Mr Joseph Gabriel<sup>1</sup>, Mr Wissam Abou Chedid<sup>1</sup>, Mr Venkata Ramana Murthy Kusuma<sup>1</sup>, Mr Dimitrios Moschonas<sup>1</sup>, Mr James Hicks<sup>1</sup>, Mr Krishna Patil<sup>1</sup>, Mr Matthew Perry<sup>1</sup>

<sup>1</sup>Royal Surrey County Hospital, Guildford, United Kingdom

P9-4 ProFocal®- novel, cooled Laser Focal Therapy. Pivotal trial results of 100 men with localised Prostate Cancer

<u>Dr Jonathan Kam</u><sup>1</sup>, Dr Mohan Arianayagam<sup>1</sup>, Dr Bertram Canagasingham<sup>1</sup>, Dr Ahmed Saeed Goolam<sup>1</sup>, Dr Nicola Jeffery<sup>1</sup>, Dr Matthew Winter<sup>1</sup>, Prof Mohamed Khadra<sup>1</sup>, A/Prof Raymond Ko<sup>1</sup>, Dr Nicholas Mehan<sup>1</sup>, Dr Isaac Thangasamy<sup>1</sup>, A/Prof Celi Varol<sup>2</sup>, Rick Popert

Nepean Urology Research Group, Sydney, Australia, <sup>2</sup>Medlogical Innovations, Sydney, Australia

P9-5 The Man Van Project: Subgroup Analysis of Patients From A Single Primary Care Centre

Mr Masood Moghul<sup>1,2</sup>, Miss Fionnuala Croft<sup>1</sup>, Dr Netty Kinsella<sup>1</sup>, Mr Declan Cahill<sup>1</sup>, Professor Nicholas James<sup>1,2</sup>

<sup>1</sup>Royal Marsden Hospital, London, United Kingdom, <sup>2</sup>Institute of Cancer Research, London, United Kingdom

P9-6 Development and Internal Validation of a Multivariable Prognostic Model for Mental Wellbeing Outcomes in Prostate Cancer Patients

<u>Mr Oliver Brunckhorst</u><sup>1</sup>, Mr Jaroslaw Liszka<sup>1</sup>, Dr Jack Fanshawe<sup>2</sup>, Dr Robert Thomas<sup>3</sup>, Mr Shahid Khan<sup>4</sup>, Mr Matin Sheriff<sup>5</sup>, Prof Hashim Ahmed<sup>6</sup>, Prof Mieke Van Hemelrijck<sup>1</sup>, Prof Prokar Dasgupta<sup>1</sup>, Mr Kamran Ahmed<sup>1</sup>, et al.,

<sup>1</sup>King's College London, London, United Kingdom, <sup>2</sup>Queen Elizabeth Hospital, London, United Kingdom, <sup>3</sup>Bedfordshire Hospitals NHS Foundation Trust, Bedford, United Kingdom, <sup>4</sup>East Surrey Hospital, Redhill, United Kingdom, <sup>5</sup>Medway NHS Foundation Trust, Gillingham, United Kingdom, <sup>6</sup>Imperial College London, London, United Kingdom



## P9-7 IDEAL Stage 2 implementation of the Medtronic Hugo Robotic-Assisted Surgery (RAS) in radical prostatectomy: Comparative study from the first UK centre

Mr Mehrshad Sultani Tehrani<sup>1</sup>, Mr Andrew Shepherd<sup>2</sup>, Mr Angus Bruce<sup>2</sup>, Mr Daniel Chia<sup>2</sup>, Mr Findlay MacAskill<sup>3</sup>, Mr Christian Brown<sup>2</sup>, Mr Jonathan Noel<sup>2</sup>, Mr Ata Jaffer<sup>2</sup>, Mr Prokar Dasgupta<sup>2</sup>, Mr Ben Challacombe<sup>2</sup>

<sup>1</sup>King's College London, London, United Kingdom, <sup>2</sup>Guy's and St Thomas' NHS trust, London, United Kingdom, <sup>3</sup>Guy's and St Thomas' NHS trust on behalf of Guy's Post Pelvic Surgery Research Group, London, United Kingdom

P9-8 Morphine, Naloxone and Beta-endorphin inhibit the proliferation of PC3, LNCaP and a benign prostate cell line and inhibit TNF-Alpha-induced release of IL-6, IL-8 and IL-1 Beta in vitro: Clinical significance in prostate cancer management?

<u>Miss Prapussara Sirikhansaeng</u><sup>1</sup>, Muhammadbakhoree Yusuh<sup>1</sup>, Laurie Lau<sup>2</sup>, Omar Abdelwahab<sup>1</sup>, Associate Professor Brian Birch<sup>3</sup>, Professor Bashir Lwaleed<sup>1</sup>

<sup>1</sup>University Of Southampton, Faculty of Health Sciences, Southampton, United Kingdom, <sup>2</sup>University of Southampton, Faculty of Medicine, Southampton, United Kingdom, <sup>3</sup>University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom

P9-9 Empowering local communities: The "ThisVanCan" Experience. An awareness campaign and mobile case finding project for black men and other high-risk individuals for developing prostate cancer

Mr Harry Alexander Rudman<sup>1</sup>, Ms Hannah Leather<sup>1</sup>, Ms Millie Wadley<sup>1</sup>, Mr Sotonye Karl Tolofari<sup>1</sup> Salford Care Organisation (Northern Care Alliance), Salford, United Kingdom

P9-10 Omentoplasty improves anastamotic leak rate and post operative catheter dwell time after salvage robotic prostatectomy

Mr Arjun Nathan<sup>1</sup>, Dr Aqua Asif<sup>1</sup>, Dr Gulz Dhanoya<sup>1</sup>, Dr Tushar Narain<sup>1</sup>, Professor Senthil Nathan<sup>1</sup> <sup>1</sup>UCL, London, United Kingdom



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Wednesday 26 June, 0800-0930, Hall 10

## ePoster Session 10 TUF-BAUS Best of the Regions

Chairs: Details to Follow

P10-1

#### P10-2 Regional disparities in BOO surgical management in 2023: a pilot study

<u>Dr Edward Armstrong</u><sup>1</sup>, Mr Richard Menzies-Wilson, Professor Ben Turney <sup>1</sup>Oxford University Hospitals, Oxford, United Kingdom

#### P10-3 Malignancy Rate of Bosniak 3 and 4 Complex Renal Cystic Lesions

Mr Abhishek Reekhaye<sup>1</sup>, Kathryn Brown<sup>1</sup>, Joanne Oakley<sup>1</sup>, Harbinder Sharma<sup>1</sup>, Amr Emara<sup>1</sup>, Manar Malki<sup>1</sup>, Neil Barber<sup>1</sup>, Muddassar Hussain<sup>1</sup>
<sup>1</sup>Frimley Park Hospital, Frimley, United Kingdom

#### P10-4 Robotic Assisted Partial Nephrectomy - A Belfast Experience

Mr Andrew Carlile, Ms Aisling Devine, Mr David Curry Belfast City Hospital, Belfast, United Kingdom

### P10-5 The impact of a new primary ureteroscopy service for the emergency treatment of ureteric stones in a busy university hospital

Ms Maryam Rasheed<sup>1</sup>, Mr Tarek Aly, Mr Khaled Ghanem, Dr Kevin George, Dr Mazharuddin Shaikh, Mr Junaid Masood

<sup>1</sup>Barking, Havering and Redbridge University Hospitals, Romford, United Kingdom

#### P10-6 Outcomes of men undergoing surgery for Gleason 8-10 prostate cancer: A UK tertiary centre experience

Miss Stephanie Smith<sup>1</sup>, Miss Kate Manley<sup>1</sup>, Mr Rob Mills<sup>1</sup>
<sup>1</sup>Norfolk And Norwich University Hospitals, Norwich, United Kingdom

#### P10-7 Is there a need for flexible cystoscopies in patients with recurrent Urinary Tract Infections?

Mr Anton Wong<sup>1</sup>, Miss Beverly James<sup>1</sup>, Miss Anna Mainwaring<sup>1</sup>, Mr Pradeep Bose<sup>1</sup>, Mr Gokul Kandaswamy<sup>1</sup>

<sup>1</sup>Swansea Bay Hospitals, Swansea, United Kingdom

#### P10-8 Scrub team-led theatre fluoroscopy radiation: ALARA? An update

<u>Miss Feng Tse</u><sup>1</sup>, Mrs Sharon Scriven, Mr Dhaval Bodiwala, Mr Hari Ratan, Mr Stephen Miller, Miss Susan Hall, Mr Jerry Raju

<sup>1</sup>Nottingham City Hospital, Nottingham, United Kingdom

### P10-9 Cardiovascular Risk associated with LHRH analogue treatment and assessing those at risk: A Retrospective Cohort Study

<u>Dr John Gibson</u><sup>1</sup>, Mr Craig Jones<sup>2</sup>, Mr Stephen Bromage<sup>2</sup>

<sup>1</sup>East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom, <sup>2</sup>Stockport NHS Foundation Trust, Stockport, United Kingdom



## P10-10 Real word high-risk non-muscle invasive bladder cancer: Long-term outcomes from a consecutive cohort screened for the BRAVO randomised feasibility trial of radical cystectomy versus intravesical BCG immunotherapy

<u>Miss Samantha Conroy</u><sup>1</sup>, Mr Ibrahim Jubber<sup>1</sup>, Mr Aidan P Noon<sup>1</sup>, Dr Jon Griffin<sup>1</sup>, Prof Derek Rosario<sup>4</sup>, Dr Rachel Hubbard<sup>1</sup>, Mr Ramanan Rajasundaram<sup>2</sup>, Mr Suresh Venogupal<sup>3</sup>, Prof Syed Hussain<sup>1</sup>, Prof James Catto<sup>1</sup>

<sup>1</sup>Sheffield Teaching Hospitals and University Of Sheffield, Sheffield, United Kingdom, <sup>2</sup>Doncaster Royal Infirmary, Doncaster, United Kingdom, <sup>3</sup>The Royal Liverpool and Broadgreen University Hospitals, Liverpool, United Kingdom, <sup>4</sup>Sheffield Teaching Hospitals and Sheffield Hallam University, Sheffield, United Kingdom

#### P10-11

#### P10-12 Scottish National Complex Renal Cyst Surveillance Protocol

<u>Dr Benjamin Parkin</u><sup>1</sup>, Mr Gavin Lamb, Dr Nikolas Arestis, Ms Jane Hendry, Mr James Blackmur, Ms Sara Ramsey, Mr Ross Clark, Dr Anna Brown, Dr Zack Slevin, Mr Steve Leung, Et al. <sup>1</sup>Ayr Hospital, Ayr, United Kingdom

### P10-13 Is there a geographical incidence variation in upper urinary tract urothelial carcinoma in the Highlands and Islands?

<u>Miss Charlotte Gunner,</u> Dr Caitlin Critchley, Dr Siddharth Basetti, Mr Ian Wilson <sup>1</sup>NHS Highland, Inverness, United Kingdom

## P10-14 Robotic Assisted Retroperitoneal Lymph Node Dissection: Defining Selection Parameters and Assessment of Morbidity and Short-Term Oncological Outcomes: A B-SAFE approach

Mr Kamran Haq¹, Mr Usman M Haroon¹, Mr Akinlolu Oluwole-Ojo¹, Mr Daniel Chia¹, Miss Fairleigh Reeves, Dr Hema Verma¹, Dr Sarah Rudman¹, Dr Jonathan Shamash², Mr Timothy O Brien¹, Miss Archana Fernando¹, Mr Ben Challacombe¹

<sup>1</sup>Guy's Hospital London, London , United Kingdom, <sup>2</sup>BARTS Health London , London

### P10-15 Characterisation of iatrogenic human ureteral injury due to contact from the Ho:YAG laser at commonly used lithotripsy settings

Ms Sorcha O'Meara<sup>1</sup>, Dr. K. Sheehan<sup>2,3</sup>, Dr. J. Fay<sup>2,6</sup>, Dr. T. O'Grady<sup>2,6</sup>, Ms. S.M. Croghan<sup>1,4,5</sup>, Dr. E.M. Cunnane<sup>7,8</sup>, Prof. M.T. Walsh<sup>7,8</sup>, Prof. F.J. O'Brien<sup>9</sup>, Prof. N.F. Davis<sup>4,5</sup>

<sup>1</sup>Royal College Of Surgeons Of Ireland, Dublin, Ireland, <sup>2</sup>Dept. of Pathology, Royal College of Surgeons of Ireland, Dublin, Ireland, <sup>3</sup>Dept. of Pathology, Blackrock Health, Ireland, <sup>4</sup>Dept. of Urology, Blackrock Health, Ireland, <sup>5</sup>Dept. of Urology, Beaumont Hospital, Ireland, <sup>6</sup>RCSI Biobank, Royal College of Surgeons of Ireland, Ireland, <sup>7</sup>Biomaterials Cluster, Bernal Institute, University of Limerick, Ireland, <sup>8</sup>School of Engineering, University of Limerick, Ireland, <sup>9</sup>Tissue Engineering Research Group, Royal College of Surgeons in Ireland, Ireland



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Wednesday 26 June, 0800-0900, Hall 11A

## ePoster Session 11 General Urology

Chairs: **Matthew Thomas,** Diana, Princess of Wales Hospital, Grimsby and **Melissa Davies,** Salisbury District Hospital

#### P11-1 Efficacy of different surgical treatment modalities for radiation cystitislessons from 7 years of a specialist radiation cystitis service

<u>Dr Jonathan Kam</u><sup>1</sup>, Ms Yasmin Abu-Ghanem<sup>1</sup>, Ms Elsie Mensah<sup>1</sup>, Mr Rajesh Nair<sup>1</sup>, Prof Shamim Khan<sup>1</sup>, Mr Ramesh Thurairajah<sup>1</sup>, Georgia Heaverwren<sup>1</sup>

Guy's Hospital, London, United Kingdom

# P11-2 Life expectancy in patients undergoing renal tract decompression for extramural ureteric obstruction is lower than those managed conservatively. Such patients require thorough counselling regarding their options and palliative care should be strongly considered

<u>Dr Tom Pugh</u><sup>1</sup>, Mr Amit Mevcha<sup>1</sup>
<sup>1</sup>Royal Bournemouth Hospital, Bournemouth, United Kingdom

### P11-3 Gram Negative Bacteria related Urinary Tract Infections: spectrum of antimicrobial resistance over 9 years in a University tertiary referral Hospital

<u>Dr Carlotta Nedbal</u><sup>1,2</sup>, Dr Nitin Mahobia<sup>1</sup>, Mr Dave Browning<sup>1</sup>, Prof Bhaskar Somani<sup>1</sup>, Dr Clara Cerrato<sup>1</sup>

<sup>1</sup>University Hospital Southampton NHS Trust, Southampton, United Kingdom, <sup>2</sup>Azienda Ospedaliero-Universitaria delle Marche, Polytechnic University of Le Marche, Ancona, Italy

## P11-4 Baseline lower urinary tract symptoms correlation with motor and cognitive function in patients with treatment naïve and non-treatment naïve Parkinson's Disease

<u>Mr Nikan Golesorkhi</u><sup>1</sup>, Dr Leta Valentina<sup>2</sup>, Professor Kallol Ray Chaudhuri<sup>2</sup>, Mr Nicholas Faure Walker<sup>3</sup>

<sup>1</sup>King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom, <sup>2</sup>King's College London, Dept. of Neurology, London, United Kingdom, <sup>3</sup>King's College London, Dept. of Urology, London, United Kingdom

#### P11-5 Aligning the Patient Pathway: Getting It Right First Time in Bladder Outlet Obstruction

Mr Abdul Shugaba<sup>1</sup>, Mr Neil Harvey<sup>1</sup>
<sup>1</sup>Royal Bolton Hospital, Bolton, United Kingdom

#### P11-6 Rezum steam ablation of the prostate for patients with urinary retention

Mr Arthur Day<sup>1</sup>, Mr Omar El-Taji<sup>1</sup>, Mr Nicholas Harrison<sup>1</sup>, Mr John McCabe<sup>1</sup>

Mersey and West Lancashire Teaching Hospitals NHS Trust, Prescot, United Kingdom

### P11-7 The Comparing UroLift Experience Against Rezūm (CLEAR) RCT: Preliminary analyses suggest a superior early patient experience with UroLift PUL (PUL)

Mr Mark Rochester<sup>1</sup>, Mr. Neil Barber<sup>2</sup>, Dr. Brian Mazzarella<sup>3</sup>, Dr. Christopher Cantrill<sup>4</sup>, Dr. Bilal Chughtai<sup>5</sup>, Dr. Arnold Cinman<sup>6</sup>, Dr. Jeffrey Schiff<sup>7</sup>, Dr. Claus Roehrborn<sup>8</sup>

<sup>1</sup>Norfolk and Norwich University Hospital, Norwich, United Kingdom, <sup>2</sup>Frimley Park Hospital, United Kingdom, <sup>3</sup>Urology Austin, United States, <sup>4</sup>Urology San Antonio, United States, <sup>5</sup>Weill Cornell Medicine, United States, <sup>6</sup>Tower Urology, United States, <sup>7</sup>NYU Langone, United States, <sup>8</sup>UT Southwestern, United States



### P11-8 Robotic water jet ablation (Aquablation™) to treat urinary retention in men with benign prostatic enlargement

<u>Nadia Bitar</u><sup>1</sup>, Ayesha Unadkat<sup>1</sup>, Ahmed Khattak<sup>1</sup>, Oussama Elhage<sup>1</sup>, Jonathan Noel<sup>1</sup>, Rick Popert<sup>1</sup>, Mr Sachin Malde<sup>1</sup>

<sup>1</sup>Guy's And St Thomas' Hospital, London, United Kingdom

## P11-9 A comparison of aquablation versus holmium laser enucleation of the prostate (HoLEP) as a treatment option for BPH: Preliminary analysis of our perioperative experience

Mr Mohammed Shahid<sup>1</sup>, Mr William Finch<sup>1</sup>, Mr Robert Mills<sup>1</sup>, Mr Utsav Reddy<sup>1</sup>, Mr Mark Rochester<sup>1</sup> Norfolk And Norwich University Hospitals NHS Trust, Norwich, United Kingdom

## P11-10 Inter-operator variability in performing HoLEP: a single-centre study assessing the impact of surgeon experience and technique on procedural efficiency

Mr Enamur Rahman<sup>1</sup>, Mr Branimir Penev<sup>1</sup>, Mr Mark Cynk<sup>1</sup>
<sup>1</sup>Maidstone And Tunbridge Wells Nhs Trust, Maidstone, United Kingdom



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Wednesday 26 June, 0800-0900, Hall 11B

#### **ePoster Session 12**

## Management/Governance/Education/Quality Improvement 2

Chairs: Shabi Ahmad, Sandwell District General Hospital, West Bromwich and Details to Follow

### P12-1 Developing a robust Urology Pre-Operative Urine Culture pathway to reduce patient cancellations: a full cycle Quality Improvement Project

Mr Rustam Karanjia<sup>1</sup>, Miss Oluwabunmi Tayo<sup>1</sup>, Mr Pallab Sarkar<sup>1</sup>, Miss Christine Boswell<sup>1</sup>, Mr Michael Conroy<sup>1</sup>, Dr Stephen Glass<sup>1</sup>, Miss Jemma Hale<sup>1</sup>

<sup>1</sup>Kent & Canterbury Hospital, Canterbury, United Kingdom

## P12-2 Assessment of the investigation and management of patients presenting with symptoms of Urinary Tract Infections in primary care: A multi-disciplinary, closed loop audit

Miss Molly Nichols1

<sup>1</sup>Whipps Cross University Hospital, London, United Kingdom

### P12-3 Initial experience of Uromune® in Cornwall to reduce frequency of UTI in patients with recurrent UTI

Mr Nadeem Iqbal<sup>1</sup>, Mr Buraq Imran<sup>1</sup>, Mr Matthew Hotston<sup>1</sup>, Mr Christopher Blake<sup>1</sup>
<sup>1</sup>Rcht, Truro, Cornwall, United Kingdom<sup>4</sup>

#### P12-4 Total Cost and Hidden Cost of Equipment Choices for Flexible Cystoscopy and LATP

Mr Toni Mihailidis<sup>1</sup>, Mr Jonathan Ord

<sup>1</sup>Cheltenham General Hospital, Cheltenham, United Kingdom

#### P12-5 A Cost-Consequence Analysis of the Man Van Project: Comparing Prostatespecific Antigen Testing on a Nurse-led Mobile Service with Primary Care

Mr Masood Moghul<sup>1,2</sup>, Miss Deokhee Yi<sup>3</sup>, Miss Fionnuala Croft<sup>1</sup>, Miss Fiona Mutch<sup>1</sup>, Miss Elizabeth Westaway<sup>1</sup>, Dr Netty Kinsella<sup>1</sup>, Mr Declan Cahill<sup>1</sup>, Professor Nicholas James<sup>1,2</sup>

<sup>1</sup>Royal Marsden Hospital, London, United Kingdom, <sup>2</sup>Institute of Cancer Research, London, United Kingdom, <sup>3</sup>Imperial College London (Convergence Science Centre), London, United Kingdom

<sup>12</sup>-<sup>6</sup> Developing evidence-based guidance for the use of prostate specific antigen testing in men over <sup>8</sup>O years old Dr David Faluyi<sup>1</sup>, Mr Ben Lamb<sup>2</sup>, Ms Elizabeth Bright<sup>3</sup>

<sup>1</sup>Academy Of Medical Royal Colleges, London, United Kingdom, <sup>2</sup>Cambridge University Hospitals NHS Foundation Trust, <sup>3</sup>Royal Cornwall NHS Hospital Trust

<sup>12</sup>-<sup>7</sup> Facilitating the move to outpatient LA Rezum water vapour therapy; The Schelin catheter

Mr Mohamed Alnoomani<sup>1</sup>, Mr Omar Alabed Allat<sup>1</sup>, Mr Mohamed Noureldin<sup>1</sup>, Mr Ramzy Elnabarawy<sup>1</sup>, Patricia Musuka<sup>1</sup>, Emma Potter<sup>1</sup>, Prof Richard Hindley<sup>1</sup>, Mr Amr Emara<sup>1</sup> Basingstoke And North Hampshire Hospitals, Basingstoke, United Kingdom

### P12-8 Quality and readability of google search information on HoLEP for benign prostate hyperplasia

<u>Dr Yam Ting Ho</u><sup>1</sup>, Dr Jeremy Saad<sup>1,2</sup>, Dr Femi Ayeni<sup>2</sup>, Dr Mohamed Khadra<sup>1,2</sup>, Dr Mohan Arianayagam<sup>1</sup>, Dr Bertram Canagasingham<sup>1</sup>, Dr Nicholas Mehan<sup>1</sup>, Dr Celi Varol<sup>1</sup>, Dr Nicola Jeffrey<sup>1</sup>, Dr Isaac Thangasamy<sup>1,2</sup>, et al.,

<sup>1</sup>Nepean Hospital, Kingswood, Australia, <sup>2</sup>University of Sydney, Camperdown, Australia



#### P12-9 DESCENT: Departmental Evaluation of Scrotal imaging Considering European and National Testicle Guidelines

Mr Darryl Bernstein<sup>2</sup>, Dr Harry Manning<sup>1</sup>, Dr Kapila Jain<sup>1</sup>, Dr Sebastian Chang<sup>1</sup>, Mr Abraham Cherian<sup>3</sup>, Miss Shabnam Undre<sup>1</sup>

East and North Hertfordshire Hospitals NHS Trust, Stevanage, United Kingdom, <sup>2</sup>Division of Surgery and Interventional Science, University College London, London, United Kingdom, <sup>3</sup>Great Ormond Street Hospital, London, United Kingdom

### P12-10 Improving the Emergency Urology Stone Pathway with Elective Theatre Utilisation: A Closed Loop Audit

Mr Arjun Nathan<sup>1</sup>, Dr Luke Zhu<sup>2</sup>, Dr Natacha Rosa<sup>2</sup>, Dr Alexander Ng<sup>2</sup>, Mr Maen Khalifeh<sup>2</sup>, Dr Matthew Riley<sup>2</sup>, Mr Gidon Ellis<sup>2</sup>, Mr Rajesh Kucheria<sup>2</sup>, Mr Leye Ajayi<sup>2</sup>, Urology Consultants and CNS<sup>2</sup>

<sup>1</sup>UCL, London, United Kingdom, <sup>2</sup>Royal Free Hospital, London, United Kingdom



6 minutes for each ePoster Presentation 4 minutes for presentation | 2 minutes for Q&A and turnaround

Wednesday 26 June, 1400-1500, Hall 9

## ePoster Session 13 Prostate Cancer 2

Chairs: **Rohit Chahal,** Bradford Royal Infirmary and **Flora Rodger,** Queen Elizabeth University Hospital, Glasgow

### P13-1 Real world assessment of MRI predictors of rectal complications following transperineal SpaceOAR Hydrogel Insertion

<u>Dr Jonathan Kam</u><sup>1</sup>, Dr Luke Kissane<sup>1</sup>, Dr Stuart Jackson<sup>1</sup>, Dr Mohan Arianayagam<sup>1</sup>, Dr Bertram Canagasingham<sup>1</sup>, Dr Ahmed Saeed Goolam<sup>1</sup>, Dr Matthew Winter<sup>1</sup>, Prof Mohamed Khadra<sup>1</sup>, A/Prof Raymond Ko<sup>1</sup>, Dr Nicholas Mehan<sup>1</sup>, Dr Isaac Thangasamy<sup>1</sup>, A/Prof Celi Varol<sup>1</sup>, Dr Maria Azzi<sup>1</sup>, Dr Nicola Jeffery<sup>1</sup>

<sup>1</sup>Nepean Urology Research Group, Sydney, Australia

### P13-2 Urinary Continence Definitions following Robot-assisted Radical Prostatectomy (RARP): A Systematic Review

<u>Miss Nikki Kerdegari</u><sup>1,3</sup>, Mr Findlay MacAskill<sup>2,3</sup>, Mr Majed Shabbir<sup>2,3</sup>, Mr Arun Sahai<sup>2,3</sup> <sup>1</sup>King's College London, London, United Kingdom, <sup>2</sup>Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, <sup>3</sup>Guy's PPS Research Group, London, United Kingdom

#### P13-3 The Man Van Project: Second Phase Interim Results

Mr Masood Moghul<sup>1,2</sup>, Miss Fionnuala Croft<sup>1</sup>, Miss Fiona Mutch<sup>1</sup>, Miss Elisabeth Westaway<sup>1</sup>, Dr Netty Kinsella<sup>1</sup>, Mr Declan Cahill<sup>1</sup>, Professor Nicholas James<sup>1,2</sup>

Royal Marsden Hospital, London, United Kingdom, <sup>2</sup>Institute of Cancer Research, London, United Kingdom

## P13-4 Are Systematic Prostate Biopsies necessary? A comparative analysis of Targeted vs Combination Local Anaesthetic Transperineal (LATP) Biopsies on Cancer Detection and Clinical Impact on Patient Management

Mr Rustam Karanjia<sup>1</sup>, Dr Ben King<sup>1</sup>, Mr Pallab Sarkar<sup>1</sup>, Mr Osama Haider<sup>1</sup>, Mr Vishnu Basavaraju<sup>1</sup>, Mr Curtis Phelan<sup>1</sup>, Miss Oluwabunmi Tayo<sup>1</sup>, Mr Edward Streeter<sup>1</sup>, Mr Ben Eddy<sup>2</sup>, Professor Sashi Kommu<sup>1</sup>

<sup>1</sup>Kent & Canterbury Hospital, Canterbury, United Kingdom, <sup>2</sup>East Kent University Hospitals NHS Foundation Trust, School of Bioscience University of Kent, Canterbury, United Kingdom, Canterbury, United Kingdom

### P13-5 Mind and body in Prostate Cancer: Is there an association between mental wellbeing and 1-year functional outcomes?

Mr Oliver Brunckhorst<sup>1</sup>, Mr Jaroslaw Liszka<sup>1</sup>, Dr Jack Fanshawe<sup>2</sup>, Prof Robert Thomas<sup>3</sup>, Mr Shahid Khan<sup>4</sup>, Prof Matin Sheriff<sup>5</sup>, Prof Hashim Ahmed<sup>6</sup>, Prof Mieke Van Hemelrijck<sup>1</sup>, Prof Prokar Dasgupta<sup>1</sup>, Mr Kamran Ahmed<sup>1</sup>, et al.,

¹King's College London, London, United Kingdom, ²Queen Elizabeth Hospital, London, United Kingdom, ³Bedfordshire Hospitals NHS Foundation Trust, Bedford, United Kingdom, ⁴East Surrey Hospital, Redhill, United Kingdom, ⁵Medway NHS Foundation Trust, Gillingham, United Kingdom, ⁵Imperial College London, London, United Kingdom

### P13-6 Identification of factors associated with the detection of localised radiorecurrent prostate cancer: an analysis from the FORECAST trial

Mr Alexander Light<sup>1</sup>, Ms Abi Kanthabalan<sup>2</sup>, Prof Shonit Punwani<sup>2</sup>, Prof Hashim U. Ahmed<sup>1</sup>, Mr Taimur T. Shah<sup>1</sup>, FORECAST Trial Study Group

 $^{1}\text{Imperial Prostate, Imperial College London, London, United Kingdom, }^{2}\text{University College London, London, United Kingdom}$ 



### P13-7 Salvage focal ablation versus radical prostatectomy for localised radiorecurrent prostate cancer: a propensity-score matched comparison

Mr Alexander Light<sup>1</sup>, Giorgio Calleris<sup>2</sup>, Paolo Gontero<sup>2</sup>, Hashim U. Ahmed<sup>1</sup>, Giancarlo Marra<sup>2</sup>, Taimur T. Shah<sup>1</sup>, HEAT and ICE User Group, Salvage Radical Prostatectomy Consortium <sup>1</sup>Imperial Prostate, Imperial College London, London, United Kingdom, <sup>2</sup>University of Turin, Turin, Italy

### P13-8 The Trans-Atlantic Recommendations for prostate Gland Evaluation with MRI after focal Therapy (TARGET) international consensus recommendations

Mr Alexander Light<sup>1</sup>, Nikhil Mayor<sup>1</sup>, Emma Cullen<sup>1</sup>, Jan van der Meulen<sup>2</sup>, Hashim U. Ahmed<sup>1</sup>, Taimur T. Shah<sup>1</sup>, TARGET Working Group

<sup>1</sup>Imperial Prostate, Imperial College London, London, United Kingdom, <sup>2</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom

#### P13-9 Focal HIFU and cryotherapy for prostate cancer: a HEAT and ICE analysis of 15-year usage trends in the United Kingdom

Mr Alexander Light<sup>1</sup>, Hashim U. Ahmed<sup>1</sup>, Taimur T. Shah<sup>1</sup>, HEAT and ICE Users Group <sup>1</sup>Imperial Prostate, Imperial College London, London, United Kingdom

## P13-10 Morphine inhibits PC3 cell proliferation of and pro-inflammatory cytokine release fin vitro via the inhibition of the JNK/PI3K-Akt/GSK-3 Beta/Src/Lck signalling pathway: Clinical significance in prostate cancer management?

<u>Miss Prapussara Sirikhansaeng</u><sup>1</sup>, Muhammadbakhoree Yusuh<sup>1</sup>, Laurie Lau<sup>2</sup>, Omar Abdelwahab<sup>1</sup>, Associate Professor Brian Birch<sup>3</sup>, Professor Bashir Lwaleed<sup>1</sup>

<sup>1</sup>University of Southampton, Faculty of Health Sciences, Southampton, United Kingdom, <sup>2</sup>University of Southampton, Faculty of Medicine,, Southampton, United Kingdom, <sup>3</sup>University Hospital Southampton NHS Foundation Trust, Dept. of Urology, Southampton, United Kingdom



Monday 24 June, 1015-1100, Hall 3 Exhibition Gallery Level

## Gallery Poster Display 1 Prostate Cancer

Chairs: Details to Follow

### GP1-1 Does inhalational methoxyflurane (Penthrox®) improve pain control during local anaesthetic transperineal biopsy of the prostate?

Miss Danielle Whiting<sup>1</sup>, Azka Yousaf, Mr Constantinos Adamou, Mr Danny Darlington, Mr Dimitrios Papadopoulos, Mr Umberto Carbonara, Mr Murthy Kusuma, Mr Krishna Patil, Mr Dimitrios Moschonas, Mr Matthew Perry, Mr Wissam Abou Chedid <sup>1</sup>Frimley Park Hospital, Camberley, United Kingdom

### GP1-2 Did the robot (and centralisation) improve margin rates, and has this influenced PSA recurrence in organ-confined prostate cancer?

<u>Mr Ibrahim Ibrahim</u><sup>1</sup>, Dr Sanjana Ilangovan<sup>1</sup>, Dr Melanie Sneddon<sup>1</sup>, Ms Sarika Nalagatla<sup>1</sup>, Ms Carol Marshall<sup>1</sup>, Professor Imran Ahmad<sup>1</sup>

<sup>1</sup>Queen Elizabeth University Hospital, Glasgow, United Kingdom

#### **GP1-3** Justified Risks or Risky Justifications: Outcomes of locally advanced prostate cancer patients who underwent radical prostatectomy

<u>Dr Ziting Wang</u><sup>1</sup>, Dr Netty Kinsella<sup>1</sup>, Mr Bradley Russell<sup>1</sup>, Ms Justyna Sobczak<sup>1</sup>, Dr Rahul Jena<sup>1</sup>, Dr Declan Cahill<sup>1</sup>

<sup>1</sup>The Royal Marsden, London, United Kingdom

### **GP1-4** Evaluation of Spinal vs Non-spinal anaesthetic regime in day-case Robotic Assisted Radical Prostatectomy

Mr Dimitrios Papadopoulos<sup>1</sup>, Mr Danny Darlington Carbin<sup>1</sup>, Dr Piers Johnston<sup>1</sup>, Dr Zara Edwards<sup>1</sup>, Mr Krishna Patil<sup>1</sup>, Mr James Hicks<sup>1</sup>, Mr Murthy Venkata Kusuma, Mr Dimitrios Moschonas<sup>1</sup>, Mr Matthew James Alexander Perry<sup>1</sup>, Mr Wissam Abou Chedid<sup>1</sup>

<sup>1</sup>Royal Surrey County Hospital, Surrey, United Kingdom

### GP1-5 The PI-RADS 3 lesion: Pi-RADS alone oversimplifies decision-to-biopsy but what should the ideal nomogram include?

<u>Miss Madhavi Natarajan</u><sup>1</sup>, Dr Azka Yousaf<sup>1</sup>, Dr Santiago Uribe<sup>1</sup>, Mr Umberto Carbonara<sup>1</sup>, Mr Wissam Abou-Chedid<sup>1</sup>, Mr Dimitrios Moschonas<sup>1</sup>, Mr Krishnaji Patil<sup>1</sup>, Mr Murthy Kusuma<sup>1</sup>, Mr Matthew Perry<sup>1</sup>

<sup>1</sup>Royal Surrey Hospital, Guildford, United Kingdom

### **GP1-6** Prostate cancer and multiparametric MRI scanning: Is a bone scan still required?

<u>Mr Thomas Farmer</u><sup>1</sup>, Miss Lauren Holt, Mr Mamoon Siraj, Mr Oladapo Feyisetan <sup>1</sup>Leighton Hospital, Crewe, United Kingdom

## GP1-7 Radiogenomics map-based molecular and imaging phenotypical characterization in localised prostate cancer using pre-biopsy biparametric MR imaging

Miss Abeer Al-hussaini, Dr Chidozie Ogbonnaya, Dr Neil Kernohan, Professor Ghulam Nabi<sup>1</sup> University of Dundee, DUNDEE, United Kingdom



**GP1-8** Local anaesthetic trans-perineal biopsy of the prostate for patients with no rectum.

Mr NaderMudassir Gaballa<sup>1</sup>, Mr Nader Gaballa<sup>1</sup>, Mr Keval Patel<sup>1</sup>, Mr Balraj Dhesi<sup>1</sup> <sup>1</sup>University Hospital Birmingham, Birmingham, United Kingdom



Tuesday 25 June, 1100-1130, Hall 3 Exhibition Gallery Level

## **Gallery Poster Display 2 Bladder Cancer**

Chairs: Details to Follow

### **GP2-9** Investigation of sexual function and oncological outcomes following prostate capsule- and nerve-sparing robot-assisted radical cystectomy.

<u>Dr Lazaros Tzelves</u><sup>1</sup>, Dr Elizabeth Day<sup>1</sup>, Mr Amit Bhudia<sup>1</sup>, Mr Mark Markov<sup>1</sup>, Dr Osama Al-Bermani<sup>1</sup>, Dr Joanna Olphert<sup>1</sup>, Mr Ashwin Sridhar<sup>1</sup>, Professor John Kelly<sup>1</sup>, Dr Anthony Ta<sup>1</sup>
Department of Urology, University College London Hospitals, London, United Kingdom

## **GP2-10** Age-Related Differences in Outcomes of Patients with Non-Muscle-Invasive Bladder Cancer: A Biological Basis for Epidemiological Disparities?

<u>Miss Niyati Lobo</u><sup>1</sup>, Dr Zhigang Duan<sup>2</sup>, Dr Akshay Sood<sup>2</sup>, Dr Sia Lindskrog<sup>3</sup>, Professor Lars Dyrskjøt<sup>3</sup>, Dr Hui Zhao<sup>2</sup>, Dr Stephen B. Williams<sup>4</sup>, Dr Sharon H. Giordano<sup>2</sup>, Professor Ashish M. Kamat<sup>2</sup>

Royal Free London NHS Foundation Trust, London, United Kingdom, <sup>2</sup>University of Texas MD Anderson Cancer Center, Houston, United States of America, <sup>3</sup>Aarhus University, Aarhus, Denmark, <sup>4</sup>University of Texas Medical Branch, Galveston, United States of America

### **GP2-11** Compliance and outcomes following risk-adapted changes to national Quality Performance Indicators (QPIs) for NMIBC.

Professor Paramananthan Mariappan<sup>1</sup>, Mr Mathew Trail<sup>3,4</sup>, Mr Allan Johnston<sup>5</sup>, Ms Lucy Drummond<sup>6</sup>, Mrs Claire Sharpe<sup>7</sup>, Mr Sami Hamid<sup>4</sup>, Mr Barend A Dreyer<sup>6</sup>, Ms Sara Ramsey<sup>8</sup>, Dr Luisa Padovani<sup>3</sup>, Ms Roberta Garau<sup>3</sup>, Dr Alasdair Boden<sup>9</sup>, Mr Gianluca Maresca<sup>10</sup>, Mr Rami Hasan<sup>3,11</sup>, Mr Graham Hollins<sup>11</sup>, Mr Benjamin G Thomas<sup>3</sup>,<sup>12</sup>, Mr Angus Reid<sup>13</sup>, Mr Lucas Ho<sup>13</sup>, Ms Julia Guerrero Enriquez<sup>13</sup>, Mr Saad Siddiqui<sup>10</sup>, Mr Muhammad Arshad Khalil<sup>10</sup>, Ms Helen Simpson<sup>6</sup>, Mr Suriaraj Karppaya<sup>1</sup>, Mr Jaimin Bhatt<sup>5</sup>, Professor Imran Ahmad<sup>5</sup>, <sup>14</sup>, Mr Ghulam M Nandwani<sup>4</sup>, Mr Altaf H Chaudhry<sup>7</sup>, Mr Rehan S Khan<sup>9</sup>, Mr Ross Clark<sup>11</sup>, Mr Konstantinos Dimitropoulos<sup>10</sup>, Dr Catriona Graham<sup>15</sup>, Mr David Hendry<sup>5</sup>, The Scottish Bladder Cancer QPI collaborative <sup>1</sup>Edinburgh Bladder Cancer Surgery (EBCS), Western General Hospital, Edinburgh, United Kingdom, <sup>2</sup>The University of Edinburgh, Edinburgh, United Kingdom, <sup>3</sup>Department of Urology, Western General Hospital, Edinburgh, United Kingdom, <sup>4</sup>Department of Urology, Ninewells Hospital, Dundee, United Kingdom, <sup>5</sup>Department of Urology, Queen Elizabeth University Hospital, Glasgow, United Kingdom, <sup>6</sup>Department of Urology, Victoria Hospital, Kirkcaldy, United Kingdom, <sup>7</sup>Department of Urology, Dumfries & Galloway Royal Infirmary, Dumfries, United Kingdom, <sup>8</sup>Department of Urology, Raigmore Hospital, Inverness, United Kingdom, <sup>9</sup>Department of Urology, University Hospital Monklands, Airdrie, United Kingdom, <sup>10</sup>Department of Urology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom, <sup>11</sup>Department of Urology, University Hospital Ayr, Ayr, United Kingdom, <sup>12</sup>Department of Urology, Borders General Hospital, Melrose, United Kingdom, <sup>13</sup>Edinburgh Medical School, The University of Edinburgh, Edinburgh, United Kingdom, <sup>14</sup>School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom, <sup>15</sup>Edinburgh Clinical Research Facility, University of Edinburgh, Western General Hospital, Edinburgh, United Kingdom

### **GP2-12** Cancer following reconstruction for benign urological conditions: Case series and systematic review to describe management and outcomes.

<u>Dr Alisha Pati-Alam</u><sup>1</sup>, Miss Elizabeth Day<sup>1</sup>, Miss Hyka Shaikh, Dr Anastasia Frost<sup>1</sup>, Mr Ashwin Sridhar<sup>1</sup>, Professor John Kelly<sup>1</sup>, Professor Anthony Mundy<sup>1</sup>, Mr Jeremy Ockrim<sup>1</sup>, Miss Tamsin Greenwell<sup>1</sup>, Mr Anthony Oluwaseun Noah<sup>1</sup>

<sup>1</sup>University College Hospital, London, London, United Kingdom



#### **GP2-13 Female Sexual Function after Radical Cystectomy: a cross-sectional study**

<u>Miss Riya Sabharwal,</u> Mr Santosh Nagasubramian, Ms Elizabeth Day, Mr Anthony Ta, Mr Ashwin Sridhar, Professor John Kelly

<sup>1</sup>University College London Hospital, United Kingdom

### **GP2-14** The 'Pluck Procedure' in a Laparoscopic Nephroureterectomy: Does it affect oncological outcomes?

<u>Dr Shri-Ishvarya Rajamoorthy</u><sup>1</sup>, Mr Dominic Thompson<sup>1</sup>, Mr Neil John Fenn<sup>1</sup> <sup>1</sup>Department of Urology, Morriston Hospital, Swansea, United Kingdom



Tuesday 25 June, 1500-1530, Hall 3 Exhibition Gallery Level

# Gallery Poster Display 3 Management/Governance/Education/Quality Improvement

Chairs: Details to Follow

#### **GP3-15** PSA text message reminders to improve prostate cancer surveillance at a single centre

<u>Dr Alisha Pati-Alam</u><sup>2</sup>, Miss Sascha Ali<sup>1</sup>, Mr Mohamed Ferdous Hussain<sup>1</sup>, Ms Vanita Patel<sup>1</sup>, Mr Anish Patel<sup>1</sup>, Miss Lehana Yeo<sup>1</sup>, Miss Jhumur Pati<sup>1</sup>

<sup>1</sup>Homerton Univeristy Hospital, London, United Kingdom, <sup>2</sup>University College Hospital, London, London, United Kingdom

#### **GP3-16** Audit on Faster Diagnosis Standards in 2-Week Wait (2WW) Haematuria Clinic

<u>Dr Yamin Pa Pa Lin, Dr Ashwini Kulkarni, Ms Kate Warren</u>
<sup>1</sup>Bristol Urological Institute, Bristol, United Kingdom, <sup>2</sup>North Bristol NHS Trust, Bristol, United Kingdom

#### **GP3-17** How effective is a dedicated smoking cessation service in a standard haematuria clinic?

Mrs Brinda Loganathan<sup>1</sup>, Miss Tania Fortes<sup>1</sup>, Mr Benjamin Ayres<sup>1</sup>
St George's University Hospitals, London, United Kingdom

### **GP3-18** Evaluating the clinical need for Group and Save for TURBT at a District General Hospital in London

<u>Dr Mami Samejima</u>¹, Dr Mami Samejima¹, Dr Omololu Ajayi¹, Mr Garfield Parker¹, Mr Damiete Harry¹, Mr Gopalakrishnan Nair¹

<sup>1</sup>North Middlesex University Hospital, London, United Kingdom

#### GP3-19 Introduction of the 'Uro-Go' grab-bag for difficult catheterisation

<u>Dr Rachael O'Halloran</u><sup>1</sup>, Miss Samara Fleville<sup>1</sup>, Mr Ajay Pahuja<sup>1</sup> <sup>1</sup>Ulster Hospital Dundondald, Belfast, United Kingdom

### GP3-20 Patient-initiated Follow up (PIFU) is a more preferable outpatient model for patients and clinician: a local Urology outpatient programme review.

Mr Fouad Maqboul<sup>1</sup>, Mr Srijit Banerjee<sup>1</sup>, Dr Daniella Mateescu<sup>1</sup>, Dr Sally Spur<sup>1</sup> Darent Valley Hospital, Dartford, United Kingdom



Wednesday 26 June, 1100-1130, Hall 3 Exhibition Gallery Level

## Gallery Poster Display 4 Stones / Imaging / Upper Tract Disorders

Chairs: Details to Follow

### **GP4-21** Long term outcomes in Nephrocalcinosis: Comparative study between Renal Tubular Acidosis and Medullary Sponge Kidney

<u>Dr Ahmed Farag</u><sup>1</sup>, Ms Emily Cooper, Dr Graham Lipkin, Mr Kesavapilla Subramonian <sup>1</sup>University Hospitals Birmingham, Birmingham, United Kingdom

#### GP4-22 Is stent on a string (SOS) the new gold standard for post-ureteroscopy ureteric drainage? Evidence from a systematic review

Mr Nick Harrison<sup>1</sup>, Dr Charlotte Hughes, Professor Bhaksar Somani

Mersey And West Lancashire Teaching Hospitals Nhs Trust, Prescot, United Kingdom

## GP4-23 Nephrectomy in enlarged autosomal dominant polycystic kidneys- should hand-assisted laparoscopic approach be the new standard of care? Retrospective Experience at a single tertiary care center

Mr Abhishek Chandna<sup>1</sup>, Miss Artemisia Lango, Mr Anurag Golash, Mr Pankaj Panwar, Mr Herman Fernando, Mr Christopher Luscombe, Dr Kerry Tomlinson, Dr Julie Wessels, Dr Dominic de Takats

University Hospitals North Midland NHS Trust, Stoke On Trent, United Kingdom

## GP4-24 Comparison of ureteoroscopy and laser stone fragmentation (URSL) between Holmium:YAG laser with MOSES vs Non-MOSES technology: A prospective single-centre propensity score-matched analysis using similar laser settings

<u>Dr Victoria Jahrreiss</u><sup>1,2</sup>, Dr Francesco Ripa<sup>3</sup>, Dr Clara Cerrato<sup>1</sup>, Dr Carlotta Nedbal<sup>1</sup>, Dr Amelia Pietropaolo<sup>1</sup>, Prof Bhaskar Somani<sup>1</sup>

<sup>1</sup>University Hospital Southampton, Southampton, United Kingdom, <sup>2</sup>Medical University Vienna, Vienna, Austria, <sup>3</sup>University College London Hospitals, London, United Kingdom

#### GP4-25 Percutaneous nephrolithotomy; Is supine superior? Experience at a single tertiary care unit in Sri Lanka

Mr Sagara Ruwan Kumara Maduwe Gedara<sup>1</sup>, Mr Ambegoda Madura<sup>3</sup>, Dr Anuruddha Abeygunasekera<sup>2</sup>, Prof. Srinath Chandrasekara<sup>2</sup>, Dr Ashantha Weerakkody<sup>2</sup>, Dr Sinthuja Mahadevan<sup>2</sup>

<sup>1</sup>Royal Cornwall Hospitals NHS Trust, TRURO, United Kingdom, <sup>2</sup>Colombo South Teaching Hospital, Colombo, Sri Lanka, <sup>3</sup>Chesterfield Royal Hospital, Chesterfield, United Kingdom

#### GP4-26 The impact of a new primary ureteroscopy service for the emergency treatment of ureteric stones in a busy university hospital

<u>Dr Tarek Aly</u><sup>1</sup>, Mrs Raya Rasheed, Dr Kevin George, Mr Khaled Ghanem, Dr Mazharuddin Shaikh, Mr Shailesh Kulkarni, Mr Junaid Masood.

Queens Hospital, Barking, Havering And Redbridge University Hospitals, Romford, United Kingdom



#### **TEACHING & SKILLS COURSES**





#### By the Honorary Secretary Elect

Welcome to the BAUS 2024 programme. Education and skill development is a central priority for our BAUS membership and we have therefore focussed this year on ensuring novel and relevant teaching courses.

We have ensured a broad range of courses to appeal to our whole membership, reflecting the feedback from last year with predominately new leadership and a focus on new courses. There is a significant emphasis on face to face this year.

We are delighted to announce a collection of hands-on training courses: ultrasound training led by Asad Abedin with a team of consultant radiologist and radiographers, which no doubt will prove to be popular with both trainees and consultants. Stefanos Bolomytis will lead the Cognitive/MRI Fusion LA Transperineal Biopsy of Prostate incorporating the latest in prostate biopsy techniques along with Consultant Radiologists and specialist nurses. Vishwanath Hanchanale will offer another opportunity to attend the successful introduction to robotics course.

I am particularly pleased to announce brand-new courses focused on important and growing areas of practice: We have Managing Active Surveillance for Prostate Cancer directed by Mr Vincent Gnanapragasam. A new medico legal course provided by The Medical Protection Society and led by Dr James Thorpe which will support us in an increasingly litigious environment. We also have a new course on the Management of Functional Urology Emergencies will be led by Sachin Malde, addressing an educational need in urological practice.

From the newly formed SAS and Trust Section Adham Ahmed will update us and provide a detailed guide on achieving GMC speciality registration in urology, via the new Portfolio Pathway. We have the pleasure of Nav Johal from Great Ormond Street Hospital leading the revamped Paediatric urology course that will increase knowledge and informed practice in this important area.

Prof Hashim Hashim will be delivering the ever-popular FNUU Course on Urodynamics, an essential part of the BAUS offering. BSoT this year will offer interview practice for Urology NTN Interviews led by Bushra Abdelqader, helping young urologists overcome an important hurdle in their career development.

Focused virtual courses include those on Penile Cancer, Male infertility and an important course on research methodology and a Bladder Cancer Masterclass.

As always I am grateful to the BAUS Section Chairs, Course Directors and the Events Team led by Harry Heald, all of whom are critical to the entire process of course generation and delivery. We look forward to seeing you in the summer at a dynamic, relevant and exciting programme in my home town of Birmingham.

#### Mo Belal

Honorary Secretary Elect



## TEACHING & SKILLS COURSES OVERVIEW ON-SITE COURSES



No. Course Title	Course Director(s)	Cost	No. of Spaces	Location	Time		
MONDAY 24 JUNE							
1 Teaching Course: Paediatric Urology	Navroop Johal	£45 BAUS Member £75 Non-Member	60	Hall 11B	1100-1230		
2 Skills Course: Hands on Ultrasound Training	Asad Abedin	£50 BAUS Member £90 Non-Member	20	Hall 7	1100-1230		
3 Teaching Course: Succeed the Portfolio Pathway	Adham Ahmed & Rickaz Raheem	£45 BAUS Member £75 Non-Member	60	Hall 11B	1400-1530		
4 Skills Course: Hands on Ultrasound Training	Asad Abedin	£50 BAUS Member £90 Non-Member	20	Hall 7	1400-1530		
5 Skills Course: Hands on Ultrasound Training	Asad Abedin	£50 BAUS Member £90 Non-Member	20	Hall 7	1630-1800		
6 Teaching Course: Good Urodynamics Practice	Hashim Hashim	£45 BAUS Member £75 Non-Member	60	Hall 11B	1630-1800		
TUESDAY 25 JUNE							
7 Skills Course: Cognitive/MRI Fusion LA Transperineal Biopsy of Prostate	Stefanos Bolomytis	£50 BAUS Member £90 Non-Member	20	Hall 7	0800-0930		
8 Teaching Course: The Medical Protection Society: Medico Legal Course	Dr James Thorpe	£45 BAUS Member £75 Non-Member	60	Hall 11B	1100-1230		
9 Skills Course: Cognitive/MRI Fusion LA Transperineal Biopsy of Prostate	Stefanos Bolomytis	£50 BAUS Member £90 Non-Member	20	Hall 7	1100-1230		
10 Teaching Course: Simulated Course for Urology NTN Interviews	Bushra Abdelqader	£25 BAUS Member £35 Non-Member	12	Hall 4	1100-1230		
11 Skills Course:  Cognitive/MRI Fusion  LA Transperineal Biopsy of Prostate	Stefanos Bolomytis	£50 BAUS Member £90 Non-Member	20	Hall 7	1400-1530		

## TEACHING & SKILLS COURSES OVERVIEW ON-SITE COURSES



No.	o. Course Title	Course Director(s)	Cost	No. of Spaces	Location	Time
12	Teaching Course: An Evidence-Based Approach to Managing Active Surveillance for Prostate Cancer	Vincent Gnanapragasam	£45 BAUS Member £75 Non-Member	r 60	Hall 11B	1400-1530
13	Skills Course: Cognitive/MRI Fusion LA Transperineal Biopsy of Prostate	Stefanos Bolomytis	£50 BAUS Membe £90 Non-Member		Hall 7	1600-1730
WEDNESDAY 26 JUNE						
14	Teaching Course: Updates in Stone Management	Bhaskar Somani & Hari Ratan	£45 BAUS Member £75 Non-Member	r 60	Hall 11B	1130-1330
15	Skills Course: Introduction to Robotics	Vishwanath Hanchanale	£50 BAUS Membe £90 Non-Member		Hall 7	1130-1300
16	Teaching Course: Management of Functional Urology Emergencies	Sachin Malde	£45 BAUS Membe £75 Non-Member	r 60	Hall 11B	1400-1530
17	Skills Course: Introduction to Robotics	Vishwanath Hanchanale	£50 BAUS Membe £90 Non-Member		Hall 7	1400-1530

## TEACHING & SKILLS COURSES OVERVIEW ONLINE COURSES



No.	Course Title	Course Director(s)	Cost	Location
18	Teaching Course: Research Methodology	Vincent J Gnanapragasam	FREE	BAUS 2024 Platform
19	Teaching Course:  Male Factor Infertility	Asif Muneer & Rowland Rees	FREE	BAUS 2024 Platform
20	Teaching Course: Penile Cancer	Asif Muneer & Rowland Rees	FREE	BAUS 2024 Platform
21	Teaching Course: Bladder Cancer Masterclass	Dominic Hodgson & Arthur McPhee	FREE	BAUS 2024 Platform

#### **BAUS ACADEMY: ON-SITE COURSES**



#### **Course 1: Teaching Course - Paediatric Urology**

Monday 24 June 2023 Hall 11B 1100-1230

60 Places Cost: £45 BAUS Member & £75 Non-Member

Course Director: Navroop Johal, Consultant Paediatric Urologist, Great Ormond St Hospital for Children

#### **Outline and Objectives**

The aim of this course is to reinforce and support the practice of paediatric urology outside a specialist unit. We are grateful that we can continue to provide a focus on children within the BAUS meeting and an opportunity for established Consultants and interested trainees to meet. There will also be didactic mini lectures on key topics, each led by a paediatric urologist and illustrated by appropriate clinical scenarios.

We do hope, as usual, to provide an interactive feast that will leave delegates better equipped - be it for forthcoming FRCS (Urol) exams or next paediatric clinic.

#### **Faculty**

Abraham Cherian, Consultant Paediatric Urologist, Great Ormond St Hospital for Children Divyesh Desai, Clinical Lead and Director of Urodynamics, Great Ormond St Hospital for Children Alex Cho, Consultant Paediatric Urologist, Great Ormond St Hospital for Children Anu Paul, Consultant Paediatric Urologist, Evelina Hospital Shabnam Undre, Consultant Urologist, Lister Hospital



# Courses 2, 4 & 5: Skills Course - Hands on Ultrasound Training

Monday 24 June 2024 Hall 7 1100-1230 Monday 24 June 2024 Hall 7 1400-1530 Monday 24 June 2024 Hall 7 1630-1800

20 Places Per Course Cost: £50 BAUS Member & £90 Non-Member

Course Director: Asad Abedin, Russells Hall Hospital, Dudley

## **Outline and Objectives**

Point of care ultrasound scanning (POCUS) is fast becoming an important skill across medicine, to improve bedside patient assessment, both in the emergency & elective setting. To this end, this course will allow delegates to be taught hands on ultrasound scanning technique of the kidneys, bladder and testes, in small groups of three, with a faculty member. We have arranged for patients who have appropriate pathologies, to be present as subjects for scanning. High end ultrasound machines will be provided by Fujifilm (formerly Hitachi). Each station will have 3 candidates with one faculty member and patients with some of the following pathologies. The aim is to help candidates in becoming confident in level 1 urological ultrasound scanning, i.e. being able to recognise normal anatomy, detecting when something is abnormal and referring on for further imaging.

The following areas will be covered within this course:

- Technique of performing an ultrasound scan of the kidneys, urinary bladder, testes and transabdominal scan of the prostate (measuring prostate volume).
- How to optimise an ultrasound image, using the common machine knobs controlling overall gain, time-gain compensation, focus, depth and scanning frequency. Faculty members will briefly discuss different ultrasound tools such as tissue harmonic imaging, compounding and reducing sectoral width to achieve clearer images.
- · Recognition of the normal appearance of the kidneys, urinary bladder, testes and prostate.
- Recognition of some of these common abnormalities within the urinary tract:
  - > Renal cysts
  - > Hydronephrosis
  - Renal stones
  - Small renal masses
  - > Thick walled bladder & trabeculation
  - > Prostate enlargement, median lobe of the prostate
  - > Epidydimal cysts
  - > Hydrocele
  - > Varicocele

#### **Faculty**

**Kiran Randhawa**, Consultant Radiologist, Russells Hall Hospital, Dudley **Ian Wright,** Senior Ultrasonographer, Dudley Group NHS Foundation Trust



# **Course 3: Teaching Course - Succeed the Portfolio Pathway**

Monday 24 June 2024 Hall 11B 14030-1530

60 Places Cost: £45 BAUS Member & £75 Non-Member

Course Director: Adham Ahmed, West Suffolk Hospital and Rickaz Raheem, Bedford Hospital

#### **Outline and Objectives**

Understand the essential curriculum requirements for the portfolio pathway in urology. Master the evidence collection procedure necessary for completing the portfolio pathway application. Acquire the knowledge and skills needed to prepare a robust and compelling application for the urology portfolio pathway.

1400-1403	Introduction
1403-1418	Navigating the Portfolio Pathway in Urology: Key components from the curriculum Mehwash Nadeem, James Cook University Hospital, Middlesbrough and Trust CESR lead
1418-1433	Evidence collection for portfolio pathway: A pragmatic approach Murugu Kalai Selvan Masilamani, New Cross Hospital, Wolverhampton
1433-1440	Portfolio Pathway Journey in Urology: Navigating Struggles and Overcoming obstacles Archana Raysee, Maidstone and Tunbridge wells NHS Foundation Trust
1440-1500	Requirement and expectations: From assessor's perspective  Justine Royle, Aberdeen Royal Infirmary and Chair, SAC in Urology
1500-1530	Q&A and Panel Discussion: Building a Robust Application: focus on the solutions to tackle the challenges

## **Faculty**

Justine Royle, Aberdeen Royal Infirmary and Chair, SAC in Urology
Tharani Nitkunan, Epsom and St Helier University Hospitals
Mehwash Nadeem, James Cook University Hospital, Middlesbrough and Trust CESR lead
Murugu Kalai Selvan Masilamani, New Cross Hospital, Wolverhampton
Archana Raysee, Maidstone and Tunbridge wells NHS Foundation Trust



# **Courses 6: Teaching Course - Good Urodynamics Practice**

Monday 24 June 2023 Hall 11B 1630-1800

60 Places Per Course Cost: £45 BAUS Member & £75 Non-Member

Course Director: Hashim Hashim, Southmead Hospital, Bristol

#### **Outline and Objectives**

This course aims to provide focused teaching to enable urologists to improve their skills in urodynamics. There will be an emphasis on practical aspects of urodynamics including interpretation of traces, quality control and troubleshooting. The speakers are involved in similar courses, which have been running successfully in the United Kingdom and Internationally. The small group format has been shown to work well in addressing individual needs. Access to teaching aids will simulate the clinical scenario as much as possible. The aim is to teach and emphasise good urodynamic practice using accepted international standards. At the end of the workshop delegates should feel more confident in their practice of urodynamics, specifically interpretation of traces which is a required skill for the FRCS (Urol) viva examination.

#### **Introduction (5 mins)**

Hashim Hashim, Bristol Urological Institute

Physics of Urodynamics in a nutshell (15 mins)

Laura Thomas, Clinical Scientist, Bristol Urological Institute

**Update on Good Urodynamics Practice (15 mins)** 

Hashim Hashim, Bristol Urological Institute

**Troubleshooting (20 mins)** 

Laura Thomas, Clinical Scientist, Bristol Urological Institute

Interpretation of Results and Traces using clinical scenarios (30 mins)

Hashim Hashim, Bristol Urological Institute

**Conclusion (5 mins)** 

Hashim Hashim, Bristol Urological Institute

#### **Faculty**

Laura Thomas, Clinical Scientist, Bristol Urological Institute



# Course 7, 9, 11 & 13: Skills Course - Cognitive/MRI Fusion LA Transperineal Biopsy of Prostate

 Tuesday 25 June 2024
 Hall 7
 0800-0930

 Tuesday 25 June 2024
 Hall 7
 1100-1230

 Tuesday 25 June 2024
 Hall 7
 1400-1530

 Tuesday 25 June 2024
 Hall 7
 1600-1730

20 Places Cost: £50 BAUS Member & £90 Non-Member

Course Directors: Stefanos Bolomytis, Southmead Hospital, Bristol

### **Outline and Objectives**

- Develop hands-on skills for performing transperineal prostate biopsies under local anesthesia.
- Understand and apply proper procedural techniques.
- · Gain basic skills in incorporating MRI fusion technology into the biopsy procedure.
- Learn the principles of aligning pre-biopsy MRI images with real-time ultrasound for targeted biopsy.
- Enhance the ability to interpret prostate MRI scans.
- Identify and understand imaging features relevant to biopsy decision-making and cognitive targeting.
- Develop effective communication skills for explaining the procedure and its benefits to patients.

These objectives aim to provide participants with a comprehensive skill set, integrating both the technical aspects of the biopsy procedure and the nuanced interpretation of MRI scans for improved diagnostic accuracy.

#### **Faculty**

Neil Trent, Musgrove Park Hospital, Taunton
Mohamed Noureldin, Basingstoke and North Hampshire Hospital
Douglas Kopcke, Consultant Radiologist, North Bristol NHS Foundation Trust
Angus McCormick, Nurse Practitioner, North Bristol NHS Foundation Trust
Jonah Rusere, Nurse Practitioner, Guy's and St Thomas Hospital, London



# **Courses 8: Teaching Course: The Medical Protection Society: Medico Legal Course**

Tuesday 25 June 2024 Hall 11B 1130-1230

60 Places Per Course Cost: £45 BAUS Member & £75 Non-Member

Course Directors: **Dr James Thorpe**, The Medical Protection Society (MPS)

**Outline and Objectives** 

Details to Follow

**Faculty** 

Details to Follow



# Course 10: Teaching Course - Simulated Course for Urology NTN Interviews

Tuesday 25 June 2024 Hall 4 1100-1230

60 Places Cost: £25 BAUS Member & £35 Non-Member

Course Directors: Bushra Abdelqader, St George's Hospital, London

### **Outline and Objectives**

The primary objective of this course is to provide participants with a comprehensive understanding of the national ST3 interview format while offering invaluable individualized feedback. Furthermore, candidates will have the opportunity to engage in one-on-one portfolio sessions to enhance their preparation for the selection process.

## **Target Participants**

This course is tailored for Core Surgical Training level trainees and trust grade doctors who are gearing up to apply for national selection in either 2025 or 2026. It is designed to cater to individuals seeking to strengthen their interview skills and optimize their portfolios for a successful application.

#### **Programme**

The session will kick off with a dynamic 10-minute presentation delivered by candidates who have excelled in recent rounds of national selection. They will share invaluable insights, strategies, and practical advice on how to maximise their portfolio scores, as well as how to prepare meticulously for the interview.

Following the presentation, the course will feature five structured stations, each lasting 15 minutes, aimed at providing participants with a holistic understanding of the ST3 interview process:

- 1. Portfolio Station
- 2. Emergency Station
- 3. Outpatient Station
- 4. Communication Skills Station
- 5. Skills Station station

Overall, the programme aims to provide participants with a comprehensive and immersive experience, equipping them with the knowledge, skills, and confidence necessary to excel in the Urology NTN interview process.

#### **Faculty**

Abida Sultana, Charing Cross Hospital, London
Adnan Malik, University Hospitals Coventry and Warwickshire
Mini Sardar, Royal Cornwall Hospital, Truro
Martina Spazzapan, Guy's & Thomas's Hospital
Islam Abu-Nayla, Royal Bournemouth General Hospital
Samara Fleville, Craigavon Area Hospital, Portadown
Islam Fakhri, Details to Follow
Kamran Haq, Freeman Hospital, Newcastle
Anthony Emmanuel, Guy's & Thomas's Hospital
Yehia Abdelmotagly, The James Cook University Hospital, Middlesbrough
Harmony Uwadiae, Southport and Ormskirk Hospital



# Course 12: Teaching Course - An Evidence Based Approach to Managing Active Surveillance for Prostate Cancer

Tuesday 25 June 2023 Hall 11B 1400-1530

60 Places Cost: £45 BAUS Member & £75 Non-Member

Course Director: Vincent Gnanapragasam, University of Cambridge

### **Outline and Objectives**

The aim of this course is to educate and inform clinicians at all levels on the evidence base around management of early prostate cancer and in particular, disease suitable for active surveillance (AS). The course will cover recent understanding on the epidemiology and natural history of prostate cancer and the importance of competing risks in deciding the benefit of treatment versus a conservative approach. The use and value of risk estimation aids to help new patients understand their prognosis will be explored and how they underpin informed decision making and confidence in active surveillance. The integration of these concepts in an evidence-based approach to AS will be outlines as well as how it can be used to stratify and rationalise follow up and refine use of imaging, clinic visits and biopsy. Lectures will also cover the process and practical aspects of setting up a robust and reliable AS service and also explore patient empowerment and support when on AS. The overall aim is to help participants develop a structured AS programme in their units and reduce the current significant variability in how AS is managed across the NHS. Time will be allotted to question-and-answer sessions and also practical aspects of setting up a high-quality AS service.

Recommended Pre-course online free seminar series: https://vimeo.com/showcase/cpc-cap-course

The importance of understanding risk and prognosis in prostate cancer

Vincent Gnanapragasam, University of Cambridge

Using prognosis to inform risk stratified active surveillance: from arbitrary to data driven

Vincent Gnanapragasam, University of Cambridge

Setting up and delivering a new risk based active surveillance programme - challenges and opportunities

Barnaby Barrass, Luton and Dunstable Hospital

Jennifer Arnold, Prostate CNS, Luton and Dunstable Hospital

The role of the CNS in guiding decision making and supporting active surveillance – using evidence to support patients

Vineetha Thankapannair, Lead CNS, Cambridge University Hospitals NHS Trust

Interactive discussion and questions

All panel and participants

#### **Faculty**

**Barnaby Barrass,** Luton and Dunstable Hospital **Vineetha Thankapannair,** Lead CNS, Cambridge University Hospitals NHS Trust **Jennifer Arnold,** Prostate CNS, Luton and Dunstable Hospital



## **Courses 15 & 17: Skills Course - Introduction to Robotics**

Wednesday 26 June 2024 Hall 7 1130-1300 Wednesday 26 June 2024 Hall 7 1400-1530

20 Places Cost: £50 BAUS Member & £90 Non-Member

Course Director: **Vishwanath Hanchanale,** Royal Liverpool University Hospital and **Justine Royle,** Aberdeen Royal Infirmary

#### **Outline**

Delegates will be split into two groups, with first group having practical skills session and the second learn the basic concepts in robotics with emphasis on robotic urological procedures.

**Group 1:** 2 trainees at each station (12-15 minutes with each station)

- Station A: Robotic skills with the simulator
- Station B: Patient positioning, docking, undocking,
- Station C: Approach, instruments, energy sources

#### Group 2:

Learning Concept of Robotic Urology with emphasis on robotic urological procedures

#### **Didactics**

- Welcome
- Introductions to Robotics
- Emergency scenarios and troubleshooting
- · Robotic Urological procedures

#### **Practical Elements**

- Introduction to the robotic platform robot features, movement and positioning in theatre, sterile draping.
- Instruments; insertion/removal
- · Docking and undocking
- Emergency undocking and communication

### **Faculty**

Bhavan Rai, Freeman Hospital, Newcastle

Ashwin Sridhar, University College Hospital, London

Mohantha Dooldeniya, Mid Yorks NHS Trust, Wakefield

Robin Weston, Liverpool University Hospitals NHS Foundation Trust

Philip Charlesworth, The Royal Marsden, London

Arjun Nambiar, Freeman Hospital, Newcastle

Muddassar Hussain, Frimley Park Hospital, London

Nina Patrick, Arrowe Park Hospital, Wirral

Gokul Kandaswamy, Morriston Hospital, Swansea

Sotonye Tolofari, Salford Royal NHS Trust, Manchester

Murthy Kusuma, Royal Surrey Hospital, Guildford

**Jamie Dudley,** Surgical Care Practitioner (Urology), Liverpool University Hospitals NHS Foundation Trust **Sherly Jose,** Surgical Care Practitioner (Urology), Liverpool University Hospitals NHS Foundation Trust



## **Course 14: Teaching Course - Updates in Stone Management**

Wednesday 26 June 2024 Hall 11B 1130-1330

60 Places Cost: £45 BAUS Member & £75 Non-Member

Course Director: **Bhaskar Somani,** Southampton General Hospital & Editor-in-chief JCU and Hari Ratan, Nottingham University Hospitals

### **Outline and Objectives**

This course will provide an update for management of stone disease taking into account the latest developments in ESWL, Ureteroscopy, PCNL, Metabolic and Conservative management. We will also cover the latest technological concepts, nuances and evidence base to support it.

We will then have a few cases or video-based presentations from the faculty with discussion and audience participation. It will cover some practical aspects and 'tips and tricks' to help with decision making at all stages of patient journey.

### **Faculty**

**Sian Allen,** University College Hospital, London **Kim Davenport,** Cheltenham General Hospital **Jake Patterson,** Royal Hallamshire Hospital, Sheffield



# Course 16: Teaching Course - Management of Functional Urology Emergencies

Wednesday 26 June 2023 Hall 11B 1400-1530

60 Places Cost: £45 BAUS Member & £75 Non-Member

Course Director: Sachin Malde, Guy's & Thomas's Hospital, London

## **Outline and Objectives**

This course is essential for all urologists that will encounter functional urological emergencies in their practice, especially for those with a specialist interest in functional and reconstructive urology. Through interactive lectures, this course aims to provide a step-by-step practical guide for the diagnosis, evaluation, and treatment of commonly encountered emergencies. This includes the management of iatrogenic urinary tract injuries, ureteric and bladder reconstruction, emergencies in neuropaths, and emergencies in pregnancy, where relevant to functional and reconstructive urology.

Bladder/ureteric injury and fistula (15 mins)

Suzanne Biers, Addenbrooke's Hospital, Cambridge

Prosthesis (AUS/SNM) emergencies (15 mins)

Andy Kozan, St James's University Hospital, Leeds

Emergencies in reconstructed urinary tracts/continent bladder replacement/Mitrofanoff (15 mins)

Sachin Malde, Guy's & Thomas's Hospital, London

Emergencies in neuropaths - autonomic dysreflexia, neurogenic bladder and spinal shock, cauda equina? (15 mins)

Nicholas Faure Walker, King's College Hospital, London

Management of Intraoperative Complications in Open Procedures - arterial, venous, rectal (15 mins)

Muhammad Shamim Khan, Guy's & St Thomas' Hospitals, London

#### **Faculty**

Suzanne Biers, Addenbrooke's Hospital, Cambridge Andy Kozan, St James's University Hospital, Leeds Nicholas Faure Walker, King's College Hospital, London Muhammad Shamim Khan, Guy's & St Thomas' Hospitals, London

## **EMERGENCY PROCEDURES**



### **Emergency announcement**

If it becomes necessary to evacuate the building, the following message will be broadcast: "Ladies and Gentlemen, may I have your attention please. We must ask you to leave the building by the nearest exit as quickly as possible. Do not use the lifts and do not stop to collect personal belongings"

### **First Aid Emergencies**

In cases of medical emergency call Security Control (0121 200 2000 option 1) giving the exact location of the casualty and details of injuries sustained. Security Control will then arrange for all necessary assistance. Alternatively, please contact the nearest Host.

#### **Fire Procedures**

An intelligent fire alarm system and audible sounders protect the ICC and Symphony Hall. There are portable fire extinguishers, fire hoses and a sprinkler system throughout.

In the event of discovering a fire in your vicinity:


- 1) Raise the alarm by breaking the glass in the fire alarm call point.
- 2) Inform the Security Control Room on an internal telephone by dialling 3333 or inform the nearest Host giving location and nature of the fire.
- 3) Turn off all electrical equipment in your area, where safe and practicable to do so.
- 4) Follow Hosts' instructions.
- 5) Make your way to the nearest fire exit; do NOT use lifts or escalators.
- 6) Do NOT go back to collect personal belongings.
- 7) Report to the assembly point on Civic Centre Estate and await instructions.
- 8) Please notify a Security Officer if you believe a member of your team is missing.
- 9) Only return to the building when instructed by a fire officer.

## **Security**

Please remember to be vigilant throughout your event to ensure the safety of your property. If items cannot be watched then it is important that they are properly secured.

#### **Evacuation Area**

Located at Civic Centre Estate





www.baus.org.uk @BAUSurology